Clinical Trials on Alzheimer's Disease

11th edition of

Clinical Trials on Alzheimer's Disease

PROGRAM

PALAU DE CONGRESSOS DE CATALUNYA

Barcelona, October 24-27, 2018

Montpellier ‘08 / Las Vegas ‘09 / Toulouse ‘10 / San Diego ‘11
Monte Carlo ‘12 / San Diego ‘13 / Philadelphia ‘14
Barcelona ‘15 / San Diego ‘16 / Boston ‘17

www.ctad-alzheimer.com
Organizing and Scientific Committees .......................................................... p. 3
Keynote Speakers .......................................................................................... p. 4
Lifetime Achievement Award ....................................................................... p. 6
Program at a glance ...................................................................................... p. 7
  – Wednesday, October 24 ........................................................................ p. 9
  – Thursday, October 25 ........................................................................... p. 10
  – Friday, October 26 .............................................................................. p. 14
  – Saturday, October 27 .......................................................................... p. 18
Poster presentations .................................................................................... p. 21
Theme 1. Clinical trials: Methodology ....................................................... p. 22-24
Theme 2. Clinical trials: Results ................................................................. p. 25-27
Theme 3. Clinical trials: Imaging ............................................................... p. 28-29
Theme 4. Clinical trials: Biomarkers including plasma ............................ p. 30-34
Theme 7. Behavioral disorders and clinical trials ..................................... p. 43
Theme 8. Health economics and clinical trials ........................................ p. 44
Theme 9. Epidemiology and clinical trials ............................................... p. 45-46
Theme 11. New therapies and clinical trials .......................................... p. 48-49
Privileged partners .................................................................................. p. 50
General information ................................................................................ p. 51
CTAD Scientific Committee

- Susan ABUSHAKRA (San Francisco)
- Paul AISEN (San Diego)
- Kaj BLENNOW (Molndal)
- Merce BOADA (Barcelona)
- Maria CARRILLO (Chicago)
- Mony John DE LEON (New York)
- Steven DEKOSKY (Miami)
- Rachelle DOODY (Basel)
- Bruno DUBOIS (Paris)
- Howard FELDMAN (San Diego)
- Nick FOX (London)
- Giovanni B. FRISONI (Brescia, Geneva)
- Luz FROELICH (Mannheim)
- Serge GAUTHIER (Montreal)
- Ezio GIACOBINI (Geneva)
- Michael GRUNDMANN (San Diego)
- Harald HAMPEL (Paris)
- Takeshi IWATSUBO (Tokyo)
- Ara KHACHATURIAN (Washington DC)
- Zaven KHACHATURIAN (Washington DC)
- Virginia LEE (Philadelphia)

- Constantine G. LYKETSOS (Baltimore)
- José Luis MOLINUEVO (Barcelona)
- Jean-Marc ORGOZO (Bordeaux)
- Ronald PETERSEN (Minnesota)
- Craig W. RITCHIE (Edinburgh)
- Augustin RUIZ (Barcelona)
- Robert RISSMAN (San Diego)
- Stephen SALLOWAY (Providence)
- Rachel SCHINDLER (New York)
- Philip SCHELTENS (Amsterdam)
- Lon SCHNEIDER (Los Angeles)
- Eric SIEMERS (Philadelphia)
- Peter SNYDER (Rhode Island)
- Reisa SPERLING (Boston)
- Yaakov STERN (New York)
- Jacques TOUCHON (Montpellier)
- John TROJANOWSKI (Philadelphia)
- Bruno VELLAS (Toulouse)
- Michael W. WEINER (San Francisco)
- Bengt WINBLAD (Stockholm)
«Blood biomarkers for AD clinical trials»
Randall Bateman, MD, PhD

Charles F. and Joanne Knight Distinguished Professor of Neurology at the Washington University School of Medicine, St. Louis, USA

Dr. Randall Bateman, the Charles F. and Joanne Knight Distinguished Professor of Neurology at the Washington University School of Medicine, is the PI of the Dominantly Inherited Alzheimer Network (DIAN) and DIAN Trials Unit which coordinates with pharmaceutical, regulatory, and patient advocacy groups for clinical trials in dominantly inherited Alzheimer’s disease. Dr. Bateman’s laboratory investigates the causes and future diagnosis and treatments of Alzheimer’s disease utilizing a wide variety of assays and techniques. His lab measures the pathophysiology of Alzheimer’s disease in humans utilizing amyloid-beta, apolipoprotein E, APP, and tau protein kinetics. His work has been supported by the NIH, foundations, and Pharma, and he has consulted for the FDA, NIH and Pharma. He has served as a co-investigator on multiple multi-site trials including ADNI and AD clinical trials. Dr. Bateman mentors junior faculty members, fellows, and students, all successful in their desired career trajectory. His contributions have been recognized with awards from the AlzForum Community, Alzheimer’s Association (Zenith Award), Scientific American, the Glenn Award for Aging Research, and the MetLife Foundation.

«What have we learned from Aducanumab?»
Samantha Budd Haeberlein, PhD

Vice President of Alzheimer’s Disease Discovery & Development, Biogen, Boston, USA

Samantha Budd Haeberlein, Ph.D., joined Biogen in February 2015 as Vice President of Alzheimer’s Disease Discovery & Development. Dr. Budd Haeberlein was previously Vice President of Translational Science at AstraZeneca where for fifteen years she led multi-disciplinary teams and functions across Research, Strategy, Translational Medicine and Clinical Development in the US, Canada and Sweden. Dr. Budd Haeberlein has a BSc (Hons.) and PhD in Biochemistry from the University of Dundee in Scotland, and conducted research at Brigham & Women’s Hospital Harvard Medical School in Boston, and at The Burnham Institute in San Diego.

«Anti-Tau Treatments: Potential, Challenges, and Progress»
Lennart Mucke, MD

Director of the Gladstone Institute of Neurological Disease and Joseph B. Martin Distinguished Professor of Neuroscience and Professor of Neurology at the University of California, San Francisco (UCSF), USA

Dr. Mucke is the founding director of the Gladstone Institute of Neurological Disease and holds joint appointments as the Joseph B. Martin Distinguished Professor of Neurosciences and Professor of Neurology at the University of California, San Francisco. He trained at the Free University Berlin, the Georg-August University and the Max Planck Institute for Biophysical Chemistry in Göttingen, the Cleveland Clinic, the Massachusetts General Hospital and Harvard Medical School, and The Scripps Research Institute. Dr. Mucke’s research focuses on mechanisms that result in functional deficits in Alzheimer’s disease and other cognitive disorders. He has generated informative experimental models of these conditions and used them to identify novel strategies to prevent neurological decline. For his contributions, Dr. Mucke has received the Potamkin Prize, MetLife Foundation Award for Medical Research, Kalid Iqbal Lifetime Achievement Award, Zenith Award, American Pacesetter Award, MERIT Award, and an Award for Excellence in Direct Teaching and Mentoring. He is a member of the American Neurological Association and the Association of American Physicians, chairs the Senate of the German Center for Neurodegenerative Diseases, and has served on the Medical and Scientific Advisory Council of the Alzheimer’s Association and on the National Advisory Council on Aging for the NIH.
«How BIG and GOOD Data are revolutionizing Neurodegenerative Disease Research»

Cristina Sampaio, MD, PhD
Chief Medical Officer, CHDI Foundation, Princeton, USA

Professor Cristina Sampaio joined CHDI Foundation as Chief Clinical Officer 6 years ago. She also holds the position of Professor of Clinical Pharmacology and Therapeutics at Faculdade de Medicina de Lisboa (currently on unpaid leave). At CHDI Professor Sampaio oversees an extensive portfolio of clinical projects ranging from experimental medicine, through biomarker and rating scale development to support drug development activities, to the development and maintenance of a global clinical research platform, Enroll-HD. Professor Sampaio spent 25 years of her career in academia where her primary research interests centered on clinical research methodology, clinical trial design, and related aspects of meta-research applied to movement disorders. Together with several colleagues she founded the Cochrane Movement Disorders Group (MovDisCRG) and became its coordinating editor in 1996, a position that she has shared with Professor Joao Costa from 2013 to 2018. She is now an Editor of The MovDisCRG. Professor Sampaio published 170 peer review papers and book chapters. From 1998 to 2011, Professor Sampaio was a member of the Committee on Human Medicinal Products and the Scientific Advice Working Party at the European Medicines Agency. During this period, she had a very active role in the development of the standards of regulatory science for CNS medicinal products in the European Union. She was rapporteur, coordinator, or assessor of over 400 medicinal products files submitted to EMA for licensing or scientific advice and she coordinated the first clinical biomarker qualification in the EU. Professor Sampaio obtained her MD in 1986 and her PhD in clinical pharmacology in 1997 from the University of Lisbon. She is a board-certified clinical pharmacologist, receiving neurological training in the Neurology department of Hospital St Maria in Lisbon. She was a staff member of the Movement Disorders Clinic from 1988 to 2011, President of the Portuguese Movement Disorders Society 2008−2012, and Chair of the Evidence-based Medicine Committee of the International Parkinson and Movement Disorder Society 2010−2014.

«Combination therapy in AD»

Daniel M. Skovronsky, MD, PhD
Senior Vice President of Clinical and Product Development at Eli Lilly and Company, Indianapolis, USA

Dr. Daniel M. Skovronsky, serves as Senior Vice President of Clinical and Product Development at Eli Lilly and Company. Dr. Skovronsky is responsible for developing the Lilly pipeline of molecules. He was the Founder, Chief Executive Officer and President at Avid Radiopharmaceuticals Inc. Dr. Skovronsky founded Avid Radiopharmaceuticals in 2004. Prior to establishing the firm, he served as Scientific Director of High Throughput Screening and Drug Discovery at the Center for Neurodegenerative Disease Research at the University of Pennsylvania. Dr. Skovronsky served as Vice President of Radiopharmaceutical Development at Theracor Pharmaceuticals. He served as a Member of Advisory Board of Safeguard Scientifics, Inc., until October 21, 2015 and previously served as a Member of its Life Sciences Advisory Board. Dr. Skovronsky serves as a Director of Avid Radiopharmaceuticals, Inc. He has more than 20 peer-reviewed publications and two NIH-funded grants on Alzheimer’s disease research. He is the recipient of numerous scientific and business awards and was named by the Philadelphia Business Journal as one of their Forty under Forty business leaders in the region. Dr. Skovronsky received the Ernst & Young Entrepreneur Of The Year 2009 Award in the Emerging Company category, which recognizes outstanding entrepreneurs who are building and leading dynamic, growing businesses. He trained as a resident in Pathology and completed a Fellowship in Neuropathology at the Hospital of the University of Pennsylvania. Dr. Skovronsky received his MD and PhD from the University of Pennsylvania and did BS degree in Molecular Biochemistry at Yale University.
Rachelle Doody MD, PhD

Rachelle Doody MD, PhD is the Global Head of Neurodegeneration in Pharma Development, Neuroscience for Roche Pharmaceutical Company and its US entity, Genentech. Prior to joining Genentech/Roche in September, 2016, Dr. Doody was the Effie Marie Cain Chair in Alzheimer’s Disease Research at Baylor College of Medicine, in Houston, Texas where she founded and directed the Alzheimer’s Disease and Memory Disorders Center over a period of 27 years.

While at Baylor, she published over 200 original research articles, served on the steering committees for the National Institutes of Health-funded Alzheimer’s Disease Cooperative Study (ADCS) and Alzheimer’s Disease Neuroimaging Initiative (ADNI), and the executive committee for the Alzheimer’s Therapeutic Research Institute (ATRI).

In her role as a practicing Neurologist, Dr. Doody was elected to Best Doctors in America from 1996-2016. She has received many awards from professional and civic groups, including Distinguished Alumni Award from Rice University in 2009 and Distinguished Faculty Award from Baylor College of Medicine in 2011.
<table>
<thead>
<tr>
<th>Time</th>
<th>Event</th>
</tr>
</thead>
<tbody>
<tr>
<td>4.00 - 4.30 p.m.</td>
<td>Opening Ceremony and CTAD Lifetime Achievement Award</td>
</tr>
<tr>
<td>4.30 - 5.00 p.m.</td>
<td>Keynote 1 - Blood biomarkers for AD clinical trials</td>
</tr>
<tr>
<td>5.00 - 5.50 p.m.</td>
<td>Symposium 1 - APECS trial of the BACE1 inhibitor verubecestat for prodromal Alzheimer’s disease</td>
</tr>
<tr>
<td>5.50 - 6.40 p.m.</td>
<td>Emerging Results From Other BACE Inhibitor Trials</td>
</tr>
<tr>
<td>6.40 - 7.00 p.m.</td>
<td>Late breaking oral communication</td>
</tr>
<tr>
<td>8.30 - 10.00 a.m.</td>
<td>Oral communications</td>
</tr>
<tr>
<td>10.00 - 10.30 a.m.</td>
<td>Coffee break and poster session</td>
</tr>
<tr>
<td>10.30 - 11.30 a.m.</td>
<td>Symposium 2 - Is BACE1 a suitable drug target for prevention and treatment of Alzheimer’s disease?</td>
</tr>
<tr>
<td>11.30 - 12.30 p.m.</td>
<td>Oral communications</td>
</tr>
<tr>
<td>12.30 - 13.00 p.m.</td>
<td>Lunch and poster session</td>
</tr>
<tr>
<td>1.30 - 2.00 p.m.</td>
<td>Keynote 2 - What have we learned from Aducanumab?</td>
</tr>
<tr>
<td>2.00 - 2.30 p.m.</td>
<td>Late breaking oral communications</td>
</tr>
<tr>
<td>2.30 - 3.30 p.m.</td>
<td>Symposium 3 - Clinical and Biomarker Updates from BAN2401 Study 201 in Early AD</td>
</tr>
<tr>
<td>3.30 - 4.30 p.m.</td>
<td>Oral communications</td>
</tr>
<tr>
<td>4.30 - 5.00 p.m.</td>
<td>Coffee break and poster session</td>
</tr>
<tr>
<td>5.00 - 6.00 p.m.</td>
<td>Symposium 4 - Aβ blood based test as surrogate markers of cortical amyloid pathology for clinical trials on Alzheimer’s disease.</td>
</tr>
</tbody>
</table>
### Friday, October 26

<table>
<thead>
<tr>
<th>Time</th>
<th>Session</th>
</tr>
</thead>
<tbody>
<tr>
<td>8.30 - 10.00 a.m.</td>
<td>Oral communications</td>
</tr>
<tr>
<td>10.00 - 10.30 a.m.</td>
<td>Coffee break and poster session</td>
</tr>
<tr>
<td>10.30 - 11.00 a.m.</td>
<td>Keynote 3 - Anti-Tau treatments: Potential, challenges, and progress</td>
</tr>
<tr>
<td>11.00 - 11.30 p.m.</td>
<td>Late Breaking communications</td>
</tr>
<tr>
<td>11.30 - 12.30 p.m.</td>
<td>Symposium 5 - Towards the Development of a Complete Solution for Patients with Alzheimer’s Disease (AD)</td>
</tr>
<tr>
<td>12.30 - 1.30 p.m.</td>
<td>Lunch and poster session</td>
</tr>
<tr>
<td>1.30 - 2.45 p.m.</td>
<td>Oral communications</td>
</tr>
<tr>
<td>2.45 - 4.00 p.m.</td>
<td>Late Breaking communications</td>
</tr>
<tr>
<td>4.00 - 4.30 p.m.</td>
<td>Coffee break and poster session</td>
</tr>
<tr>
<td>4.30 - 5.00 p.m.</td>
<td>Keynote 4 - Combination therapy in AD</td>
</tr>
<tr>
<td>5.00 - 6.00 p.m.</td>
<td>Symposium 6 - Endpoints for early Alzheimer’s disease clinical trials: Interpretation and application of the draft FDA guidance</td>
</tr>
</tbody>
</table>

### Saturday, October 27

<table>
<thead>
<tr>
<th>Time</th>
<th>Session</th>
</tr>
</thead>
<tbody>
<tr>
<td>8.30 - 9.15 a.m.</td>
<td>Presentation and panel discussion: AMBAR (Alzheimer’s Management By Albumin Replacement) Phase IIb/III Results</td>
</tr>
<tr>
<td>9.15 - 9.45 a.m.</td>
<td>Keynote 5 - How BIG and GOOD Data are revolutionizing neurodegenerative disease research</td>
</tr>
<tr>
<td>9.45 - 10.15 a.m.</td>
<td>Coffee break and poster session</td>
</tr>
<tr>
<td>10.15 - 11.15 a.m.</td>
<td>Oral communications</td>
</tr>
<tr>
<td>11.15 - 12.15 p.m.</td>
<td>Symposium 7 - Disclosure of Alzheimer’s risk biomarkers to cognitively normal older adults</td>
</tr>
<tr>
<td>12.15 - 1.15 p.m.</td>
<td>Lunch and poster session</td>
</tr>
<tr>
<td>1.15 - 3.45 p.m.</td>
<td>Oral communications</td>
</tr>
<tr>
<td>4.00 p.m.</td>
<td>End of conference</td>
</tr>
</tbody>
</table>
Wednesday, October 24

Opening Ceremony and CTAD Lifetime Achievement Award
Jacques Touchon, Paul Aisen, Bruno Vellas, Milt Weiner, Merce Boada, Jose Luis Molinuevo. The recipient of this year’s CTAD Lifetime Achievement Award is Rachelle S. Doody M.D., Ph.D. Global Head of Neurodegeneration, Roche, Basel - Switzerland for her work dedicated to academic and industrial research in AD clinical trials.

Keynote 1
Blood biomarkers for AD clinical trials
Introduction by: Bruno Vellas, MD, PhD
Randall Bateman, MD, PhD - Charles F. and Joanne Knight Distinguished Professor of Neurology at the Washington University School of Medicine, St. Louis, USA

Symposium 1 - APECS trial of the BACE1 inhibitor verubecestat for prodromal Alzheimer’s disease
Symposium moderator: Jeffrey L. Cummings, MD, ScD, Cleveland Clinic, Las Vegas, NV, USA
Communication 1: Results from the APECS trial
Michael F. Egan, MD, Tiffini Voss, MD, Yuki Mukai, MD, James Kost, PhD, Paul S Aisen, MD, Jeffrey L. Cummings, MD, ScD, Pierre N. Tariot, MD, Bruno Vellas, MD, PhD, Christopher H. van Dyck, MD, Ying Zhang, PhD, Wen Li, PhD, Christine Furtiet, BS, Enn Mahoney, BA, Lyn Harper Mozley, PhD, Yi Mo, PhD, Cyrille Sur, PhD, David Michelson, MD, Merck & Co, Inc, Kenilworth, NJ, USA; University of Southern California, San Diego, CA, USA; Cleveland Clinic, Las Vegas, NV, USA; Banner Alzheimer’s Institute, Phoenix, AZ, USA; Inserm U 1027, Alzheimer’s Disease Research and Clinical Center, Toulouse University Hospital, Toulouse, France; Yale University School of Medicine, New Haven, CT, USA
Communication 2: Panel discussion
Paul S. Aisen, MD, Maria C. Carrillo, PhD, Pierre N. Tariot, MD, Bruno Vellas, MD, PhD, University of Southern California, San Diego, CA, USA; The Alzheimer Association, Chicago, IL, USA; Banner Alzheimer’s Institute, Phoenix, AZ, USA; Inserm U 1027, Alzheimer’s Disease Research and Clinical Center, Toulouse University Hospital, Toulouse, France

Emerging Results From Other BACE Inhibitor Trials
Discussion of BACEi Trial Findings: Challenges and Opportunities
CoChairs: Reisa Sperling, MD, Brigham & Women’s Hospital, Maria C. Carrillo, PhD, Alzheimer’s Association
Presentation 1: Preliminary analyses of data from an ongoing trial of atabecestat in preclinical Alzheimer’s disease.
Gary Romano, MD, PhD Janssen R&D, USA
Presentation 2: LBI - Results from the phase 2 NAVIGATE-AD clinical trial evaluating LY3202626 BACE inhibitor in patients with mild Alzheimer’s disease dementia.
Albert C Lo, Cynthia Duggan Evans, Michele Mancini, Qun Lin, Hong Wang, Peng Liu, Sergey Shcherbinin, Ming Lu, Arnaud Charil, Brian A Willis, Michael Irizarry
Eli Lilly and Company, Indianapolis, IN, USA; Avid Radiopharmaceuticals, a wholly owned subsidiary of Eli Lilly and Company, Indianapolis, IN, USA; Eli Lilly and Company, Indianapolis, IN, USA; now at Eisai Inc, Woodcliff Lake, NJ
Panel discussion: Reisa Sperling, MD, Brigham & Women’s Hospital, Maria C. Carrillo, PhD, Alzheimer’s Association, Mark Mintun, MD, Eli Lilly & Co, Michael Egan, MD, Merck & Co, Gary Romano, MD, PhD Janssen R&D, Ana Graf, MD, Novartis & Amgen, Inc, Johan Luthman, MD, Eisai Co., Ltd, John Sims, MD, Lilly/AD Alliance

Late Breaking Oral communication
Chair: Maria Carrillo, PhD
LB2 - TOMMORROW: a trial to delay the onset of MCI due to AD and qualify a genetic biomarker algorithm: topline results
Robert Alexander, MD, Daniel K. Burns, PhD, Kathleen A. Welsh-Bohmer, PhD, Carl Chiang, PhD, Meredith Culp, BS, Janet O’Neill, MBA, Brenda L. Plassman, PhD, Craig Metz, PhD, Deborah Yarbrough, MS, MBA, Jingtao Wu, PhD, Rebecca Evans, MD, Kumar Budur, MD, Stephen K. Brannan, MD, Ann M. Saunders, PhD, Emiliano Ratti, PhD, for the TOMMORROW Study Investigators
Takeda Development Center Americas, Inc, Cambridge, MA, USA; Zinfandel Pharmaceuticals, Inc, Durham, NC, USA; Duke University Bryan ADRC, Durham, NC, USA; Takeda Development Center Americas, Inc, Deerfield, IL, USA
Oral communications

8.30 - 10.00 a.m.

Chairs: Suzanne Craft, MD, PhD and Rachel Schindler, PhD

8.30 - 8.45 a.m.

OC1 - Phase 2a trial of AZD0530 evaluating 18F-FDG PET, safety, and tolerability in mild Alzheimer’s dementia
Christopher H. van Dyck, MD,1 Haakon B. Nygaard, MD, PhD,2 Kewei Chen, PhD,2 Michael C. Donohue, PhD,2 Rema Raman, PhD,2 Robert A. Rissman, PhD,2,3 James B. Brewer, MD, PhD,2 Robert A. Koeppe, PhD,4 Tiffany W. Chow, MD,4 Michael S. Rafii, MD,4 R. Scott Turner, MD, PhD,4 Jeffrey A. Kaye, MD,4 Seth A. Gale, MD,4 Eric M. Reiman, MD,4 Paul S. Aisen, MD,4, Stephen M. Strittmatter, MD, PhD2,7

1Yale University School of Medicine, New Haven, USA 2The University of British Columbia, Vancouver, Canada 3Banner Alzheimer’s Institute, Phoenix, Arizona, USA 4Alzheimer’s Therapeutic Research Institute, University of Southern California, San Diego, USA 5University of California San Diego, La Jolla, USA 6University of Michigan, Ann Arbor, USA 7Georgetown University, Washington, DC, USA 8Oregon Health & Science University, Portland, USA 9Harvard Medical School, Boston, USA

8.45 - 9.00 a.m.

OC2 - Primary results from a phase II/III trial of intranasal insulin: A novel multi-target molecule and delivery mode for AD therapeutics
Suzanne Craft, PhD1, Rema Raman, PhD2, Tiffany Chow, MD2, Michael S Rafii, MD2, Robert A. Rissman, PhD2, James B. Brewer, MD2, Michael Donohue, PhD2, Chung-Kai Sun, MS2, Kelly Harless2, Devon Gessert2, Paul S. Aisen, MD2

1Wake Forest School of Medicine, Winston-Salem, USA, 2University of Southern California, Los Angeles, USA

9.00 - 9.15 a.m.

OC3 - Phase 3 clinical trial for a novel and multi-targeted oligosaccharide in patients with mild-moderate AD in China
Shifu Xiao, MD1, Zhenxin Zhang, MD2, Meiyu Geng, PhD3, GV-971 Study Group

1Department of Gerontology, Shanghai Mental Health Center, Shanghai Jiao Tong University, Shanghai, China 2Peking Union Medical College Hospital, Beijing, China 3State Key Laboratory of Drug Research, Shanghai Institute of Materia Medica, Chinese Academy of Sciences, Shanghai, China

9.15 - 9.30 a.m.

OC4 - Active Anti-amyloid Immunotherapy with UB-311 Vaccine: Design, baseline data and study update of a Phase IIa, Randomized, Double-Blind, Placebo-Controlled, 3-Arm Parallel-Group, Multicenter Study
Ajay Verma, Hui Jing Yu, Hui-Chen Chen, and Chang Yi Wang on behalf of the UB-311 Phase IIa Study Team

United Neuroscience, Inc. Hauppauge, NY, USA

9.30 - 9.45 a.m.

OC5 - Elenbecestat in MCI-to-moderate Alzheimer’s disease: Safety and effectiveness as measured by amyloid PET and the ADCOMS clinical endpoints
Shau Yu Lynch, PhD1, June Kaplow, PhD1, Jim Zhao, MS, MM1, Shobha Dhadda, PhD1, Johan Luthman, PhD, DDS1, Bruce Aiba, PhD1

1Eisai Inc., Woodcliff Lake, NJ, USA

9.45 - 10.00 a.m.

OC6 - ALLOPREGNANOLONE regenerative therapeutic for mild cognitive impairment and mild Alzheimer’s disease: Phase Ib/2a outcomes update
Robertia D. Brinton, PhD1, Gerson D. Hernandez, MD, MPH1, Naoko Kono, MPH1, Claudia M. Lopez, BS1, Christine Solinsky, PhD1, Kathleen Rodgers, PhD1, Jin Gaehn, PhD1, Dogu Aydogan, PhD1, Yonggang Shi, PhD1, Sonia Pawluczyk, MD1, Meng Law, MD1, Wendy Mach, PhD1, Lon Schneider, MD, MS5

1Center for Innovation in Brain Science, University of Arizona, Tucson, Arizona, USA 2Department of Preventive Medicine, University of Southern California, Los Angeles, CA, USA 3School of Pharmacy, University of Southern California, Los Angeles, CA, USA, 4USC Institute for Neuroimaging and Informatics, University of Southern California, Los Angeles, CA, USA 5Department of Psychiatry & The Behavioral Sciences, Keck School of Medicine of the University of Southern California, Los Angeles, CA, USA

10.00 - 10.30 a.m.

Coffee break and poster session
Symposium 2
Is BACE1 a suitable drug target for prevention and treatment of Alzheimer’s disease?

Symposium moderator: Randall J. Bateman, MD, Department of Neurology, St. Louis, MO, USA

Communication 1: Physiological substrates of BACE1: safety issues or biomarkers?
Stefan F. Lichtenthaler, PhD German Center for Neurodegenerative Diseases (DZNE) and Technical University of Munich (TUM), Germany

Communication 2: Secretase inhibitors in AD prevention trials: optimizing success and mitigating risk.
Eric McDade, DO, Department of Neurology, St. Louis, MO, USA

Communication 3: Considerations and lessons learned for the design and implementation of AD clinical trials evaluating BACE inhibitors.
Bruce Albala, PhD and Johan Luthman, PhD; Eisai, Inc, NJ, USA

Oral communications

11.30 - 12.30 p.m.

Chair: Lon Schneider, MD

11.30 - 11.45 a.m.
OC7 - Impact of Amyloid PET on the management of cognitively impaired patients: Results from the IDEAS study
Gil D. Rabinovici,1 Constantine Gatsonis,2 Charles Apgar,3 Kiran Chaudhary,1 Ilana Gareen,1 Lucy Hanna,1 James Hendrix,3, Bruce E. Hillner,3, Cynthia Olson,1 Ort Leisman-Segev,1 Justin Romanoff,2 Barry A. Siegel,2 Rachel A. Whitmer,3 Maria C. Carrillo,4 on behalf of the IDEAS investigators.
1Department of Neurology, University of California San Francisco, 2Center for Statistical Sciences, Brown University, 3American College of Radiology, 4Alzheimer’s Association

11.45 - 12.00 p.m.
OC8 - Safety and efficacy of estrogen receptor-β targeted PhytoSERM formulation for cognitive complaints and vasomotor symptoms: Phase 1b/2a trial outcomes
Lon S. Schneider, MD,1 Gerson Hernandez MD MPH1, Liqun Zhao PhD1, Sonia Pawluczyk MD,1 Wendy J. Mack, PhD1, Roberta D. Brinton PhD2
1Keck School of Medicine of the University of Southern California, Los Angeles, USA, 2University of Arizona, Center for Innovation in Brain Science, Tucson, USA

12.00 - 12.15 p.m.
OC9 - Interim safety and efficacy results of pilot trial of GM-CSF/sargramostim in mild to moderate AD
Huntington Potter, PhD Jonathan H. Woodcoch, Timothy Boyd, Stefan H. Sillau, Thomas Borges, Brianne M. Bettcher, Joseph Daniels
Rocky Mountain Alzheimer’s Disease Center, Department of Neurology University of Colorado School of Medicine

12.15 - 12.30 p.m.
OC10 - Untangled – peptide-based inhibitors of tau aggregation as a potential treatment for Alzheimer’s disease
David Allison PhD1,2, Anthony Aggidis MSc1, Nigel Fullwood PhD1, Mark Taylor PhD1,2, Penny Foulds PhD1,2, Shoona Vincent PhD1, Mark Dale MD1
1Division of Biomedical and Life Sciences, Faculty of Health and Medicine, Lancaster University, Lancaster, UK, 2Peptide Innovations Limited, Affiliated Company of MAC Research, Blackpool, UK

12.30 - 1.30 p.m.
Lunch and poster session

1.30 - 2.00 p.m.
Keynote 2
What have we learned from Aducanumab?

Introduction: Jacques Touchon, MD, PhD
Samantha Budd Haeberlein, PhD - Vice President of Alzheimer’s Disease Discovery & Development, Biogen, Boston, USA
Late Breaking Oral communications

Chair: Reisa Sperling, MD, PhD

2.00 - 2.15 p.m.

LB3 - Lu AF20513, an active immunotherapy against amyloid beta, in development for patients in early stages of Alzheimer’s disease
Bernt Sperling, MD, Lars Østergaard Pedersen, PhD, Neli Boneva, MD, Dorthe Daugaard, MD, Yudong Zhao, PhD
H. Lundbeck A/S, Valby, Denmark

2.15 - 2.30 p.m.

LB4 - Predictors of [18F]Flortaucipir (tau) load in Alzheimer’s disease and other neurodegenerative disorders
Oskar Hansson, MD, PhD, Gil D. Rabinovici MD, PhD, Chul H. Lyoo, MD, PhD & Rik Ossenkoppele, PhD
1Lund University, Clinical Memory Research Unit, Lund, Sweden, 2Memory Clinic, St.åne University Hospital, Malmo, Sweden, 3Department of Neurology, University of California San Francisco, San Francisco, USA, Memory and Aging Center, 4Department of Neurology, Gangnam Severance Hospital, Yonsei University College of Medicine, Seoul, South Korea, 5VU University Medical Center, Department of Neurology and Alzheimer Center, Amsterdam Neuroscience, Amsterdam, the Netherlands

2.30 - 3.30 p.m.

Symposium 3
Clinical and Biomarker Updates from BAN2401 Study 201 in Early AD

Communication 1: BAN2401 Study 201 Study Design and Topline Results
Jeffrey L. Cummings, MD, ScD, Cleveland Clinic Lou Ruvo Center for Brain Health, Las Vegas, NV, USA

Communication 2: Pre-specified Subgroup Analysis in BAN2401 Study 201
Chad J. Swanson, PhD, Eisai Inc.

Communication 3: Effect of BAN2401 on Underlying AD Pathophysiology
Chad J. Swanson, PhD, Eisai Inc.

Communication 4: Totality of Results from BAN2401 Study 201
Jeffrey L. Cummings, MD, ScD, Cleveland Clinic Lou Ruvo Center for Brain Health, Las Vegas, NV, USA

Q&A followed by a panel discussion: Jeffrey L. Cummings, MD, ScD, Chad J. Swanson, PhD, Akihiko Koyama, PhD, Eisai Inc.

3.30 - 4.00 p.m.

Oral communications
Chair: Michael Egan, MD

3.30 - 3.45 p.m.

OC11 - Safety and efficacy of lemborexant for sleep-wake regulation in patients with irregular sleep wake rhythm disorder and Alzheimer’s disease dementia
Margaret Moline, PhD, Mohammad Bsharat, PhD, Manuel Kemethofer, MSc, Gleb Filippov, MD, PhD, Naoki Kubota, MPHarm, Patricia Murphy, PhD
1Eisai, Inc., Woodcliff Lake, USA, 2The Siesta Group, Vienna, Austria, 3Eisai Co. Ltd., Tokyo, Japan

3.45 - 4.00 p.m.

OC12 - Tau PET imaging as a screening tool for clinical trials of disease modifying therapies
Adam S Fleisher, MD, Michael J Pontecorvo, MD, Michael D Devous, MD, Ming Lu, Sergey Schcherbinin, Anupa K Arora, Mark A Mintun
1Eli Lilly & Co, Indianapolis, IN, USA, 2Avid Radiopharmaceuticals, Inc., Philadelphia, PA, USA

4.00- 4.15 p.m.

OC13 - BACE inhibition by verubecestat produces a rapid, non-progressive reduction in brain and hippocampal volume in Alzheimer’s disease
Cyrille Sur, PhD, James Kost, PhD, David Scott, PhD, Katarzyna Adamczuk, PhD, Nick C Fox, PhD, Jeffrey Cummings, MD, ScD, Pierre Tariot, MD, Paul Aisen, MD, Bruno Vellas, MD, PhD, Tiffini Voss, MD, Yuki Muta, MD, David Michelson, MD, Michael Egan, MD
1Merck & Co., Inc, Kenilworth, NJ, USA, 2Bioclinica, Newark, CA, USA, 3University College London, London, UK, 4Banner/Alzheimer’s Insitute, Phoenix, AZ, USA, 5University of California San Diego, San Diego, CA, USA, 6Geronpopale, Toulouse University Hospital, Toulouse, France
Symposium 4

Aβ blood based test as surrogate markers of cortical amyloid pathology for clinical trials on Alzheimer’s disease.

Moderator: Pedro Pesini PhD, Araclon Biotech-Grifols, Spain.

Communication 1: Developing Aβ blood based test into screening tools for clinical trials in early stages of AD
Victor L. Villemagne, M.D., Dept of Molecular Imaging & Therapy, Austin Health, Dept of Medicine, The University of Melbourne.

Communication 2: Plasma ratio of total Aβ42 to total Aβ40 in amnestic MCI patients is associated with FDG-PET, amyloid-PET, CSF and the risk of progression to AD dementia.
Anne Fagan PhD, Washington University, Saint Louis, Missouri.

Communication 3: Total Aβ42 to total Aβ40 as a biomarker of cortical amyloid burden in subjects with subjective memory complaints.
Agustín Ruiz MD PhD, Research Director, Research Center and Memory Clinic, Fundació ACE, Institut Català de Neurociències Aplicades, Universitat Internacional de Catalunya (UIC), Barcelona, Spain.

Coffee break and poster session
**Oral communications**

8.45 - 9.00 a.m.  
**OC16 - Rationale and design of a prospective, randomized, double-blind, dose-comparison safety and tolerability study of GRF6019 in mild-to-moderate Alzheimer’s disease**  
Jonas Hannestad, MD PhD 1, Ian Gallager, PhD 1, Katie Koborsi, MS 1, S. Sakuta Minami, PhD 1, Darby Stephens, MBA 1, Vittoria Kheifets, PhD 1, Steven Braithwaite, PhD 1  
1Alkahest, Inc., San Carlos, USA

9.00 - 9.15 a.m.  
**OC17 - Machine learning algorithm helps identify non-diagnosed prodromal Alzheimer’s disease patients in general population**  
Olga Uspenskaya-Cadoz 1, Chaitanya Alamuri 2, Sam Khinda 3, Yuliya Nigmatullina 2, Carolina Rubel 3, Lanhui Wang 2, Mengting Yang 2, Tao Cao 2, Nitih Kaya 2  
1IQVIA CNS Center of Excellence, 2IQVIA Analytics Center of Excellence, 3IQVIA Project Leadership

9.15 - 9.30 a.m.  
**OC18 - ABBV-8E12, a humanized anti-tau monoclonal antibody, for treating early Alzheimer’s disease: Updated design and baseline characteristics of phase 2 study**  
Hana Florian, MD 1, Steven E. Arnold, MD 2, Randall J. Bateman, MD 3, Joel B. Braunstein, MD, MBA 4, Kumar Budur, MD 1, Diana R. Kerwin, MD 1, Holly Soares, PhD 1, Debi Wang, PhD 1, David M. Holtzman, MD 1  
1AbbVie, Inc., North Chicago, IL, USA, 2Massachusetts General Hospital, Boston, MA, USA, 3Washington University, St. Louis, MO, USA, 4C2N Diagnostics LLC, St. Louis, MO, USA, 5Texas Health Presbyterian Hospital, Dallas, TX, USA

9.30 - 9.45 a.m.  
**OC19 - Assessment of clinical meaningfulness of endpoints in the Generation Program by the Insights to Model Alzheimer’s Progression in real life (IMAP) study**  
A. Graf 1, V. Risson 1, S. Tziveleki 1, A. Gustavsson 1, V. Bezyaht 1, A. Caputol 1, P. N. Tariot 1, J. B. Langbaum 1, C. Lopez Lopez 1, V. Viglietta 1  
1Novartis Pharma AG, 2Amgen, Inc., 3Quantify Research, 4Banner Alzheimer’s Institute

10.00 - 10.30 a.m.  
**OC20 - Characterizing clinical severity among biomarker positive individuals: Applying the 2018 NIA-AA research criteria for Alzheimer’s disease to four large study cohorts.**  
Roos J. Jutten, MSC 1, Rebecca E. Amaregllo, PhD 2, Gad A. Marshall, MD, PhD 2, Doreen M. Rentz, PhD 2, Wiesje M. Van der Filer, PhD 1, Philip Scheltes, MD, PhD 1, Keith A. Johnson 1, Reisa A. Sperling, MD 2, Sietske A.M. Siktens, PhD 1, Kathryn V. Papp, PhD 2  
1Alzheimer Center, VU University Medical Center, Amsterdam, The Netherlands, 2Department of Neurology, Brigham and Women’s Hospital, Harvard Medical School, Boston MA, USA, 3Department of Neurology, Massachusetts General Hospital, Harvard Medical School, Boston MA, USA, 4Department of Radiology, Massachusetts General Hospital, Harvard Medical School, Boston MA, USA

**Coffee break and poster session**

10.30 - 11.00 a.m.  
**Keynote 3**  
**Anti-Tau treatments: Potential, challenges, and progress**  
Introduction: Paul Aisen, MD  
Lennart Muische, MD Director of the Gladstone Institute of Neurological Disease and Joseph B. Martin Distinguished Professor of Neuroscience and Professor of Neurology at the University of California, San Francisco (UCSF), USA
11.00 - 11.30 a.m. Late Breaking communication and panel discussion

**LB5 - 18F-AV-1451-A16: A clinico-pathological study of the correspondence between flortaucipir PET imaging and post-mortem assessment of tau pathology**

Mark A. Mintun1, Adam S. Fleisher1, Michael D. Devous2, Ming Lu2, Anupa K. Arora2, Thomas G. Beach3, Thomas J. Montine4, Michael J. Pontecorvo5

Eli Lilly and Company, Indianapolis, IN, USA; 2Avid Radiopharmaceuticals, Inc., Philadelphia, PA, USA; 3Civin Laboratory for Neuropathology, Banner Sun Health Research Institute, Phoenix, AZ, USA; 4Department of Pathology, Stanford University, Stanford, CA, USA

11.30 - 12.30 p.m. Symposium 5

Towards the Development of a Complete Solution for Patients with Alzheimer’s Disease (AD)

Moderator: Rachelle Doody, MD, PhD1,2

1Genentech, Inc., South San Francisco, CA, USA; 2F. Hoffmann-La Roche Ltd, Basel, Switzerland

Communication 1: Self-detection of cognitive problems: benefits and challenges of online and digital tools

Mary Sano, PhD1,2

1Director, Alzheimer’s Disease Research Center, Icahn School of Medicine at Mount Sinai, New York, NY; 2Department of Psychiatry, Icahn School of Medicine at Mount Sinai, New York, NY, USA

Communication 2: Enhancing earlier and more reliable diagnosis of AD through the use of emerging biomarkers

Christopher van Dyck, MD1,2

1Alzheimer’s Disease Research Unit, Yale University School of Medicine, New Haven, CT, USA; 2Department of Psychiatry, Yale University School of Medicine, New Haven, CT, USA

Communication 3: Moving towards combination therapies for disease modification in AD

Dennis J. Selkoe, MD1,2

1Ann Romney Center for Neurologic Diseases, Brigham and Women’s Hospital, Boston, MA, USA; 2Harvard Medical School, Boston, MA, USA

12.30 - 1.30 p.m. Lunch and poster session

1.30 - 2.45 p.m. Oral communications

Chairs: Sandrine Andrieu, MD, PhD and Gregory Klein, PhD

1.30 - 1.45 p.m. Oral communications

**OC21 - Extension and validation of an amyloid staging model: Associations with clinical measures**

Lyduine Collij, MSc1; Fiona Heeman, MSc1; Gemma Salvadó Blasco, MSc2; Elles Konijnenberg, MD, MSc2; Anoult den Braber, PhD3; Maqsood Yaqub, PhD4; Pieter Jelle Visser, MD, PhD1; Alle Meije Wink, Ir, PhD1; Philip Scheltens, MD, PhD3; Ronald Boellaard, PhD3; Bart N.M. van Berckel, MD, PhD1; Juan Domingo Gispert López, PhD4; Mark Schmidt, MD, PhD5; Frederik Barkhof, MD, PhD1,6; Isadora Lopes Alves, PhD1

1Dept. of Radiology and Nuclear Medicine, VU University Medical Center, Amsterdam, The Netherlands; 2Barcelonaβeta Brain Research Center, Barcelona, Spain; 3Alzheimer Center and Dept. of Neurology, VU University Medical Center, Amsterdam, The Netherlands; 4Dept. of Biological Psychology, VU University Amsterdam, The Netherlands; 5Janssen Pharmaceutica, Beerse, Belgium; 6Institute of Neurology and Healthcare Engineering, University College London, London, United Kingdom

1.45 - 2.00 p.m. Oral communications

**OC22 - Twenty-four-month amyloid PET results of the gantenerumab high-dose SCarlet and Marguerite RoAD open- label extension studies**

Gregory Klein, PhD1; Paul Delmar, PhD1; Carsten Hofmann, PhD2; Danielle Abi-Saab, PsyD2; Mirjana Andjeljovic, PhD2; Smiljana Ristic, MD2; Nicola Voyle, PhD2; Jacob Hesterman, PhD2; John Seibyl3; Ken Marek4; Ferenc Martenyi, MD, PhD5; Monika Baudler, PhD6; Paulo Fontoura, MD, PhD7; Rachelle Doody, MD, PhD7

1Roche Pharma Research and Early Development, Basel, Switzerland; 2Roche / Genentech Product Development, Neuroscience, Basel, Switzerland; 3Roche Products Ltd, Welwyn Garden City, UK; 4InviCRO, LLC, Boston, MA, US; 5Roche Products Ltd, Welwyn Garden City, UK; 6Institute of Neurology and Healthcare Engineering, University College London, London, United Kingdom; 7Roche Products Ltd, Welwyn Garden City, UK
Friday, October 26

2.00 - 2.15 p.m.  **OC23** - Multi-domain interventions to prevent dementia: from FINGER to World-Wide FINGERS
Mia Kiivipelo\textsuperscript{1,2,3}, On behalf of the World-Wide FINGERS network
\textsuperscript{1}Karolinska Institute, Department of Clinical Geriatrics, Center for Alzheimer Research, Stockholm, Sweden, \textsuperscript{2}University of Eastern Finland, Institute of Clinical Medicine/Neurology, Kuopio, Finland, \textsuperscript{3}Imperial College London, NEA, School of Public Health, UK

2.15 - 2.30 p.m.  **OC24** - Identifying risk of cognitive decline in Mild Cognitive Impairment for population enrichment of clinical trials
Christian Dansereau\textsuperscript{1,2}, PhD, Maor Zaltzhendler\textsuperscript{1}, MEng, Angela Tam\textsuperscript{2,3}, MSc, Pedro Rosa-Neto\textsuperscript{1}, MD, PhD, Serge Gauthier\textsuperscript{2,4}, MD, Pierre Bellec\textsuperscript{2,4}, PhD
\textsuperscript{1}Perceiv Research Inc., Montreal, CAN, \textsuperscript{2}Centre de Recherche de l’Institut Universitaire de Gériatrie de Montréal, CAN, \textsuperscript{3}Douglas Mental Health University Institute, McGill University, CAN, \textsuperscript{4}Department of Computer Science and Operations Research, University of Montreal, CAN

2.30 - 2.45 p.m.  **OC25** - Study update on XanADu: Phase II study of Xanamem\textsuperscript{TM} in subjects with mild dementia due to Alzheimer’s disease
Craig Ritchie, MD, PhD, Centre for Dementia Prevention, University of Edinburgh, UK

Late Breaking communications

2.45 - 4.00 p.m.

2.45 - 3.00 p.m.  **LB6** - Age and ApoE genotype-specific population frequencies of cerebral β-amyloidosis and hippocampal atrophy among cognitively normal individuals in CHARIOT-PRO
Hany Rofael, MD, PhD\textsuperscript{1}, Gerald Novak MD\textsuperscript{1}, Luc Bracoud MSc\textsuperscript{2}, Nandini Raghavan PhD\textsuperscript{1}, Ziad Saad PhD\textsuperscript{1}, S Einstein MS\textsuperscript{1,2}, Robert Brashear\textsuperscript{1}, David Scott PhD\textsuperscript{1}, Joel Scherer PhD\textsuperscript{1}, Celeste de Jager PhD\textsuperscript{1,5}, Chi Udeh-Momoh, PhD\textsuperscript{1}, the Alzheimer’s Disease Neuroimaging Initiative (ADNI), and Lefkos Middleton MD\textsuperscript{5}
\textsuperscript{1}Cleveland Clinic Lou Ruvo Center for Brain Health, Las Vegas, NV, USA, \textsuperscript{2}Tv Therapeutics LLC, High Point, NC, USA, \textsuperscript{3}Cato Research LTD, Durham, NC, USA, \textsuperscript{4}Climinec LLC, Longboat Key, FL, USA

3.00 - 3.15 p.m.  **LB7** - Safety and efficacy results from the phase 3, multicenter, 18-month STEADFAST trial of azeliragon in participants with mild Alzheimer’s disease
Marwan Sabbagh, MD\textsuperscript{1}, Imogene Dunn, PhD\textsuperscript{1}, Ann Gooch, PhD\textsuperscript{1}, Tom Soeder, MS\textsuperscript{1}, Karl Kieburz, MD, MPH\textsuperscript{1}, Carmen Valcarce, PhD\textsuperscript{1}, Larry D Altstiel, MD, PhD\textsuperscript{2}, Aaron Hurstein, PharmD\textsuperscript{2}
\textsuperscript{1}Cleveland Clinic Lou Ruvo Center for Brain Health, Las Vegas, NV, USA, \textsuperscript{2}Tv Therapeutics LLC, High Point, NC, USA

3.15 - 3.30 p.m.  **LB8** - Aducanumab titration dosing regimen: 36-month analyses from PRIME, a Phase Ib study in patients with early Alzheimer’s disease
Samantha Budd Haeberlein, PhD\textsuperscript{1}, Carmen Castirillo-Viguera, MD\textsuperscript{1}, Tianle Chen, PhD\textsuperscript{1}, John O’Gorman, PhD\textsuperscript{1}, Raj Rajagovindan, PhD\textsuperscript{1}, Dathshaben Patel, PhD\textsuperscript{1}, Philipp von Rosenstiel, MD\textsuperscript{1}, Guanfang Wang, PhD\textsuperscript{1}, Spyros Chaltiras, MD\textsuperscript{1}, Le Anne Shordors PharmD\textsuperscript{1}, Claudia Prada, MD\textsuperscript{1}, Christoph Hoch, MD\textsuperscript{1}, Roger M Nitsch, MD\textsuperscript{1}, Alfred Sandrock, MD, PhD\textsuperscript{1,5}
\textsuperscript{1}Biogen, Cambridge, MA, USA, \textsuperscript{2}Biogen, Maidenhead, UK, \textsuperscript{3}Cybel, Cambridge, MA, USA, \textsuperscript{4}Neurimmune, Schlieren-Zurich, and University of Zurich, Switzerland

3.30 - 3.45 p.m.  **LB9** - Longitudinal 148-Week Extension Study for ANAVEX\textsuperscript{®}2-73 Phase 2a Alzheimer’s Disease Demonstrates Maintained Activities of Daily Living Score (ADCS-ADL) and Reduced Cognitive Decline (MMSE) for Patient Cohort on Higher Drug Concentration and Confirms Role of Patient Selection Biomarkers
Harald Hampel, MD, PhD\textsuperscript{1}, Mohammad Afshar, MD, PhD\textsuperscript{1}, Frédéric Parmentier, PhD\textsuperscript{1}, Coralie Williams, MSc\textsuperscript{1}, Adrien Etcheto, MSc\textsuperscript{2}, Federico Goodsaid, PhD\textsuperscript{1}, Christopher U Missling, PhD\textsuperscript{1}
\textsuperscript{1}Department of Neurology, Sorbonne University, Paris, France, \textsuperscript{2}Ariana Pharma, Paris, France, \textsuperscript{3}Regulatory Pathfinders LLC, San Francisco, CA, \textsuperscript{4}Anavex Life Sciences Corp., New York, NY

3.45 - 4.00 p.m.  **LB10** - Predictive performance of CSF and imaging AD biomarkers in ADNI1/GO/2 MCI participants using the NIA-AA research framework
Leslie M Shaw, PhD\textsuperscript{1}, Michael Figurski, PhD\textsuperscript{1}, Susan Landau, PhD\textsuperscript{1}, William Jagust, MD\textsuperscript{1}, Clifford R Jack, MD\textsuperscript{1}, Paul S Aisen, MD\textsuperscript{1}, Ronald C Petersen, MD\textsuperscript{1}, Michael W Weiner, MD\textsuperscript{1}, John Q Trojanowski, MD, PhD\textsuperscript{1}
\textsuperscript{1}University of Pennsylvania, Philadelphia, USA, \textsuperscript{2}University of California, Berkeley, Berkeley, USA, \textsuperscript{3}Mayo Clinic, Rochester, USA, \textsuperscript{4}University of Southern California, San Diego, USA, \textsuperscript{5}University of California, San Francisco, San Francisco, USA
Friday, October 26

4.00 - 4.30 p.m.  
Coffee break and poster session

4.30 - 5.00 p.m.  
**Keynote 4**  
Combination therapy in AD  
*Introduction: Jeffrey Cummings, MD, PhD*  
Daniel M. Showroonsky, MD, PhD - Senior Vice President of Clinical and Product Development at Eli Lilly and Company, Indianapolis, USA

5.00 - 6.00 p.m.  
**Symposium 6**  
Endpoints for early Alzheimer’s disease clinical trials: Interpretation and application of the draft FDA guidance  
*Symposium moderator: Eric Siemers, MD, Cogstate Ltd, New Haven, CT, USA*  

**Communication 1: Clinical Endpoints in Stage 1, 2 and 3 Disease**  
Reisa Sperling, MD1, Ronald C. Petersen, MD, PhD2, Gary Romano, MD, PhD3, Paul Maruff, PhD4  
1Department of Neurology, Brigham and Women’s Hospital, Boston, MA, USA, 2Department of Neurology, Mayo Clinic, Rochester, MN, USA, 3Janssen R&D, Titusville, NJ, USA, 4Cogstate Ltd, Melbourne, Victoria, Australia

**Communication 2: Biomarkers in Stage 1, 2 and 3 Disease**  
Samantha Budd Haeberlein PhD1, Jose Luis Molinuevo, MD, PhD2, Christopher C. Rowe, PhD3, Maria C. Carrillo PhD4, Clifford R. Jack, Jr., MD5  
1Biogen, Cambridge, MA, USA, 2BarcelonaBeta Brain Research Center, Pasqual Maragall Foundation and Hospital Clinic-IDIBAPS, Barcelona, Spain, 3Department of Molecular Imaging, Austin Health, University of Melbourne, Melbourne, Australia, 4Alzheimer’s Association, Chicago, IL, USA, 5Department of Radiology, Mayo Clinic, Rochester, MN, USA

**Communication 3: Approaches to Establishing the Meaningfulness of Treatment Effects**  
Chris J. Edgar, PhD1, George Vradenburg, JD2, Jason Hassenstab, PhD3  
1Cogstate Ltd London, UK, 2UsAgainstAlzheimer’s and Alzheimer’s Disease Patient and Caregiver Engagement (AD PACE), Chevy Chase, MD, USA, 3Department of Neurology, Washington University School of Medicine, St. Louis, MO, USA

4.30 - 5.00 p.m.  
**Keynote 4**  
Combination therapy in AD  
*Introduction: Jeffrey Cummings, MD, PhD*  
Daniel M. Showroonsky, MD, PhD - Senior Vice President of Clinical and Product Development at Eli Lilly and Company, Indianapolis, USA
8.30 - 9.15 a.m. Presentation and panel discussion:
**AMBAR (Alzheimer’s Management By Albumin Replacement) Phase IIb/III Results**

*Presentation by Antonio Páez MD, Grifols S.A., Barcelona, Spain*

*Followed by Panel Discussion with:*

- Mercè Boada MD, PhD, Fundació ACE, Universitat Internacional de Catalunya, Barcelona, Spain
- Oscar L. Lopez MD, PhD, University of Pittsburgh School of Medicine, Pittsburgh, PA, USA
- Zbigniew M. Szczepiorkowski, MD, PhD, Dartmouth Hitchcock Medical Center, Lebanon, NH, USA
- Bruno Vellas, MD, PhD, University Hospital, Toulouse, France

9.15 - 9.45 a.m. Keynote 5

**How BIG and GOOD Data are revolutionizing neurodegenerative disease research**

*Introduction: Bruno Vellas, MD, PhD*

*Cristina Sampaio, MD, PhD - Chief Medical Officer, CHDI Foundation, Princeton, USA*

9.45 - 10.15 a.m. Coffee break and poster session

10.15 - 11.15 a.m. Oral communications

**OC26 - First longitudinal evaluation of the tau tracer [18F]MK-6240 for the use in clinical trials**

*Tharick A. Pascoal MD, Sulantha Mathotaarachchi MSc, Mira Chamoun PhD, Joseph Therriault BSc, Robert Hopewell PhD, Cassan Massarweh PhD, Andrea L. Benedet, MSc, BSc, Min Su Kang, Jean-Paul Soucy MD, Serge Gauthier, MD, Pedro Rosa-Neto, MD, PhD*

*Translational Neuroimaging Laboratory, McGill University Research Centre for Studies in Aging, McGill University, Montreal, Canada, Montreal Neurological Institute, McGill University, Montreal, Canada*

**OC27 - Implementation of the NIA-AA research framework: toward a biological definition of Alzheimer’s disease in AIBL**

*Samantha C Burnham, Preciosa M Coloma, Qiao-Xing Li, Steven Collins, Greg Savage, Simon Laws, James Doeche, Paul Maruff, Ralph N Martins, David Ames, Colin L Masters, Victor L Villemagne*

*eHealth, CSIRO, Parkville, VIC, Australia, School of Medical Sciences, Edith Cowan University, Joondalup, Australia, Product Development Personalised Health Care - Data Science, F. Hoffmann-La Roche Ltd, Basel, Switzerland, The Florey Institute of Neuroscience and Mental Health, The University of Melbourne, Victoria, Australia, Department of Pathology, University of Melbourne, Parkville, Australia, Macquarie University, Sydney, Australia, eHealth, CSIRO, Herston, QLD, Australia, Cogstate Ltd, Melbourne, Australia, Macquarie University, North Ryde, Australia, National Ageing Research Institute, Melbourne, Australia, Austin Health, Melbourne, Australia, Brain Health, Las Vegas, NV, USA*

**OC28 - The neuroprotective effect of a new photobiomodulation technique on Aβ25-35 peptide-induced toxicity dramatically impact gut microbiota dysbiosis**

*Jacques Touchon, MD, PhD, Laura Auboyer, PhD, Johann Meunier, PhD, Laura Ceolin, PhD, François J. Roman, PhD, Remy Burcelin, PhD, Guillaume J. Blivet, MS*

*Montpellier University, France, INSERMU061, Montpellier, France, REGENLIFE SAS, Montpellier, France, Amylgen SAS, Montferrier-sur-Lez, France, Vaiomer SAS, Labège, France*
Disclosure of Alzheimer’s risk biomarkers to cognitively normal older adults

Symposium co-moderators: Athene Lee PhD* and Jessica Alber PhD*
Warren Alpert Medical School of Brown University, Providence, RI, USA
Butler Hospital, Providence, RI, USA

Communication 1: “Not just a colonoscopy” – cognitively normal older adults reactions to learning an amyloid PET result
Jason Karlawish, MD1, Kristin Harkins, MPH2, Emily Largent, JD, PhD3, Pamela Sanhar, PhD4, Jeff Burns, MD5, David Sulzer, MD5, Joshua Grill, PhD6
1Departments of Medicine, Medical Ethics and Health Policy, and Neurology, University of Pennsylvania, Philadelphia, PA, USA
2Department of Medicine, University of Pennsylvania, Philadelphia, PA, USA
3Department of Medical Ethics and Health Policy, University of Pennsylvania, Philadelphia, PA, USA
4Department of Neurology, University of Kansas, Kansas City, KS, USA
5Department of Psychiatry, University of California, Los Angeles, CA, USA
6Department of Psychiatry and Human Behavior, University of California, Irvine, CA, USA

Communication 2: Remote genetic counseling and disclosure of APOE genotype within the Generation study 1
Elisabeth McCarty Wood, MS1, Cara Cacioppo, MS1, Neeraja Reddy, MS2, Dare Henry-Moss, MPH1, Demetrios Ofidis, BS1, Brian L. Egleston, PhD1, Jason Karlawish, MD1, J Scott Roberts, PhD1, Scott Kim, MD, PhD1, Carolyn Langlois, MA6, Eric M. Reiman, MD6, Pierre N. Tariot, MD6, Jessica B. Langbaum, PhD6, Angela R. Bradbury, MD1
1University of Pennsylvania, Philadelphia, PA, USA
2Mapmygenome, Navi Mumbai, India
3Fox Chase Cancer Center, Philadelphia, PA, USA
4University of Michigan, Ann Arbor, MI, USA
5National Institutes of Health, Bethesda, MD, USA
6Banner Alzheimer’s Institute, Phoenix, AZ, USA

Communication 3: Application of an APOE disclosure model at a clinical trial site and the impact of dual disclosure of amyloid PET results
Louisa Thompson, PhD1,2, Athene Lee, PhD1,2, Meghan Collier, PhD1,2, Danielle Goldfarb, MD1, Brittany Dawson, FNP1, Stephan Salloway, MD1,2, Jessica Alber, PhD1,2
Warren Alpert Medical School of Brown University, Providence, RI, USA
Butler Hospital, Providence, RI, USA

Lunch and poster session

Oral communications

OC30 - Adult conditional BACE1 knockout mice exhibit axonal organization defects in the hippocampus
Robert Vassar, PhD Department of Neurology, Feinberg School of Medicine, Northwestern University, Chicago, USA

OC31 - TRC-PAD: Accelerating participant recruitment in AD clinical trials through innovation
Gustavo A. Jimenez-Maggiora, MBA1, Rema Raman, PhD1, Michael S. Rafii, MD, PhD1, Reisa Anne Sperling, MD1, Jeffrey Lee Cummings, MD2, Paul S. Aisen, MD1
1Alzheimer’s Therapeutics Research Institute, University of Southern California, San Diego, CA, USA
2Department of Neurology, Massachusetts General Hospital, Harvard Medical School, Boston, MA, USA
3Department of Radiology, Division of Nuclear Medicine and Molecular Imaging, Massachusetts General Hospital, Harvard Medical School, Boston, MA, USA
4Cleveland Clinic Lou Ruvo Center for Brain Health, Las Vegas, NV, USA

OC32 - Detecting brain amyloid status using fully automated plasma Aβ biomarker assays
Sebastian Palmqvist1, Shorena Janelidze, PhD1; Erik Stomrud, MD PhD1; Henrik Zetterberg, MD PhD2; Johann Karl, PhD2; Niklas Mattsson, MD PhD2; Kaj Blennow, MD PhD2; Udo Eichenlaub, PhD3; Oskar Hansson, MD PhD1
1Clinical Memory Research Unit, Lund University, Sweden
2Department of Psychiatry and Neurochemistry, Institute of Neuroscience and Physiology, the Sahlgrenska Academy at the University of Gothenburg, Sweden
3Roche Diagnostics GmbH, Penzberg, Germany
### Schedule:

<table>
<thead>
<tr>
<th>Time</th>
<th>Session</th>
</tr>
</thead>
<tbody>
<tr>
<td>2.00 - 2.15 p.m.</td>
<td>OC33 - Concordance of florbetapir (18F) PET and Elecsys® β-Amyloid(1-42) CSF immunoassay in the CREAD (BN29552) study of crenezumab in prodromal-to-mild AD</td>
</tr>
<tr>
<td>2.15 - 2.30 p.m.</td>
<td>OC34 - Development of Aβ, tau and cognitive changes during the time course of sporadic Alzheimer’s disease</td>
</tr>
<tr>
<td>2.30 - 2.45 p.m.</td>
<td>OC35 - U.S. POINTER: Study design and trial kick-off</td>
</tr>
<tr>
<td>2.45 - 3.00 p.m.</td>
<td>OC36 - Implications for AD clinical trials and opportunities to leverage the first Alzheimer’s association U.S. National Best Clinical Practice Guidelines for the evaluation of cognitive behavioral syndromes, Alzheimer’s disease, and related dementias</td>
</tr>
<tr>
<td>3.00 - 3.15 p.m.</td>
<td>OC37 - Pros and cons of AD composite endpoints considering recently revised regulatory guidance and 2018 NIA-AA research framework</td>
</tr>
<tr>
<td>3.15 - 3.30 p.m.</td>
<td>OC38 - The European Prevention of Alzheimer’s Dementia (EPAD); Summary of First Formal Data Loch (EPAD V500.O) and predictors of amyloid status</td>
</tr>
<tr>
<td>3.30 - 3.45 p.m.</td>
<td>LB11 - ADCOMS: a post-hoc analysis using data from the LipiDiDiet trial in prodromal Alzheimer’s disease</td>
</tr>
<tr>
<td>3.45 - 4.00 p.m.</td>
<td>LB12 - Identification and characterization of Small Molecule clinical candidates Targeting intracellular Tau pathology</td>
</tr>
</tbody>
</table>

---

**End of conference**
■ Theme 1. Clinical trials: Methodology
  P21, P45, P54, P59, P61, P82, P86, P90 to P101 and LBP1 to LBP12
  pages 22 - 24

■ Theme 2. Clinical trials: Results
  P7, P12, P13, P15, P16, P18, P36, P80, P109 to P112 and LBP13
  pages 25 - 27

■ Theme 3. Clinical trials: Imaging
  P10, P35, P62, P76, P113 to P124 and LBP21 to LBP24
  pages 28 - 29

■ Theme 4. Clinical trials: Biomarkers including plasma
  P1, P4, P22, P28, P30, P39, P44, P57, P64 to P66, P73, P78, P81, P125 to P139
  and LBP25 to LBP40
  pages 30 - 34

■ Theme 5. Clinical trials: Cognitive and functional endpoints
  P2, P3, P8, P9, P19, P25 to P27, P53, P67, P69, P71, P74, P77, P83, P140 to P149
  and LBP41 to LBP46
  pages 35 - 38

■ Theme 6. Cognitive assessment and clinical trials
  P6, P14, P24, P29, P33, P34, P41, P42, P47 to P52, P55, P63, P68, P70,
  P72, P75, P87 to P89, P150 to P159, P162 and LBP47 to LBP52
  pages 39 - 42

■ Theme 7. Behavioral disorders and clinical trials
  P32, P37, P43, P163 and LBP53
  page 43

■ Theme 8. Health economics and clinical trials
  P17, P40, P58, P164
  page 44

■ Theme 9. Epidemiology and clinical trials
  P17, P38, P46, P165 to P168 and LBP54 to LBP56
  pages 45 - 46

■ Theme 10. Clinical Trials: Animal Models
  P102 to P104 and LBP58
  page 47

■ Theme 11. New therapies and clinical trials
  P5, P11, P20, P23, P56, P60, P79, P84, P85, P105 to P108 and LBP59 to LBP62
  pages 48 - 49
Theme 1. Clinical trials: Methodology

P21 - Patterns of MMSE subtest scores in amyloid-positive and -negative participants in J-ADNI
Ryocho Ihara, MD, Kazushi Suzuki, MD, Atsushi Iwata, MD, Takashi Iwatsubo, MD, The Japanese Alzheimer's Disease Neuroimaging Initiative
1The Unit for Early and Exploratory Clinical Development, The University of Tokyo Hospital, Tokyo, Japan; 2Department of Neurology, The University of Tokyo, Tokyo, Japan

P45 - Innovations in care community-based recruitment to clinical trial research
Jacobo Mintzer, MD, MBA¹, Mike Spline², Erin Bech, MPH³
1Research and Innovation Center, Roper St. Francis, Charleston, SC, USA; 2Managing Partner, Recruitment, Partners LLC, Columbia, MD, USA; 3Managing Partner, Recruitment Partners LLC, Columbia, MD, USA

P54 - Validation of Alzheimer’s biomarkers: β-amyloid 1-42 and total tau in CSF by automated CLEIA on lumipulse g 1200 platform
Satya Nandana Narla¹, Amanda Dider¹, Ming Hu¹, Tina LV¹, Yuan Xueling¹ and Martine Florent¹
1Immunology Department, Covance Central Laboratories, Indianapolis, USA; 2Immunology Department, Covance Central Laboratories, Shanghai, China

P59 - The impact of frailty on the risk of screen failure in randomized controlled trials on Alzheimer’s disease
Alessandro Trebbastoni, MD, PhD, Marco Canevelli, MD, PhD, Giuseppe Bruno, MD, Carlo de Lena, MD, Letizia Imbriani, Fabrizia D’Antonio, MD, Laura Pieroni
1Department of Human Neuroscience, «Sapienza» University of Rome, Italy

P61 - Concierge site services: site-specific support and capacity development improves recruitment performance
Jacobo Mintzer, MD, MBA¹, Mike Spline², Erin Bech, MPH³
1Research and Innovation Center, Roper St. Francis, Charleston, SC, USA; 2Managing Partner, Recruitment, Partners LLC, Columbia, MD, USA; 3Managing Partner, Recruitment Partners LLC, Columbia, MD, USA

P82 - Meotis3rc: Efficient network for clinical research on cognitive disorders in North and Pas-de-Calais
Catherine Adnet-Bonte, MD, Brigitte Leprince¹, Laetitia Breuilh, PhD², Florence Pasquier, MD, PhD³
1Meotis, Centre Hospitalier Universitaire de Lille, France; 2Neurology Department, Centre Hospitalier Universitaire de Lille, France; 3Excellence Laboratory DISTALZ, Inserm U971, Univ Lille

P86 - Recruiting older Latinos in senior centers with a culturally tailored Alzheimer’s presentation
Jaime Perales, PhD, MPH; W Todd Moore, MS, Mariana Ramirez, LMSW; Linda Lara, BA; Erica Davis, BA; Jason Resendez, MS; Eric D Vidoni, PhD
1University of Kansas Medical Center, Kansas-USA, 2Guadalupe Center, Kansas City-USA, 3Don Bosco Senior Center, Kansas City-USA, 4LatinosAgainstAlzheimer’s Coalition, Chevy Chase-USA1U971, Univ Lille

P90 - REVERSE-SD: ongoing phase-2b study of neflamapimod designed in accordance with emerging scientific and regulatory concepts of early Alzheimer’s disease (AD)
John Alam¹, Kelly Blatchburn, Niels Prins², Philip Schelten³
1EIP Pharma Inc., Cambridge, MA, USA; 2ClinCloud, Orlando, FL, USA; 3Brain Research Center, Amsterdam, NL

P91 - The impact of frailty on the risk of screen failure in randomized controlled trials on Alzheimer’s disease
Alessandro Trebbastoni, MD, PhD, Marco Canevelli, MD, PhD, Giuseppe Bruno, MD, Carlo de Lena, MD, Letizia Imbriani, Fabrizia D’Antonio, MD, Laura Pieroni
1Department of Human Neuroscience, «Sapienza» University of Rome, Italy

P92 - Impact of genetic testing on clinical trial participation and subject selection, a pilot study
Mareike Cajal-Berman, PhD, Jessica Branning³, Vishnuharith Nitta, MS²
1Biontica Research, Orlando, FL, USA; 2ClinCloud, Orlando, FL, USA

P93 - The impact of Transcranial Magnetic Stimulation on diagnostic confidence in patients with Alzheimer Disease eligible for clinical trials
Alberto Benussi, MD, Antonella Alberici, MD, Clarissa Ferrari, MD, Valentina Cantoni, MS, Valentina Dell’Era, MD, Rosanna Turrone, MS, Maria Sofia Cotelli, MD, Giuliano Binetti, MD, Barbara Paghera, MD, Giacomo Koch, MD, Barbara Bonnini, MD, Alessandro Padovani, MD, PhD
1Neurology Unit, Department of Clinical and Experimental Sciences, University of Brescia, Brescia, Italy; 2IRCCS Centro San Giovanni di Dio Fossebenefratelli, Brescia, Italy; 3Department of Neuroscience, Psychology, Drug Research and Child Health, University of Florence, Florence, Italy; 4Neurology Unit, Ospedale Vallecaminonica, Esine, Brescia, Italy; 5Nuclear Medicine Unit, Spedali Civili Brescia, Brescia, Italy; 6Non Invasive Brain Stimulation Unit, IRCCS Santa Lucia Foundation, Rome, Italy; 7Stroke Unit, Policlinico Tor Vergata, Rome, Italy

*These authors contributed equally to this work.
P94 - Applying patient-centred insights to optimize protocol design and increase biomarker collection acceptability in AD trials
Kenneth Stanley¹, Carolina Rubel¹, Lynne Hughes¹
¹IQVIA Project Leadership Unit

P95 - CSF biomarkers outcomes in the ETHERAL AD study
Harald Hampel¹-²-³, Carlos Buesa⁴, Tamara Maes⁵, Mabel Arevalo⁶, Michele Lufino⁷, Roger Bulloch⁸
¹AXA Research Fund & Sorbonne University Chair, Paris, France, ²Sorbonne University, QRC, n° 21, Alzheimer Precision Medicine (APM), AP-HP, Pié-Salpêtrière Hospital, Paris, France, ³Brain & Spine Institute (ICM), INSERM U1127, CNRS UMR 7225, Paris, France, ⁴Institute of Memory and Alzheimer’s Disease (IM2A), Department of Neurology, Pié-Salpêtrière Hospital, AP-HP, Paris, France, ⁵Oryzon Genomics SA, Barcelona, Spain

P96 - EMIF-AD: A unique pan-European platform for large-scale research on biomarkers and risk factors for Alzheimer's Disease
Preciosa M Coloma¹, Stephanie I. B. Vos¹, Isabelle Bos², Andy Simmons³, Rih Vandenbergh⁴, Philip Scheltens⁵, José Luis Molinuevo⁶, Flavio Nobili⁷, Sebastián Engelborghs⁸, Giovanni Frisoni⁹,¹⁰, Gaël Chetelat¹¹, Alberto Lleó¹², Andres Wallim¹³, Julius Popp¹⁴,¹⁵, Pablo Martínez-Lage¹⁶, Gonzalo Duran-Pacheco¹⁷, Pieter Jelle Visser¹⁸, Mark F Gordon¹⁹, Gerald Novák²⁰
¹Personalised Health Care, Data Science, F. Hoffmann-La Roche AG, Basel, Switzerland, ²Department of Psychiatry and Neuropsychology, Alzheimer Center Limburg, Maastricht University, Maastricht, the Netherlands, ³Institute of Psychiatry, Kings College, London, UK, ⁴University Hospital Leuven, Leuven, Belgium, ⁵Alzheimer Center, VU University Medical Center, Amsterdam, the Netherlands, ⁶Alzheimer’s disease & other cognitive disorders unit, Hospital Clinic-IDIBAPS, Barcelona, Spain, ⁷Barcelona Beta Brain Research Center, Fundació Pasqual Maragall, Barcelona, Spain, ⁸Clinical Neurology, Department of Neurosciences (DINOCM), University of Genoa and IRCCS Polyclinic San Matteo, Genoa, Italy, ⁹Department of Neurology and Memory Clinic, Hospital Netwoth Antwerp (ZNA) Middelheim and Hage Beheen, Antwerp, Belgium, ¹⁰Reference Center for Biopathological Markers of Dementia (BIDEM), Institut Bom-Bunge, University of Antwerp, Antwerp, Belgium, ¹¹University of Geneva, Geneva, Switzerland, ¹²IRCCS Istituto Centro San Giovanni di Dio Fatebenefratelli, Brescia, Italy, ¹³Inserm, INSERM UMR-S 1237, Université de Caen-Normandie, GIP Cyclic, Caen, France, ¹⁴Department of Neurology, Hospital de la Santa Creu i Sant Pau, Barcelona, Spain, ¹⁵University of Gothenburg, Sahlgrenska Academy, Institute of Neuroscience and Physiology, Section for Psychiatry and Neurochemistry, Gothenburg, Sweden, ¹⁶Geniatric Psychiatry, Department of Mental Health and Psychiatry, Geneva University Hospitals, Switzerland, ¹⁷Department of Psychiatry, University Hospital of Lausanne, Lausanne, Switzerland, ¹⁸CITA-Alzheimer Foundation, San Sebastian, Spain, ¹⁹Teva Pharmaceuticals, Malvern, PA, USA, ²⁰Janssen Pharmaceutical Research and Development, Boston, MA, USA, ²¹IQVIA Project Leadership Unit

P97 - Using transcription phenotypes to utilise basket trial methodology from oncology to create new targets in CNS disorders
Roger Bulloch¹, David Rotli⁴nt¹, Michele Lufino², Cristina Mascaro³, Carlos Buesa⁴, Tamara Maes⁵, Sonia Gutierrez⁶, Marta Valverde⁶, Tony Ramos⁸
¹Oryzon Genomics, Barcelona, Spain, ²Vall D'Hebron Hospital, Barcelona, Spain

P98 - Can online registers with small amounts of phenotypic data reduce screen failure rates in Alzheimer’s disease trials?
Piërs Kotting¹, David Rotlinton², Michele Lufino², Cristina Mascaro³, Carlos Buesa⁴, Tamara Maes⁵, Sonia Gutierrez⁶, Marta Valverde⁶, Tony Ramos⁸
¹University of Exeter Medical School, Exeter, UK, ²University of Leeds, Leeds, UK, ³Institute of Neurology, University College London, London, UK

P99 - Trial design of the GRADUATE studies: Phase III, randomized, placebo-controlled studies evaluating gantenerumab in patients with early Alzheimer’s disease
Smiijlana Ristic¹, Mercè Boada, MD², PhD², Nathalie Pross, PhD³, Daniéle Abi-Saab, PSyD², Szofia Bullain, MD³, Mirjana Andjelkovic, PhD⁴, Paul Delmar, PhD⁵, Carsten Hofmann, PhD⁶, Alison Searle, BSc⁷, Monika Baudler, PhD⁸, Paula Fontoura, MD⁹, PhD⁹, Rachelle Doody, MD, PhD⁹
¹F. Hoffmann-La Roche Ltd., Basel, Switzerland, ²Barcelona Alzheimer Treatment and Research Center, Barcelona, Spain, ³Oryzon Genomics SA, Barcelona, Spain, ⁴Roche Products Ltd., Welwyn Garden City, UK, ⁵Genentech, Inc., South San Francisco, CA, USA

P100 - Study enrollment and Alzheimer’s disease pathology in relation to cohort type and participant characteristics in the EPAD Registry
Lisa Vermunt, MD¹, Graciela Muniz-Terrera, PhD²,³, Lea ter Meulen, MSc¹, Colin Veal, PhD², Jose Luis Molinuevo, MD, PhD², Pierre-Jean Ousset, MD²,³, Niels D Prins, MD, PhD²,³, David Porteous, PhD², Craig W Ritchie, PhD², Philip Scheltens, MD, PhD², Gerald Luscan, MSc²,³, Anthony J Brookes, PhD²,³, Pieter Jelle Visser, MD, PhD²,³
¹VU University Medical Center, Amsterdam, Netherlands, ²University of Edinburgh, Edinburgh, Scotland, ³University of Victoria, Victoria, Canada, ⁴University of Cambridge, Cambridge, England, ⁵University of Leicester, Leicester, England, ⁶University of Brescia, Brescia, Italy, ⁷Inserm, INSERM UMR-S 1237, Université de Caen-Normandie, GIP Cyclic, Caen, France, ⁸Brain Research Center, Amsterdam, Netherlands, ⁹Pfizer, Paris, France, ¹⁰Maastricht University, Maastricht, Netherlands

P101 - The effects of participant characteristics and selection criteria on Alzheimer disease clinical trial outcomes
Richard E. Kennedy, MD, PhD, Quociao Wang, PhD, Machtzenie E. Fowler, MPH¹, Gary R. Cutter, PhD¹, Lon S. Schneider, MD, MS¹
¹Department of Medicine, University of Alabama at Birmingham, USA, ²Division of Biostatistics, Washington University, St. Louis, USA, ³Department of Epidemiology, University of Alabama at Birmingham, USA, ⁴Department of Biostatistics, University of Alabama at Birmingham, USA, ⁵Department of Psychiatry and the Behavioral Sciences, Keck School of Medicine of the University of Southern California, Los Angeles, USA
Late Breaking Posters

LBP1 - Harnessing the power of big data and technology innovations to advance Alzheimer's disease clinical development
Olga Uspenskaya-Cadoz1, Yuliya Nigmatullina2, Kenneth Stanley3, Chaitanya Alamuri3, Penny Randall1, Sam Khinda3, Lanhui Wang2, Mengting Yang1, Carolina Rubel1, Lynne Hughes2, Tao Cao1, Michelle O'Keefe1, Nikhil Kayal3
1IQVIA CNS Center of Excellence; 2IQVIA Analytics Center of Excellence; 3IQVIA Project Leadership

LBP2 - Course correction in A4: implementation of dose escalation
Karen Holdridge, MPH1, Roy Yaari, MD1, Brian A. Willis, PhD2, Isabella Velona, MS1, Paul Aisen, MD4, Reisa Sperling, MD5
1Eli Lilly and Company, Indianapolis, USA; 2University of Southern California, San Diego, USA; 3Brigham and Women’s Hospital, Boston, USA

LBP3 - Dose escalation in the DIAN-TU solanezumab arm. Was solanezumab in mild to moderate AD dementia too little, too late?
Karen Holdridge, MPH1, Roy Yaari, MD1, Brian A. Willis, PhD2, Isabella Velona, MS1, Susan Mills1, Randall Bateman2
1Eli Lilly and Company, Indianapolis, USA; 2Washington University, Saint Louis, USA

LBP4 - Does the US have enough clinical trials sites to keep up with the demand of new chemical and device compounds entering the NDA?
Sean Stanton1, Dan Davis1, Vishnukarthil Nitta, MS2, Jessica Branning, BS2, John Dwyer, JD3, Jason Bork, MBA4, James Taylor5, and George Vradenburg, JD6
1LifeCore Solutions, LLC; 2ClinCloud, LLC; 3Global Alzheimer's Platform; 4Bioclinica Research; 5Independent Consultant, Caregiver

LBP5 - Goal Attainment Scaling scores, without defined attainment levels, were associated with standardized measures in people with vascular and mixed dementia
Kenneth Rockwood1,2, Justin Stanley1, Taylor Dunn1, Susan E Howlett1,2
1DGI Clinical Inc., Halifax, NS, Canada; 2Dalhousie University, Halifax, NS Canada

LBP6 - Consultation for Alzheimer’s disease prevention: an effective recruitment strategy for preventive trials
Isabelle Carrie, PhD1, Julien Delrieu, MD1,2,3, Françoise Lala, MD1, Christophe Hein, MD1, Delphine Pennefather, PhD1, Pierre Jean Ousset, MD1,2,3, Bruno Vellas, MD1, PhD1,2,3
1Gerontopole, Toulouse University Hospital, Toulouse, France; 2Inserm Unit 1027, Toulouse, France; 3University of Toulouse III, Toulouse, France

LBP7 - Finding a common baseline: Insights from latent disease-time progression modeling in Alzheimer’s disease
Lars Lau Raket, PhD1
1H Lundbeck A/S, Denmark

LBP8 - The use of Machine Learning algorithms in Clinical Trials on Alzheimer’s Disease
Delia A. Gheorghe, MSc1, Sarah Bauermeister, PhD1, John Gallacher, PhD1
1University of Oxford, Department of Psychiatry, Oxford, UK

LBP9 - Predicting cerebral amyloid status and cognitive performance in cognitively normal adults
Alette Wessels, PhD1, Adrian Schembi, DPsych1, Pav Kalinowski, PhD1, Reisa Sperling, MD1, Roy Yaari, MD1, Paul Aisen, MD1, David Barfield, MS1, Scott Andersen, MS1, John R. Sims, MD1, A4 Study Team, Paul Maruff, PhD2
1Eli Lilly and Company, Indianapolis, IN, USA; 2Cogstate Ltd, New Haven, Connecticut, CT, USA; 3Center for Alzheimer Research and Treatment, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, USA; 4Alzheimer’s Therapeutic Research Institute, University of Southern California, San Diego

LBP10 - Novel patient identification and pre-screening model improves patient recruitment and retention and reduces screen-failure rates for AD clinical trials
Lucianne Dobson PhD1, Miguel Rosa Grilo MD1, Catherine Mummary PhD, FRCP1
1Dementia Research Centre, National Hospital for Neurology and Neurosurgery, Queen Square, London, UK

LBP11 - Delivery of a Patient Focused In-Trial Online Community in a Multi-Year Alzheimer’s Disease Study
Adam Butler1, Denis Curtin, PhD1, Mackenzie Johnson2, and Jeff Lee1
1CRF- Braheer, Arlington, VA, USA

LBP12 - Multi-crossover randomized controlled trial designs in Alzheimer’s disease
Steven E. Arnold, MD1, Rebecca A. Betensky, PhD2
1Massachusetts General Hospital and Harvard Medical School, Boston, USA; 2Harvard T.H. Chan School of Public Health, Boston, MA
Theme 2. Clinical trials: Results

P7 - Effects of vortioxetine on cognitive functions in patients with Alzheimer’s disease and depressive symptoms: interim results of an observational study
Eduardo Cumbo MD1, Silvia Cumbo MD2, Salvatore Torregrossa PsyD1, Daniela Migliore PsyD1
1Neurodegenerative Disorders Unit, ASP, 2Caltanissetta, Caltanissetta (Italy)

P12 - Critical Path for Alzheimer's Disease (CPAD) consortium’s vision for an aggregated, standardized, and actionable global Alzheimer disease clinical trial database
Volker D. Kern, PhD1, Stephen P. Arneric, PhD1, Maria C. Carrillo, PhD2, James Hendrix, PhD2, Billy Dunn, MD3, Stacie Weninger, PhD4, Jeffrey A. Kaye, MD4, Daniel R. Karlin, MD4, Lisa H. Gold, PhD4, Michael Gold, MD4, Samantha Budd Haeberlein, PhD4, Molly Shea, PhD5, George Vradenburg1, Daniela J. Conrado, PhD1, and Klaus Romero, MS, MD1
1Critical Path for Alzheimer’s Disease Consorium, Critical Path Institute, Tucson, AZ, USA, 2Alzheimer’s Association, Chicago, IL, USA, 3U.S. Food and Drug Administration, Silver Spring, MD, USA, 4Prime Biomedical Research Institute, Cambridge, MA, USA, 5Oregon Health & Science University, Portland, OR, USA

P13 - Effects of body weight on safety of 23mg donepezil in Alzheimer’s disease: A post-hoc analysis of a multicenter, randomized trial
Yun Jeong Hong, MD, PhD1,2, Hyun Jeong Han, MD, PhD3, Young Chul Youn, MD, PhD4, Kyung Won Park, MD, PhD5, Dong Won Yang, MD, PhD6, Sang Yun Kim, MD, PhD7, Hwa Jung Kim, MD, PhD7, Ji Eun Kim, MD, PhD7, Jae-Hong Lee, MD, PhD7, the ODESA study group
1Neurology, Asan Medical Center, University of Ulsan College of Medicine, Seoul, 2Biomedical research institute, Pusan National University Hospital, Pusan, 3Neurology, Dementia and Neurocognitive Center, Myongji Hospital, Seonam University College of Medicine, Ilsan, 4Neurology, Chung-Ang University Hospital, Seoul, 5Neurology, Dong-A University College of Medicine, Busan, 6Neurology, The Catholic University of Korea, Seoul, 7Neurology, Seoul National University Bundang Hospital, Seongnam

P15 - A single ascending dose study to assess the safety, pharmacokinetics, and pharmacodynamics of LY3303560, a tau-specific antibody, in healthy volunteers
Stephen Lowe1, Jeffrey Dager2, Ann Cleverley3, Albert Lo2, Elizabeth S. LaBell2, Haktap Gevorkyan4, Stanford Jhee5, Larry Huffman2, Boris Calderon2, Brian A. Willis2
1Lilly Centre for Clinical Pharmacology, Singapore, 2Eli Lilly and Co, Indianapolis, IN, 3Eli Lilly and Co, Erl Wood, UK, 4California Clinical Trials Medical Group, Inc., 5PAREXEL

P16 - CNP520, a novel oral BACE1 inhibitor, has no clinically meaningful effect on QTc interval up to supratherapeutic doses
Stefan Viktor Vormfelde, MD/PhD1, Nicole Pezous1, Gilbert LeFevre, PhD2, Carine Kolly, PhD2, Ulf Neumann, PhD3, Pierre Jordaan, MD2, Guenter Heimann, PhD2, Mike Ufer, MD/PhD2, Ana Graf, MD2, Eric Legangneux, MD2
1Novartis Institutes for BioMedical Research, Basel, Switzerland, 2Novartis Pharma AG, Basel, Switzerland

P18 - Differences in treatment response between males and females with mild-moderate Alzheimer disease being treated with cholinesterase inhibitors
Kenneth Rockwood, MD1,2, Justin Stanley, BSc1, Susan E Howlett, PhD1,3
1DGI Clinical Inc., Halifax, NS, Canada, 2Division of Geriatric Medicine, Dalhousie University, Halifax, NS Canada, 3Department of Pharmacology, Dalhousie University, Halifax, NS, Canada

P36 - Phase I Clinical Studies in Alzheimer’s Disease: Cerebrospinal Fluid Oligomer Change and Other Exploratory Outcomes of amyloid β Aggregate-Specific Antibody KHK6640
Marc Cantillon, MD1, Hiroyuki Shimada, MD, PhD2, Kenichiro Sugiyama, Phar.B3, Wei Sun, Ph.D4, Yoshihumi Ouchi, M Eng5, Katsuyoshi Tsuhii, MSc6, Gemma Clark, RGN RM7
1Kyowa Kirin Pharmaceutical Development, Inc., USA, 2Osaka city university hospital, Osaka, Japan, 3Kyowa Hakko Kirin Co., Ltd, Japan, 4Kyowa Kirin International plc, UK

P80 - Cumulative aducanumab safety data from PRIME: a randomized, double-blind, placebo-controlled, Phase Ib study
Philipp von Rosenstiel MD1, Tianle Chen, PhD2, John O’Gorman, PhD2, Min Yee, PharmD2, Carmen Castrillo-Viguera, MD, PhD2, Claudia Prada, MD2, Christoph Hoch, MD2, Roger M Nitsch, MD2, Samantha Budd Haeberlein, PhD2, Alfred Sandrock, MD, PhD2
1Biogen, Cambridge, MA, USA, 2Neurimmune, Schlieren-Zurich, and University of Zurich, Switzerland
PIO9 - The action for health in diabetes clinical trial: does a 10-year intensive multidomain lifestyle intervention provide cognitive benefits?
Kathleen M. Hayden, PhD1, José A. Luchsinger, MD2; Stephen R. Rapp, PhD1; Delilah R. Cook, CCRP; Rebecca H. Neiberg, MS; Judy L. Bahnsen, BA; Tara D. Beckner; Jerry M. Barnes, MA; and Mark A. Espeland, PhD for the Look AHEAD MIND Study Group
Wake Forest School of Medicine, Winston-Salem, USA, 1Columbia University, New York, USA

PIO10 - Single and multiple dose safety, tolerability and pharmacokinetics of the selective M1 receptor partial agonist HTL0018318 in healthy volunteers
Tim Tasker MBBS1, Jan Liprot PhD, Charlotte Balthar PhD2, Ellen ‘t Hart PhD, Erica Klaassen PhD, Samantha Prins MD, Thalia van der Doef PhD, Mike Walker, Giles A. Brown PhD, Alastair Brown PhD, Miles Congreve PhD, Malcolm Weir PhD, Fiona H. Marshall PhD, David M. Cross PhD, Geert Jan Groeneveld MD, PhD, Pradeep J. Nathan PhD
Sosei Heptares, Cambridge UK, 1Centre for Human Drug Research (CDHR), Leiden, Netherlands, 2Department of Psychiatry, University of Cambridge, UK, 3Cross Pharma Consulting Limited, Cambridge, UK

PIO11 - Assessing the psychological and emotional impact of APOE and amyloid disclosure in the API Generation Program: interim findings
Jessica B. Langbaum, PhD1, Jason Karlawish, MD 2, Scott Roberts, PhD1, Angela Bradbury, MD1, Scott Kim, MD, PhD1, Elisabeth McCarty Wood, MS1, Carolyn Langlois, MA1, Fonda Liu PharmD1, Marie-Emmanuelle PhD1, Marie-Laure Rouzade-Dominguez, PhD1, Angelita Caputo, PhD1, Mauritz Bezuidenhoudt, M.Sc1, Cristina Lopez-Lopez, MD, PhD, Ana Graf, MD1, Pierre N. Tariot, MD, Eric M. Reiman, MD1
1Banner Alzheimer’s Institute, Phoenix, USA, 2University of Pennsylvania, Philadelphia, USA, 3University of Michigan, Ann Arbor, USA, 4National Institutes of Health, Bethesda, USA, 5Novartis Pharmaceuticals Corporation, East Hanover, USA, 6Novartis Pharma AG, Basel, Switzerland

PIO12 - Meta-analysis of two tau aggregation inhibitor Phase 3 trials in mild Alzheimer’s disease with low dose hydromethylthionine
Bjoern Schelter, PhD1,2, Claude Wischik, MD, PhD1
1Institute for Complex Systems and Mathematical Biology, University of Aberdeen, Aberdeen, UK, 2TaulRx Therapeutics, Aberdeen, UK

Late Breaking Posters

LBP13 - Cognitive and mobility training as preventive measures in cognitively healthy patients and patients with MCI
Carine Federspiel, PhD1, Elisabeth Bourteil, PhD1, Jean-Paul Steinmetz, PhD1
1Centre for memory and mobility, ZithaAktiv, Luxembourg, 2ZithaSenior, Research&Development, Luxembourg

LBP14 - Evidence of Sustained Low Dose Bryostatin Efficacy for Treatment of Alzheimer’s Disease: Consistency of Multiple Evaluation Analyses
Daniel Alkon, PhD1, LJ Wei, PhD2, Richard Thompson, PhD3
1Neurotope,Inc, 2Harvard University, 3Johns Hopkins University

LBP15 - Enterovirus might be involved in Alzheimer’s disease - results from a phase IIa trial evaluating Apovir, an antiviral drug combination
Lars-Olof Wahlund, MD, PhD1, Lars Lindqvist MD, PhD2, Mikael Åström MSc, PhL3, Jacob Westman PhD4, Roger Bullock MD, PhD5, Suzanne Hendrix6, Nina Lindblom7, PhD8
1Karolinska University Hospital, Huddinge, Sweden, 2Karolinska University Hospital, Huddinge, Sweden, 3StatCons, Limhamn, Sweden, 4Apodemus AB, Söna, Sweden, 5Roger Bullock Consulting Ltd, Swindon, UK, 6Pentara Corporation, Sait Lake City, USA

LBP16 - A randomized, placebo controlled, repeat dose phase 1 study of COR388 in older healthy volunteers and patients with Alzheimer’s disease
Samer Kata, MD, Casey Lynch1, Mark Ryder, DMD2, Ira Goodman, MD2, Steve Thien, MD3, Steve Dominy, MD4
1Cortexyme, S. San Francisco, CA, 2UCSF, San Francisco, CA, 3Bioclinica, Orlando, FL, 4Pacific Research Network, San Diego, CA

LBP17 - Souvenaid in cognitive deterioration. Our experience after 5 years of treatment and follow-up
Miquel Aguilar MD, PhD1 and Paquita Soler. Nurse1
1Àptima Mutua Terrassa, Catalunya, SPAIN
**LBP18 - Is RAGE the missing link between diabetes and dementia? Results from a subgroup analysis of the STEADFAST trial**

Carmen Valcarce, PhD¹, Imogene Dunn, PhD¹, Tom Soeder, MS², and Aaron Burstein, PharmD³

¹Vtv Therapeutics LLC, High Point, NC, USA; ²CATO Research Ltd, Durham, NC, USA

**LBP19 - Aducanumab 48-month analyses from PRIME, a Phase 1b study in patients with early Alzheimer’s disease**

Philipp von Rosenstiel, MD¹, Samantha Budd Haeberlein, PhD¹, Carmen Castrillo-Viguera, MD¹, Tianle Chen, PhD¹, John O’Gorman, PhD¹, Raj Rajagovindan, PhD¹, Dalshaben Patel, PhD¹, Guanfang Wang, PhD¹, Spyros Chalkias, MD¹, LeAnne Sthordos PharmD¹, Claudia Prada, MD¹, Christoph Hoch, MD¹, Roger M Nitsch, MD¹, Alfred Sandrock, MD, PhD¹

¹Biogen, Cambridge, MA, USA; ²Biogen, Maidenhead, UK; ³Cytel, Cambridge, MA, USA; ⁴Neurimmune, Schilern-Zurich, and University of Zurich, Switzerland

**LBP21 - Baseline Data from the API Autosomal Dominant Alzheimer’s Disease Colombia Trial**

Pierre N. Tariot¹*, Francisco Lopera¹*, Kaycee M. Sink³, Nan Hu³, Heather Guthrie¹, Jillian Smith¹, William Cho¹, Jessica B. Langbaum¹, Ronald G. Thomas³, Kewe Chen¹, Yi Su¹, Dhruman Goradia¹, Pradeep Thiyyagura¹, Paul S VanGilder¹, Ji Luo⁴, Valentina Ghisays¹, Wendy Lee¹, Michael H. Malek-Ahmad¹, Hillary D. Protas¹, Yinhua Chen¹, Carole Ho¹, Shehnaaz Suliman¹, Sergio Alvarez², Yakeel T. Quiroz², Robert Paul¹, Silvia Rios Romenets³*, Eric M. Reiman³*, and the API ADAD Colombia Trial Group

¹Banner Alzheimer’s Institute, Phoenix, AZ, USA; ²Grupo de Neurociencias de Antioquia of Universidad de Antioquia, Medellin, CO; ³Genentech Inc, South San Francisco, CA, USA; ⁴Roche Products Ltd, Welwyn Garden City, UK; ⁵University of California, San Diego, CA, USA; ⁶Hospital Pablo Tobon Uribe, Medellin, CO; ⁷Harvard Medical School and Massachusetts General Hospital, Boston MA, USA
P10 - Diagnostic accuracy of [18F]FC119S PET for identifying Alzheimer’s disease  
Byung Hyeon Byun, MD, PhD1, Sang Moo Lim, MD, PhD1  
1Department of nuclear medicine, Korea cancer center hospital, Korea institute of radiological & medical sciences, seoul, republic of Korea

P35 - Annual atrophy rate in normal aging from a large single-center cohort in Korea  
Yu Yong Choi1, Byeonq C. Kim2, Seong-Min Choi3, Kee Hyung Park4, Kyu Yeong Choi, Kun Ho Lee4  
1National research center for dementia, chosun university, guangju, south korea, 2department of neurology, Chonnam national university hospital, guangju, south korea, 3department of nuclear medicine, Chosun University college of medicine, incheon, south korea, 4department of biomedicine, Chosun University, guangju, south korea

P62 - Impact of cerebral blood flow changes on 18F-Flobetaben SUVR. A simulation study  
Santiago Bullich, PhD1, Norman Koglin, PhD1, Susan De Santi, PhD1, Georg A. Becker, PhD2, Audrey Perrotin, PhD1, Aleksandar Jovalekic, PhD2, Andrew Stephens, MD, PhD1, Henryk Barthel, MD, PhD3, OsamSabri, MD, PhD3  
1Priramal imaging gmbh, Berlin, Germany, 2Priramal Pharma Inc., Boston, MA, USA, 3department of nuclear medicine, University hospital Leipzig, Leipzig, Germany

P76 - F-AV-1451 in TDP-43 associated frontotemporal dementia  
Ruben Smith, MD, PhD1, Alexander F Santillo, MD2, Maria Landquist Waldö, MD, PhD2, Oskar Hanssson, MD, PhD3  
1Clinical memory research unit, department of clinical sciences Malmö, Lund university, Lund, sweden, 2Memory clinic, Angelholm hospital, Angelholm, Sweden, 3Memory Clinic, Shdne University Hospital, Malmo, Sweden

P113 - Predicting amyloid burden from cognitive assessment  
Donald R. Royall, MD, PhD1, Raymond F. Palmer, PhD1 for the Alzheimer’s Disease Neuroimaging Initiative  
1Department of psychiatry, the university of texaS health science center at san antonio (UTHSCSA), san antonio, texas, USA, 2department of medicine, UTHSCSA, san antonia, texas, USA, 3department of family & community medicine. UTHSCSA, san antonia, texas, USA, 4South Texas Veterans health administration geriatric research education and clinical center (GRECC), san antonio, Texas, USA

P114 - The triple use of amyloid PET in Alzheimer’s disease  
Michela Rampini, MS1,2, Moira Marizzoni, PhD1, Valentina Caribotto, MD1, Michela Pieveani, PhD1, Giovanni B Frisoni, MD3  
1IRCCS Fatebenefratelli, Brescia, Italy, 2University of brescia, brescia, italy, 3Geneva university hospital, Geneva, Switzerland

P115 - A comparison of cortical reporter regions for longitudinal analysis of 18F-AV1451 PET data  
David Scott, PhD1, Katarzyna Adamczuk, PhD2, Beth gorman, BS CNMT2, Maureen Runtle, BS CNMT R.T.(N.)3, Joyce suhy, PhD4 and the Alzheimer’s Disease Neuroimaging Initiative  
1Bciclinca, NewAt, CA, USA, 2Bciclinca, Philadelphia, PA, USA

P116 - Can tau PET imaging be instrumental in predicting an elevated amyloid level in clinical trials?  
Sergey Shcherbinin, PhD1, Michael J. Pontecorvo, PhD2, Ming lu, MD, MS, MPH3, Michael D. Devous Sr, PhD1, A. Joshi, PhD2, Sudeepi Southeetak, PhD2, Emily C. Collins, Phd3, Adam S. Fleisher, MD1, Mark A. Mintun, MD3  
1Eli Lilly & Co, Indianapolis, IN, USA, 2Avid radiopharmaceuticals, Inc., Philadelphia, PA, USA

P117 - Supratentorial white matter is a better reference for longitudinal quantification of [18F]Flutemetamol scans  
Gemma Salvadó MSc1, Chris Foley PhD1, Elisabetta Grecchi, PhD23, M. Jorge Cardoso, PhD34, Isadora Lopes-Alves, PhD2, Pawel Markiewicz, PhD2, Carles Falcón, PhD1, Mark battle MSc1, Adriana A. Lammertsma, PhD1, Mark schmidt, MD, PhD2, José Luis Molinuevo MD PhD5, Frederik Barkhof, MD, PhD54, Juan Domingo Gispert, PhD1  
1Barcelonaβeta Brain Research Center, BarcelonA, Spain, 2GE Healthcare, AmershAm, United Kingdom, 3XiCO, London, United Kingdom, 4King’s college London, London, United Kingdom, 5University College London, London, United Kingdom, 6VU medical center, Amsterdam, The netherlands, 7Janssen PharMaceutica, Beerse, Belgium

P118 - Clinical validation of 18F-PI-2620 for quantification of tau in subjects with Alzheimer’s disease  
Andrew Stephens1, Andre Mueller1, Santiago Bullich1, Mathias Berndt1, John selby2, Olivier Barret2, Jennifer madonia2, Heiko Kroth1, Andrea Pfeifer1, Andreas Muhs1, Gilles tamagnan2, Kenneth Marek1, Ludger Dintelbor1  
1Priramal imaging, Berlin, Germany, 2Inviqro, New Haven, USA, 3AC Immune SA, Laussanne, Switzerland

P119 - Cut-off for 18F-flutemetamol SUVR with white matter reference region  
Katarzyna Adamczuk, PhD1, David Scott, PhD2, Ben Newton, PhD3, Joyce suhy, PhD1, Michael Egan, MD3, Cyrille Sur, PhD2  
1Bciclinca, NewArt, CA, USA, 2Merch Sharp & Dohme, Kenilworth, NJ, USA, 3General Electric health care, AmershAm, UK

P120 - Amyloid PET Imaging in a Phase Ila, Randomized, Double-Blind, Placebo-Controlled, 3-Arm Parallel-Group, Multicenter Study with Ub-311  
Hui Jing Yu1, Hui-Chen Chen1, Jacob Hesterman2, Jack Heimann2, sean Holmes2, Alex Whittington2, Xue Wang2, Roger Gunn2, Ajay Verma1  
1United neuroscience, Inc. Hauppauge, NY, USA, 2Inviqro, A Konica Minolta company, Boston, MA, USA
CTAD 2018

POSTERS PRESENTATION

P121 - Cortical dopamine depletion and cognition in Lewy bodies disorders: a 123I-FP-CIT single-subject study
Andrea Pilotto1,2 and Francesca Schiano di Cola1, MD and, MD; Enrico Premi1, MD; Roberto Grassol PsyD, Rosanna Turron1e, PsyD; MD; Stefano Gipponi1, MD; Andrea Scalvini1, MD; Elisabetta Cottini1, Barbara Paghera1, Laura Bonanni1%, PhD; MD; Maria Cristina Rizzetti1, PhD; Barbara Borroni1, MD; Alessandro Padovani1, PhD, MD
1Neurology Unit, Department of Clinical and Experimental Sciences, University of Brescia, Brescia, Italy, 2Parkinson’s Disease Rehabilitation Centre, FEBI ONLUS S. Isidoro Hospital, Trescore Balneario (BG), Italy, 3Nuclear Medicine Unit, University of Brescia, Brescia, Italy, 4Department of Neuroscience Imaging and Clinical Sciences, University G. d’Annunzio of Chieti-Pescara, Chieti, Italy

P122 - Very early detection and monitoring of Alzheimer’s Disease in the retina by multimode, hyperspectral confocal scanning ophthalmoscopy
Daniel L. Farkas, PhD1, 2, Fartash Vasefi, PhD1, Jeanne M. Fontana, MD, PhD1
1The Brain Window, Inc., Sherman Oaks CA, USA, 2University of Southern California, Los Angeles CA, USA

P123 - Quantitative Analysis on The Goodness of Harmonization with Multivariate Analysis of Field Strength, Sex, Age and Total Intracranial Volume
Mirza Faisal Beg, PhD1, Da Ma, PhD, Karteek Popori1, Mahadev, MD2, Lei Wang, PhD3
1School of Engineering Science, Simon Fraser University, Vancouver, BC, Canada, 2Faculty of Medicine, University of British Columbia, Vancouver, BC, Canada, 3Feinberg School of Medicine, Northwestern University, Chicago, Illinois, USA

P124 - Prescribing Cholinesterase inhibitors in mild cognitive impairment – observations from the Alzheimer’s Disease Neuroimaging Initiative
Eddie Stage1, Diana Svaldi PhD1, Sophie Sokolow PhD MPharm2,3,4, Shannon L. Risacher PhD1, Krisztina Marosi2, Kwangil H. Nho PhD1, Jerome I Rotter MD1,4, Andrew J. Saykin PsyD, Liana G. Apostolova MD MS1
1Indiana Alzheimer Disease Center, Indianapolis, IN, USA, 2UCLA School of Nursing, Los Angeles, CA, USA, 3Division of Genomic Outcomes, Department of Pediatrics and Medicine, Harbor-UCLA Medical Center, Torrance, CA, USA, 4Institute for Translational Genomics and Population Sciences and Department of Pediatrics, Los Angeles Biomedical Research Institute, Torrance, CA, USA, 5UCLA Brain Research Institute, Los Angeles, CA, USA, 6UCLA Clinical and Translational Science Institute, Los Angeles, CA, USA

Late Breaking Posters

LBP21 - Prediction of Treatment Response to Donepezil using Automated Hippocampal Subfields Volumes Segmentation in Patients with Mild Alzheimer’s Disease
Sheng-Min Wang, MD, PhD1, Yoo Hyun Um, MD, PhD2, Chang-Ux Lee MD, PhD3, and Hyun Kook Lim, MD, PhD3
1Department of Psychiatry, Yeouido St. Mary’s Hospital, College of Medicine, The Catholic University of Korea, Seoul, Republic of Korea, 2St. Vincent’s Hospital, College of Medicine, The Catholic University of Korea, Suwon, Republic of Korea, 3St. Mary’s Hospital, College of Medicine, The Catholic University of Korea, Seoul, Republic of Korea

LBP22 - Role of Confluent White Matter Lesions in the progression to Alzheimer’s dementia in an Asian Clinic Cohort
Nagaendran Randiah
National Neuroscience Institute,Singapore

LBP23 - APOE4/4 Early to Mild AD Subjects Show High Rates of Hippocampal Atrophy and Cognitive Decline in ADNI-1 and Tramiprosate Datasets
Susan Abushakra MD1, Luc Bracoud MS2, Joel Schaerer2, Aidan Power MD1, John Hey PhD1, David Scott PhD1, Joyce Suhy PhD1, Martin Tolar MD PhD1 & the Alzheimer Disease Neuroimaging Initiative (ADNI)
1Alzheon Inc., Framingham, MA, USA, 2Baciiclinica, Lyon France, 3Baciiclinica, Newport CA, USA

LBP24 - Preliminary characterization of 18F-RO948 PET imaging among cognitively unimpaired and patients with MCI or dementia in the BioFINDER2 study
Gregory Klein1, Ruben Smith1, Sebastian Palmqvist2, Niklas Mattsson2, Daniëlle van Westen2, Olof Strandberg2, Jonas Jögi2, Tomas Ohlsson2, Edilfo Borroni1, Preciosa Coloma1, Eirik Stomrud1, Oskar Hansson2
1Roche Pharma Research and Early Development, Basel, Switzerland, 2Clinical Memory Research Unit, Lund University, Sweden
Theme 4. Clinical trials: Biomarkers including plasma

**P1** - Sustained attention and memory tasks with concurrent EEG provide potential biomarkers for mild cognitive impairment
Shani Waninger, Ph.D.1, Chris Berkal, Amir Meghdadi, Ph.D.1, David Salat, M.D.2 and Ajay Verma, M.D., Ph.D.3
1Advanced Brain Monitoring, Inc., Carlsbad, CA, 2MGH/MIT/HMS Athinoula A. Martinos Center for Biomedical Imaging, Department of Radiology, Massachusetts General Hospital, Charlestown, MA, 3United Neuroscience, Dublin, Ireland

**P4** - High correlation in the Aβ40 and Aβ42 levels in human cerebrospinal fluid as measured by ELISA and HPLC-MS/MS
José A. Allué, PhD, Leticia Sarasa, PhD, Virginia Pérez-Grijalba, PhD, Noelia Fandos, PhD, Pedro Pesini, PhD, Manuel Sarasa, PhD.
Aralcon Biotech S.L., Vila Hispanidad 21, 50.009, Zaragoza, Spain

**P22** - Cerebrospinal fluid biomarkers in J-ADNI: diagnostic accuracy in AD and predictability of future clinical change in MCI
Kazuma Suzuki MD, PhD1, Ryoto Ihara MD, PhD2, Atsushi IWata MD, PhD2, Takeshi Iwashubo MD, PhD1, Kenji Ishii MD1, Takeshi Itakeuchi MD, PhD3, Ryozo Kudono MD, PhD3, 1Japanese Alzheimer’s Disease Neuroimaging Initiative
2The University of Tokyo, Tokyo, Japan, 3Tokyo Metropolitan Institute of Gerontology, Tokyo, Japan, 4Niigata University, Niigata, Japan

**P28** - Analytical performance of the Lumipulse® G pTau 181 and Lumipulse® G β-Amyloid 1-40 assays
Manu Vandijck, Martine Dauwe, Rosina Gregirech, Els Huych, Nathalie Le Bastard, Geert Jannes, Vesna Kostanjevčki
Fujirebio Europe NV, Ghent, Belgium

**P30** - Curcumin is Detectable in Human Cerebrospinal Fluid after Oral Administration of Turmeric Extract HSRx-888
Norman Rothlin MD, PhD1, Dan Li PhD2, Joshua Costin PhD1, David Wyatt MD3
1Reltin Consulting LLC, Harrington Park, NJ 07640, 2HerbalScience Group, Naples FL, USA, 3Syneos Health, Miami FL, USA

**P39** - Diagnostic biomarkers’ clinical applicability in early onset Alzheimer’s disease
Neus Falgas1, Raquel Sánchez-Valle1, Mircea Balasa1,2, Sergi Borrego1, Magdalena Castellví1, Adrià Tort-Merino1, Jaume Oliveres1, Beatriz Bosch1, Guadalupe Fernández1, Francisco Lomera1, Núria Bargalló1, Albert Llado1
1Alzheimer’s disease and other cognitive disorders Unit. IDIIBAPS. Hospital Clinic de Barcelona, 2Atlantic Fellow for Equity in Brain Health. Global Brain Health Institute. Trinity College Dublin, Ireland, 3Nuclear Medicine Department. IDIBAPS. Hospital Clinic de Barcelona, 4Image Diagnostic Centre. IDIBAPS. Hospital Clinic de Barcelona

**P44** - Inverse association between Aβ42/40 plasma ratios and fibrillary amyloid deposition in the brain: results of the FACEHBI study
Izziar de Rojas, MSc1, Judith Romero, MSc1, Octavio Rodríguez-Gomez, MD1, Pedro Pesini, PhD1, Angéla Sanabria, PhD1, Alba Pérez-Cordon, MSc2, Carla Abdelenour, MD, PhD3, Isabel Hernández, PhD1, Maitee Rosende-Roca, MD1, Ana Espinosa, PhD1, Raquel Sánchez-Valle1, Mircea Balasa1,2, Sergi Borrego1, Magdalena Castellví1, Adrià Tort-Merino1, Jaume Oliveres1, Beatriz Bosch1, Guadalupe Fernández1, Francisco Lomera1, Núria Bargalló1, Albert Llado1
1Relkin Consulting LLC, Harrington Park, NJ 07640, 2HerbalScience Group, Naples FL, USA, 3Syneos Health, Miami FL, USA

**P57** - Concordance of the CSF Abeta42/Abeta40 ratio with amyloid-PET in the BioFINDER study
Oskar Hansson MD PhD1,2, Katharina Zinth MSc1, Simone Wahl PhD2, Monika Widmann ChTech3, Sandra Rutz PhD1, Maryline Simon PhD1, Kaj Blennow MD PhD1,2
1Clinical Memory Research Unit, Lund University, Malmö, Sweden, 2Memory Clinic, Skåne University Hospital, Malmö, Sweden, 3Centralised & Point of Care Solutions, Roche Diagnostics GmbH, Penzberg, Germany, 4Centralised & Point of Care Solutions, Roche Diagnostics GmbH, Penzberg, Germany, 5Clinical Neurochemistry Laboratory, Sahlgrenska University Hospital, Malmö, Sweden, 6Institute of Neuroscience and Physiology, Dept. of Psychiatry and Neurochemistry, The Sahlgrenska Academy at University of Gothenburg, Mölndal, Sweden

**P64** - Novel pre-analytical protocol for handling of cerebrospinal fluid samples for the analysis of Alzheimer’s Disease biomarkers in clinical practice
Oskar Hansson MD PhD1,2, Erik Stomrud MD PhD2, Sandra Rutz PhD1, Valeria Lifie PhD1, Ekaterina Bauer MBA PhD3, Udo Eichenlaub PhD3, Richard Botría MD PhD1,2, Ekaterina Manuilova MSc1, Mehmet Can Mert PhD1, Simona Wahl PhD1, Kaj Blennow, MD, PhD3
1Clinical Memory Research Unit, Lund University, Malmö, Sweden, 2Memory Clinic, Skåne University Hospital, Malmö, Sweden, 3Centralised & Point of Care Solutions, Roche Diagnostics GmbH, Penzberg, Germany, 4Centralised & Point of Care Solutions, Roche Diagnostics GmbH, Penzberg, Germany, 5Clinical Neurochemistry Laboratory, Sahlgrenska University Hospital, Malmö, Sweden, 6Institute of Neuroscience and Physiology, Dept. of Psychiatry and Neurochemistry, The Sahlgrenska Academy at University of Gothenburg, Mölndal, Sweden
P65 - Serum-Based Proteins as Novel Biomarkers for the Diagnosis of Alzheimer’s Disease
Shu Yu1, Yue-Ping Liu2
1State Key Laboratory of Military Stomatolog and National Clinical Research Center of Oral Disease and Shaanxi Clinical Research Center for Oral Disease, Department of Laboratory Medicine, School of Stomatology, Fourth Military Medical University, Xi’an, Shaanxi Province 710032, China; 2Department of Laboratory Medicine, 477th Hospital of PLA, Xiangyang, Hubei Province 400013, China. * Corresponding author

P66 - TREM2 DNA methylation: A potential biomarker or therapeutic target
Lynn Bektris1, Rumana Akhter1, Yvonne Shaol1, Maria Khrestian1, Giana D’Alleo1, Shane Formica1, James B. Leverenz2
1Genomic Medicine Institute, Lerner Research Institute, Cleveland Clinic, Cleveland, Ohio; 2Cleveland Clinic Lou Ruvo Center for Brain Health, Cleveland Clinic, Cleveland, Ohio.

P73 - Immune state in cognitive impairment of aged and the use of Actovegin and Ceraxone in out-patients of Alzheimer’s centre
Natalya Milhavlova1, Lubov Androsova2
1MD, PhD, Ceramic psychiatry Department, Mental health research center, Moscow, Russia; 2PhD, Immunology laboratory, Mental health research centre, Moscow, Russia.

P78 - Modifiable Alzheimer’s risk biomarkers
Christiane Ganz1, Alon Seifan MD1, Krista Ryon1, Elizabeth Maiche MCMSc, PA-C4
1Hunter College, NY; 2NeuroWell Free, Ft. Lauderdale, Florida; 3Hunter College, NY; 4NeuroWell Free, Ft. Lauderdale, Florida.

P81 - Serum NFL, TAU, GFAP and UCHL-1 in Alzheimer disease patients with different decline profile
MéliSSA Jacob, MD1,2, AleXandra Maceshi, PhD5, Stiene Richaert PhD1, Audrey Gabelle MD, PhD2,3, Sylvain Lehmann MD, PhD2,3
1Memory Research and Resources Center, Department of Neurology, Montpellier University Hospital, Montpellier, France; 2Université de Montpellier, MUSE, Montpellier, France; 3Inserm U1183 IRMB, Montpellier, France; 4Inserm U1061, La Colombière Montpellier University Hospital, Montpellier, France.

P125 - An ultra-sensitive molecular immuno-assay for quantification of human SNAP25 in cerebrospinal fluid
Eugene Vanmechelen, PhD1, Jeroen Vanbrabant, PhD1, Naomi De Roech, BSc2, Maria Bjørkette, PhD2, Sebastián Engelborghs, MD, PhD2,3, Ann De Vos, PhD1
1ADx NeuroSciences NV, Ghent, Belgium; 2Reference Center for Biological Markers of Dementia (BIODEM), Institute Born-Bunge, University of Antwerp, Antwerp, Belgium.

P126 - Plasma and CSF biomarkers for the diagnosis of Alzheimer’s disease in adults with Down Syndrome. A cross-sectional study
Maria Carmona-Iragui, MD, PhD1,2,3, Bessy Benezaim, MSc4, Susana Fernández, MD2, Laura Videla, MSc2,3, Isabel Barroeta, MD, PhD1,5, Daniel Alcolea, MD, PhD1, Jordi Pegueroles, MSc1,2, Laia Muñoz, MSc1,2, Olivia Belbin, PhD3, Jordi Clarión, PhD3, Mony John de Leon, EdD1, Sebastián Videla, MD, PhD1,2, Alejandra Maleska Macieschi, MSc1, Antonio Hirtz, PhD2, Constance Delaby, PhD3, Sylvain Lehmann, PhD3, Rafael Blesa, MD PhD2,3, Alberto Lleo, MD, PhD2,3, Juan Foroza, MD PhD2,3
1Memory Unit, Department of Neurology, Hospital de la Santa Creu i Sant Pau; 2Biomedical Research Institute Sant Pau-Universitat Autònoma de Barcelona, Spain; 3Barcelona Dauan Medical Center: Fundación Catalana de Síndrome de Down, Barcelona, Spain; 4Centro de Investigación Biomédica en Red de Enfermedades Neurodegenerativas (CIBERNED), Spain; 5New York University School of Medicine, NYU Center for Brain Health, Department of Psychiatry, New York, USA.

P127 - The application of Polygenic Risk Score analysis to Stratification of Subjects for Clinical Trials in Alzheimer’s Disease in carriers and non-carriers of the ApoE4 risk allele
Richard Pither PhD1, Ganna Leonenko1, Rebecca Simms1, Paula Daunt PhD1, Greg Davidson PhD1, Alex Gibson PhD1, Olusegun Oshota PhD1, Maryam Shoai PhD1, Kevin Bank3, Simon M Laws PhD1, Zsuzsanna Nagy1 and John Hardy, PhD, DSc2, Julie Williams PhD2, Valentina Escott-Price, PhD2
1Cardiff University, United Kingdom; 2Cytopex Ltd, UK; 3Oxford, United Kingdom; 4UCL Institute of Neurology, London, United Kingdom; 5Edith Cowan University, and Cooperative Research Centre (CRC) for Mental Health, Perth, Australia; 6University of Birmingham, United Kingdom; 7Dementia Research Institute, Cardiff, United Kingdom.

P128 - Do short Aβ peptides impact the time course of cognitive decline? An ADNI analysis
Markus von Ickelen, PhD1, Paul Delmar, PhD2, Katharina Buck, PhD3, Charlotte Schärfe2, Simone Wahl, PhD2, Karlheinz Baumann, PhD2, Irene Gerlach, PhD1, Tania Nikrolcheva, MD, PhD1
1pRED NORD, Roche Innovation Center Basel - Switzerland; 2Biostars and Data Management, Roche Innovation Center Munich - Germany.

P129 - Measuring oligomerization tendency of plasma as a new blood-based biomarker for Alzheimer’s disease
SangYun Kim, MD, PhD1,2, SungMin Kang, MS1, Seong Soo A. An, PhD1, Young Chul Youn, MD, PhD1
1Department of Neurology, Seoul National University College of Medicine, Clinical Neuroscience Center, Seoul National University Bundang Hospital; 2PeopleBio Company, Department of Bionano Technology, Gachon Medical Research Institute, Gachon University, Department of Neurology, Chung-Ang University College of Medicine.
P130 - Transcranial magnetic stimulation predicts cognitive decline in Alzheimer’s disease patients
Giacomo Koch MD1,2, Caterina Motta MD1, Francesco Di Lorenzo MD1, Maria Concetta Pelliciari PhD1,2, Sonia Bonni PhD3, Silvia Picazio PhD1,2, Carlo Cataltigione MD3, Alessandro Martorana MD4
1Department of Behavioral and Clinical Neurology, 2Santa Lucia Foundation IRCCS, Rome, Italy, 3University of Tor Vergata, Rome, Italy

P131 - Non-core biomarkers (neurofilament light, neurogranin, 14-3-3 and YKL-40) in the Alzheimer’s disease continuum, frontotemporal dementia and prion diseases diagnosis
Anna Antonell1, PhD1, Adrià Tort, MSc1, José Rios, MSc2, Sergi Borrego, MD1, Mireia Balasa, MD1, Cristina Muñoz-García1, Beatriz Bosch, PhD1, Neus Falgàs, MD1, Lorena Rami, PhD1, Kaj Blennow, MD, PhD1, Henrít Zetterberg, PhD4-5, José Luis Molinuevo, MD, PhD1, Albert Lladó, MD, PhD1, Raquel Sánchez-Valle, MD, PhD1
1Alzheimer’s disease and other cognitive disorders Unit. Hospital Clinic. IDIBAPS. Barcelona, Spain, 2Medical Statistics Core Facility, Institut d’Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS) and Hospital Clinic. Barcelona. Biostatistics Unit, Faculty of Medicine, Universitat Autònoma de Barcelona, 3Department of Psychiatry and Neurochemistry, Institute of Neuroscience and Physiology, The Sahlgrensa Academy, at the University of Gothenburg, Mölndal, Sweden, 4Clinical Neurochemistry Laboratory, Sahlgrenska University Hospital, Mölndal, Sweden, 5Department of Molecular Neuroscience, University College London, London, UK

P132 - Amyloid blood biomarker detect Alzheimer’s disease
Klaus Cervert, Prof. Dr.1
1Ruhr-Universität Bochum, Bochum, Germany

P133 - Early diagnosis of Mild Cognitive Impairment and Alzheimer’s disease based on salivary lactoferrin
Eva Carro1, Gorha Orive2
1Networked Biomedical Research Center in Neurodegenerative Diseases (CIBERNED), Spain; Group of Neurodegenerative Diseases, Hospital de la Santa Creu i Sant Pau, Barcelona, Spain; 2Laboratory of Immunology, Barcelona Institute for Global Health (IDISB), Autonomous University of Barcelona, Barcelona, Spain

Anna Antonell1, PhD1, Raquel Sánchez-Valle, MD, PhD1, Neus Falgàs, MD1, Mireia Balasa, MD, PhD1, Debyanan Datta, PhD2, Lluis Armengol, PhD2, Sergi Borrego, MD1, Guadalupe Fernández1, Beatriz Bosch, PhD1, Jaume Olives1, Cristina Muñoz-García1, María León1, Magdalena Castellví1, Adrià Tort1, Albert Lladó, MD, PhD1
1Alzheimer’s disease and other cognitive disorders Unit. Hospital Clinic. IDIBAPS. Barcelona, Spain, 2aGenomics (Quantitative Genomic Medicine Laboratories), Esplugues de Llobregat; Spain

P135 - The future of blood-based htnase biomarkers in Alzheimer’s disease
Jacques Hugon, Julien Dumurgier, Emmanuel Cognat, Claire Paquet
Center of Cognitive Neurology, Lariboisiere Hospital, AP-HP, University of Paris Diderot, Paris France

P136 - A prototype SIMOA assay quantifying plasma amyloid beta 1-42 and 1-40 isoforms can differentiate AD from healthy control subjects
Charlotte E. Teunissen, PhD1, Elisabeth Thijssen, MSc2, Inge M. W. Verberk, MSc2, Hugo Marcel Vanderstichele, PhD1, Hans Heijst1, Harry Twaalthoven2, Kimberly Mauroo BSc1, Philip Scheltens, MD, PhD1, and Erlik Stoops, Eng1
1Neurochemistry Laboratory and Biobank, Amsterdam University Medical Center, Amsterdam, Netherlands, 2Neurochemistry Laboratory, Department of Clinical Chemistry, Amsterdam University Neuroscience, Amsterdam University Medical Center Amsterdam, Netherlands, 3ADx NeuroSciences, Gent, Belgium, 4Amsterdam University Medical Center, Department of Neurology, Amsterdam, Netherlands

P137 - Serum-Based Proteins as Novel Biomarkers for the Diagnosis of Alzheimer’s Disease
Shu Yu1, Yue-Ping Liu2
1State Key Laboratory of Military Stomatology and National Clinical Research Center for Oral Disease and Shaanxi Clinical Research Center for Oral Disease, Department of Laboratory Medicine, School of Stomatology, Fourth Military Medical University, Xi’an, Shaanxi Province China, 2Department of Laboratory Medicine, 477th Hospital of PLA, Xiangyang, Hubei Province, China. * Corresponding author

P138 - Inflammatory markers tracking cognitive and biomarker heterogeneity in MCI stage of Alzheimer’s Disease
Jagan A Pillai MBBS PhD1,2, James Bena MS1, Lynn M Bekris PhD2, James B Leverenz MD2
1Lou Ruvo Center for Brain Health, 2Neurological Institute and 3Department of Neurology, 4Quantitative Health Sciences, 5Genomic Medicine Institute, Cleveland Clinic, Cleveland, OH, USA

P139 - The pitfalls for clinical trials of the use of time points earlier than 90 min for the [18F]MK-6240 SUVR calculation
Tharich A Pascoal MD1, Sulantha Mathotaarachchi MSc1, Mira Chamoun PhD1, Joseph Therriault BSc1, Robert Hopewell PhD2, Cassan Massarweh PhD1, Andrea L Benedet1, MSc, BSc, Min Su Kang1, Serge Gauthier1, MD, Pedro Rosa-Neto1, MD, PhD1
1Translational Neuroimaging Laboratory, McGill University Research Centre for Studies in Aging, McGill University, Montreal, Canada

P140 - Amyloid blood biomarker detect Alzheimer’s disease
Klaus Cervert, Prof. Dr.1
1Ruhr-Universität Bochum, Bochum, Germany

Anna Antonell1, PhD1, Raquel Sánchez-Valle, MD, PhD1, Neus Falgàs, MD1, Mireia Balasa, MD, PhD1, Debyanan Datta, PhD2, Lluis Armengol, PhD2, Sergi Borrego, MD1, Guadalupe Fernández1, Beatriz Bosch, PhD1, Jaume Olives1, Cristina Muñoz-García1, María León1, Magdalena Castellví1, Adrià Tort1, Albert Lladó, MD, PhD1
1Alzheimer’s disease and other cognitive disorders Unit. Hospital Clinic. IDIBAPS. Barcelona, Spain, 2aGenomics (Quantitative Genomic Medicine Laboratories), Esplugues de Llobregat; Spain

P142 - The future of blood-based htnase biomarkers in Alzheimer’s disease
Jacques Hugon, Julien Dumurgier, Emmanuel Cognat, Claire Paquet
Center of Cognitive Neurology, Lariboisiere Hospital, AP-HP, University of Paris Diderot, Paris France

P143 - A prototype SIMOA assay quantifying plasma amyloid beta 1-42 and 1-40 isoforms can differentiate AD from healthy control subjects
Charlotte E. Teunissen, PhD1, Elisabeth Thijssen, MSc2, Inge M. W. Verberk, MSc2, Hugo Marcel Vanderstichele, PhD1, Hans Heijst1, Harry Twaalthoven2, Kimberly Mauroo BSc1, Philip Scheltens, MD, PhD1, and Erlik Stoops, Eng1
1Neurochemistry Laboratory and Biobank, Amsterdam University Medical Center, Amsterdam, Netherlands, 2Neurochemistry Laboratory, Department of Clinical Chemistry, Amsterdam University Neuroscience, Amsterdam University Medical Center Amsterdam, Netherlands, 3ADx NeuroSciences, Gent, Belgium, 4Amsterdam University Medical Center, Department of Neurology, Amsterdam, Netherlands

P144 - Serum-Based Proteins as Novel Biomarkers for the Diagnosis of Alzheimer’s Disease
Shu Yu1, Yue-Ping Liu2
1State Key Laboratory of Military Stomatology and National Clinical Research Center for Oral Disease and Shaanxi Clinical Research Center for Oral Disease, Department of Laboratory Medicine, School of Stomatology, Fourth Military Medical University, Xi’an, Shaanxi Province China, 2Department of Laboratory Medicine, 477th Hospital of PLA, Xiangyang, Hubei Province, China. * Corresponding author

P145 - Inflammatory markers tracking cognitive and biomarker heterogeneity in MCI stage of Alzheimer’s Disease
Jagan A Pillai MBBS PhD1,2, James Bena MS1, Lynn M Bekris PhD2, James B Leverenz MD2
1Lou Ruvo Center for Brain Health, 2Neurological Institute and 3Department of Neurology, 4Quantitative Health Sciences, 5Genomic Medicine Institute, Cleveland Clinic, Cleveland, OH, USA

P146 - The pitfalls for clinical trials of the use of time points earlier than 90 min for the [18F]MK-6240 SUVR calculation
Tharich A Pascoal MD1, Sulantha Mathotaarachchi MSc1, Mira Chamoun PhD1, Joseph Therriault BSc1, Robert Hopewell PhD2, Cassan Massarweh PhD1, Andrea L Benedet1, MSc, BSc, Min Su Kang1, Serge Gauthier1, MD, Pedro Rosa-Neto1, MD, PhD1
1Translational Neuroimaging Laboratory, McGill University Research Centre for Studies in Aging, McGill University, Montreal, Canada
**Late Breaking Posters**

**LBP25 - Discovery of AN Endogenous Metabolite of Tramiprosate and its Prodrug ALZ-801 that Inhibits Beta Amyloid Oligomer Formation in Human Brain**

John A. Hey1, Petr Kocis, Jakub Hort2, Susan Abushaher, Aidan Power1, Martin Vyhnálek3, Jeremy Y. Yu1 and Martin Tolar1

1-Alzheimer Inc, Framingham, MA, USA, 2-International Clinical Research Centre, St. Anne's University Hospital Brno, Brno, Czech Republic, 3-Cognitive Center, Department of Neurology, Charles University, 2nd Faculty of Medicine and Motol University Hospital, Czech Republic

**LBP26 - Novel use of aptamer libraries for prediction of amyloid status from blood serum**

Gregory Pengen1, Sozic Leconteq1, Anaëlle Chopini, Simone Lista1,2, Andrea Vergallo1,2, Enrica Cavedo1,2, Francois-Xavier Lejeune1, and Harald Hampel2,3,4,5,6, the INSIGHT-preAD study group and the Alzheimer Precision Medicine Initiative (APMI)

1-Clinical Neurology, Lille University Hospital, Lille, France, 2-XXV Research Fund & Sorbonne University Chair, Paris, France, 3-Sorbonne University, CRC n° 21, Alzheimer Precision Medicine (APM), AP-HP, Pitié-Salpêtrière Paris, France, 4-Brain & Spine Institute (ICM), INSERM U 1127, CNRS UMR 7225, Paris, France, 5-Institute of Memory and Alzheimer’s Disease (M2A) Department of Neurology, Pitié-Salpêtrière Hospital, AP-HP, Paris, France

**LBP27 - Novel cerebrospinal fluid synaptic markers in Alzheimer’s disease for potential use in clinical trials**

Alberto Lleo MD, PhD1,2, Raul Nuñez-Llaves1,2, Daniel Alcolea MD, PhD3, Martí Comol-Cadena PhD3,4, Laia Muñoz2,4, Marta Querol-Vilaseca2,5, Jordi Pegueroles1,4, Lorena Rami PhD2, Albert Lladó MD, PhD3, José M. Molinuevo MD, PhD4, Mikel Tainta MD, PhD5, Jordi Clarimón PhD6,7, Tara Spirent2,3,7, Elia Blesa MD, PhD8, Juan Fortea MD, PhD8, Pablo Martínez-Lage MD, PhD9, Raquel Sánchez-Valle MD, PhD9, Alex Bayes PhD10, Olivia Belbin PhD11

1-Memory Unit, Neurology Department, Hospital de la Santa Creu i Sant Pau, Barcelona, Spain, 2-Centro de Investigación Biomédica en Red sobre Enfermedades Neurodegenerativas (CIBERNED), Madrid, Spain, 3-Biomedical Research Institute Sant Pau (IIB Sant Pau), Barcelona, Spain, 4-Alzheimer’s Disease and Other Cognitve Disorders Unit, Neurology Department, Hospital Clinic-Institut d’Investigacions Biomediques August Pi i Sunyer (IDIBAPS), Barcelona, Spain, 5-Department of Neurology, Center for Research and Advanced Therapies, CITA-Alzheimer Foundation, San Sebastian, Spain, 6-Centre for Discovery Brain Sciences and UK Dementia Research Institute, University of Edinburgh, 7-Molecular Physiology of the Synapse Laboratory, Biomedical Research Institute Sant Pau (IIB Sant Pau), Barcelona, Spain, 8-Universitat Autònoma de Barcelona, Bellaterra (Cerdanyola del Vallès), Spain

**LBP28 - Diminished platelet-derived hsa-miR-150-5p expression as biomarker for dementia with Lewy bodies versus Alzheimer’s disease**

Katriin Beyer, PhD1, Ana Gámez-Valero, PhD2, Jaume Campdelacreu, MD, PhD3, Dolores Vilas, MD, PhD3, Lourdes Isiperti, MD, PhD4, Jordi Gascón-Bayarri, MD5, Ramón René, MD, PhD5, Ramiro Álvarez, MD5, Maria P Armengol, PhD3, Francesc E. Borras, PhD5

1-Department of Pathology, Health Research Institute Germans Trias i Pujol, Universitat Autònoma de Barcelona, Spain, 2-Intramural Research Program, National Institute of Neurological Disorders and Stroke, National Institutes of Health, Bethesda, Maryland, USA, 3-Department of Neurology, Hospital Universitari de Bellvitge, L’Hospitalet de Llobregat, Spain, 4-Department of Neurology, Hospital Universitari Germans Trias i Pujol, Badalona, Spain, 5-Institute of Memory and Alzheimer’s Disease (M2A), Department of Neurology, Pitié-Salpêtrière Hospital, AP-HP, Paris, France

**LBP29 - Development of polygenic risk scores (PRS) for common neuropathology**

Julie Collens, PhD1, Milte Nalis, PhD2, Marcel van der Brug, PhD3

1-Vivad Genomics, Inc, San Diego, CA, USA

**LBP30 - The Italian Inter-Societal consensus framework for the biomarker-based diagnosis of mild cognitive impairment**

Marina Boccardi, PhD1,2, Paola Lattanzio, MD1,2, Cristina Festari, MS1,2, Angelo Bianchetti, MD1,2, Stefano Cappa, MD1,2, Davide Chiasserini, PhD2, Andrea Falini, MD1,2, Ugo Paolo Guerra, MD1,2, Flavio Nobili, MD1,2, Alessandro Padovani, MD1,2, Giulia Maria Sansevero, PhD1,2, Francesca Benedetta Pizzini, PhD1,2, Alberto Beltramello, MD1,2, Marcello Ciaccio, MD1,2, Orazio Schillaci, MD1,2, Marco Trabucchi, MD1,2, and Giovanni Battista Frisoni, MD1,2,3

1-Laboratory of Neuroimaging and Alzheimer’s Epidemiology, IRCCS Istituto Centro San Giovanni di Dio Fatebenefratelli, Brescia, Italy, 2-LANVIE Laboratory of Neuroimaging of Aging, University of Geneva, Geneva, Switzerland, 3-Université de Béziers, Department of Molecular and Translational Medicine, Béziers, France, 4-Medicine and Rehabilitation Department, Istituto Clinico San Camillo Dell’Addetta, Rome, Italy, 5-Italian Psychogeriatric Association (AIP), Brescia, Italy, 6-NECS Center, Scuola Universitaria Superiore IUSS, Pavia, Italy, 7-Italian Society of Neurology, Association for the Study of the Dementias (SIdNem), Italy, 8-Section of Neurology, Department of Medicine, University of Perugia, Perugia, Italy, 9-Iranian Society of Clinical Biochemistry and Clinical Molecular Biology, Laboratory Medicine (ISBioc), Italy, 10-Division of Neuroscience, IRCCS San Raffaele, Milan, Italy, 11-Vita-Salute San Raffaele University, Milan, Italy, 12-Neurorehabilitation Unit, IRCCS San Raffaele hospital, Milan, Italy, 13-Italian Association of Neurorehabilitation (AIReN), Italy, 14-Department of Nuclear Medicine, Poliambulanza Foundation, Brescia, Italy, 15-Italian Association of Nuclear Medicine (AIMN), Italy, 16-Clinical Neurology, Dept of Neuroscience (DINOGM), University of Genova, Italy, 17-IRCCS Ospedale Policlinico San Martino, Genova, Italy, 18-Neurology Clinic, Department of Clinical and Experimental Sciences, Brescia, Italy, 19-Department of Clinical and Behavioural Neurology, Santa Lucia Foundation, Rome, Italy, 20-Department of Neurobiology, General Hospital, Verona, Italy, 21-Dipartimento di Diagnostica per Immagini, IRCCS Ospedale Classificato «Sacro Cuore - Don Calabria», Negrar, Verona, Italy, 22-Department of Biopathology and Medical Biotechnologies, University of Palermo, Palermo, Italy, 23-Department of Biomedicine and Prevention, University Tor Vergata, Rome, Italy, 24-Tor Vergata, Rome University, Rome, Italy, 25-Division of Neurology/Neuropathology, Fondazione IRCCS Istituto Neurologico “Carlo Besta”, Milan, Italy, 26-Memory Clinic, University Hospital, Geneva, Switzerland

**LBP31 - Secondary structure of Aβ as blood biomarker**

Klaus Gerwert, Department of Biophysics Ruhr University Bochum, Germany
LBP32 - BDNF as a biomarker for the effects of p38 MAPKα inhibition on IL-1β-induced impairment of hippocampal synaptic plasticity
John Alam MD1, Charlotte Teunissen PhD2, Niels Prins MD PhD3, Hui-May Chu PhD4, Philip Scheltens MD PhD4
1EIP Pharma Inc, Cambridge MA, USA, 2Department of Clinical Chemistry, VU University Medical Center, Amsterdam, NL, 3Department of Neurology and Alzheimer Centre, VU University Medical Center, Amsterdam, NL, 4Brain Research Center, Amsterdam, NL, 5Anoixis Corporation, Framingham MA, USA

LBP33 - Impact of pre-analytical sample handling on Elecsys Aβ40, Aβ42 and tTau immunoassays in plasma
Malgorzata Rozga, PhD1, Tobias Bittner, PhD2, Richard Batrila-Utermann, MD, MBA3, Johann Karl, PhD4
1Roche Diagnostics GmbH, Penzberg, Germany, 2Genentech, A member of the Roche Group, Basel, Switzerland, 3Roche Diagnostics International AG, Rotkreuz; Switzerland

LBP34 - Agreement between visual amyloid PET and cerebrospinal fluid Aβ1-42, Aβ1-40, t-Tau and p-Tau on the LUMIPULSE G fully automated platform
Alberto Lló1,2, Jordi Pegueroles2,3, Laia Muñoz2,3, Valle Camacho2,3, Diego López-Mora1, Alejandro Fernández-León1, Nathalie Le Bastard4, Els Huych4, Alicia Nadal1, Verónica Olmedo1, Víctor Montal1,2, Eduard Vilaplana1,2, Rafael Blesa1,2, Juan Fortea1,2, Daniel Alcolea1,3
1Sant Pau Memory Unit, Neurology Department, Hospital de la Santa Creu i Sant Pau, Biomedical Research Institute Sant Pau, Universitat Autònoma de Barcelona, Barcelona, Spain, 2Centro de Investigación Biomédica en Red de Enfermedades Neurológicas y Neurodegenerativas (CIBERNED), Spain, 3Nuclear Medicine Department, Hospital de la Santa Creu i Sant Pau, Biomedical Research Institute Sant Pau, Universitat Autònoma de Barcelona, Barcelona, Spain, 4Fujirebio Europe NV, Gent, Belgium, 5Fujirebio Iberia, SLU, Barcelona, Spain

LBP35 - Does non-disclosure of APOE genotyping prevent subject interest or participation in clinical trials?
Sean Stanton1, Vishnuharkit Nitta, MSc2, Jessica Branning, BS2
1LifeCore Solutions, Winter Park, USA, 2ClinCloud, LLC, Orlando, USA

LBP36 - Measurement of pathological amyloid in a patient cohort in routine clinical assessment: comparison of visual [18F]Flutemetamol PET read and CSFs measures
Nenad Bogdanovic1, Enrico Fantoni2 & Gill Farrar2
1Karolinska Institutet, Stockholm, Sweden and University Hospital Oslo, Oslo University, Norway, 2GE Healthcare Life Sciences. Amersham, UK and Boston, USA

LBP37 - Kinetic measurement of newly generated BACE1-cleaved APP in the human central nervous system in Alzheimer’s disease: a pilot study
Robert J. Vassar, PhD1, Randall J. Bateman, MD2, Bruce W. Patterson, PhD2, Justyna A. Dobrowolska Zaharia, PhD1
1Department of Neurology, Northwestern University, Feinberg School of Medicine, Chicago, IL, USA, 2Department of Neurology, Washington University, in St. Louis, St. Louis, MO, USA, 3Department of Medicine, Washington University, in St. Louis, St. Louis, MO, USA

LBP38 - Reliability of a rapid APOE assay for Alzheimer’s risk assessment and clinical trial screening
Athene Lee, PhD1,2, William Menard, BA1, Gina Tonini, MBA2, Louisa Thompson, PhD2, Jessica Alber, PhD2,12 Stephen Salloway, MD2,12
1Warren Alpert Medical School of Brown University, Providence, RI, USA, 2Butler Hospital, Providence, RI, USA

LBP39 - Cerebrospinal fluid profiling of multiple pathophysiological pathways in Alzheimer’s disease
Steven Arnold MD, PhD1 Bianca A. Trombettta2, Befor Carroll, PhD2
1Massachusetts General Hospital and Harvard Medical School, 2Department of Neurology, Massachusetts General Hospital, Harvard Medical School, Boston, MA

LBP40 - Interim biomarker analyses of phase II study data on safety and efficacy of GMCSF in mild-to-moderate Alzheimer’s disease
Timothy D. Boyd, PhD2,3, Jonathan Woodcock, MD1,3, Stefan Sillau, PhD3,3, Vanesa Adame, BS2,3, Thomas Borges, MD1,3, Ashesh Thaker, MD1,3, Brianne Bettscher, PhD2,3, Joseph Daniels, MS1,3, Kate Heffernan, BS1, Huntington Potter, PhD2,3
1Rocky Mountain Alzheimer’s Disease Center, University of Colorado Anschutz Medical Campus, Aurora, CO, USA, 2Linda Cnac Institute for Down Syndrome, University of Colorado Anschutz Medical Campus, Aurora, CO, USA, 3Department of Neurology, University of Colorado at Anschutz Medical Campus, Aurora, CO, USA, 4Department of Radiology, University of Colorado at Anschutz Medical Campus, Aurora, CO, USA, 5Department of Neurosurgery, University of Colorado at Anschutz Medical Campus, Aurora, CO, USA
Theme 5. Clinical trials: Cognitive and functional endpoints

P2 - Objectively measured physical activity and cognitive function
Hiroyuki Umegaki1, Taeko Makino2, Kazuki Uemura3, Hiroyuki Shimada4, Xian Wu Cheng5
1MD, PhD Department of Community Healthcare & Geriatrics, Nagoya University Graduate School of Medicine, Aichi, Japan, 2PhD Institute of Innovation for Future Society, Nagoya University, Aichi, Japan, 3Liberal Arts and Sciences, Faculty of Engineering, Toyama Prefectural University, Toyama, Japan, 4Department of Preventive Gerontology, Center for Gerontology and Social Science, National Center for Geriatrics and Gerontology, Obu, Japan, 5PhD, Masafumi Kuzuya, MD, PhD, Institute of Innovation for Future Society, Nagoya University, Aichi, Japan

P3 - D-Cycloserine improves difficult discriminations in a pattern separation task in Alzheimer’s disease: Implications for dentate gyrus activity and neurogenesis
Pascal J. D. Goetghebeur1, Keith A. Wesnes2, Steven D. Targum3
1Bracket LLC, Reading, UK. 2Wesnes Cognition Ltd, Streatley on Thames, UK. 3Bracket LLC, Boston, US

P8 - A Multicenter, Open-label, 24-week Follow-up Study for Efficacy on Cognitive Function of Donepezil inBinswanger-Type Subcortical Vascular Dementia
Jay Cheol Kwon, M.D.1, Eung Gyu Kim, M.D.1, Jae Woo Kim, M.D.1, Oh Daewon Kwon, M.D.1, Bong Goo Yoo, M.D.2, Nam-Gon Kim, M.D.2, Nach Cheon Choi, M.D.2, Seon young Ahn, M.A., Byung Hwa Lee, M.D.3, Myong Jin Kang, M.D.3, Dae Seob Choi, M.D.4, The BKVD Study Group
1Department of Neurology, Changan University Pusan Paik Hospital, 2Dong-A University Medical Center, 3Dae Gung University, Medical Center, 4Kosin University Gospel Hospital, 5Gimhae Jangang Hospital, 6Cyonggsan National University Hospital, 7Department of Radiology, 8Dong-A University Medical Center, 9Cyonggsan National University Hospital

P9 - The Correlation of Diabetic Status, Ischemic and Atrophic Burdens on Brain MRI and Cognitive Decline in Seventh Decade Diabetic Patients with Cognitive Impairment. -1 Year Prospective, Observational Study
Jay Cheol Kwon, M.D., Ph.D.1, Kyungsoo Lee, M.D., Yohan Jung, M.D., Ph.D., Sungiae Cho, M.D., Ph.D. And Nach-cheon Choi, M.D., Ph.D.
1Changwon Fatima Hospital, Changwon, Korea, The Republic of, 2Samsung Changwon Hospital, Changwon, Korea, The Republic of, 3Gyeongsang National University Hospital, 4Department of Radiology, 5Cyonggsan National University Hospital, 6Chinju, Korea, The Republic of

P19 - Lanabecestat: Central monitoring of rater performance and error characteristics of efficacy assessments in theAMARANTH study
Alette M. Wessels1, Lisle R. Kingery2, Edward I. Bartolic2, Laura E. Nichelli, Jamie A. Mullen3, John R. Sims1
1Eli Lilly and Company, Indianapolis, IN, USA, 2Cogstate, New Haven, USA, 3AstraZeneca Pharmaceuticals, Cambridge, MA, USA

P26 - A German version of the “Five Word Test” – Discriminating patients with mild cognitive impairment/mild Alzheimer’s disease, healthy controls and patients with depression
Hausner L, MD, Dinu-Biringer R, PhD, Frölich L, MD, PhD
Department of Cerebral Psychiatriy, Central Institute of Mental Health, Medical Faculty Mannheim, University of Heidelberg, Germany

P27 - Use of Medications on Transcranial Doppler Vasoreactivity in Mild Cognitive Impairment
Shim YongSoo, Jung San
Department of Neurology, College of Medicine, The Catholic University of Korea, Seoul, Korea, Department of Neurology, Hallym University Medical Center, Kang Nam Sacred Heart Hospital, Seoul, Korea, Department of Neurology, Bucheon St. Mary’s Hospital, College of Medicine, The Catholic University of Korea, Republic of Korea

P53 - MMSE screening data quality for Alzheimer’s disease studies across countries
Jordan Mark Barbone, BA1, Todd M. Solomon, PhD1,2, H. Todd Feaster, PsyD1, Macarena Garcia-Valdecasas Colell, MSc1, & David S. Miller, MD, MA1
1Bracket, Wayne, PA, USA, 2Boston University School of Medicine, Boston, MA, USA, 3Bracket, Reading, UK

P67 - The presence of identical scoring on the MMSE and ADCS-ADL in Alzheimer’s disease clinical trials using enhanced eCOA devices
Todd M. Solomon, Ph.D.2, Jordan Mark Barbone, B.A.1, Sarah M. Karas, Psy.D1, Danielle T. DiGregorio, Psy.D, Michael R. Maddoch1, MA David M. Miller, MD1, H. Todd Feaster, Psy.D1
1Bracket, Wayne, PA, USA, 2Boston University School of Medicine, Boston, MA, USA
P71 - The treatment response of Goal Attainment Scaling in relation to goal number in a clinical trial of Alzheimer’s Disease Patients
Kenneth Rockwood, MD, Lisa McGarrigle, PhD
Division of Geriatric Medicine, Dalhousie University, Halifax, NS, Canada, 2DGI Clinical Inc, Halifax, NS, Canada

P74 - Predictive value and test-retest reliability of the tablet-based Brief Assessment of Cognition (BAC App) for assessment of cognition in aging: preliminary findings from an ongoing normative study
Anzallee Khan PhD, Danny Ulschen BA, Alexandra Atkins PhD, Dania Balentini BA, Adam Vaughan PhD, Heather Dickerson PhD, Brenda L. Plassman PhD, Kathleen A. Welsh-Bohmer PhD, Rich Keeffe PhD
1NeuroCog Trials, Durham, NC, USA, 2Nathan S. Kline Institute for Psychiatric Research, Orangeburg, NY, USA, 3Duke University, Durham, NC, USA

P77 - Clinical and Amyloid Screen Failure Rates in Episodic Memory Measures of Early AD Trials
Selam Negash, Christopher Weber, Christopher Randolph
MedAdvance-PrePhase, Loyola University Medical Center

P83 - Determinants of care refusal: from patients suffering from dementia to their caregivers characteristics'
Caelkel, Y, Phd, CERDA S., MD
Memory Center, Bagatelle Hospital, Talance, France

P140 - Item bias in the measurement of functional impairment: a cross-cultural comparability study in eight international cognitive aging studies
Siestere, A. M. Sibree, PhD, Mark A. Dubbelman, MSC, Meriteit Verriep, MSC, Gonzalo Sanchez Benavides, PhD, David Facal, PhD, Bruno Dubois, MD, PhD, Wiebes J. van der Flier, PhD, Hanna Johinen, PhD, Cristina Lojo-Seoane, Jose Luis Molinuevo, BD, PhD, Arturo X. Pereiro Rozas, PhD, Craig Ritchie, MD, PhD, Magdalini Tsolaki, MD, PhD, Yau-Huei Wu, PhD, Stelios Zygioures, MSC, Stephane Eipelbaum, MD, PhD, Philip Scheltens, MD, PhD
1Alzheimer Center, Department of Neurology, VU University Medical Center, Amsterdam Neuroscience, Amsterdam, the Netherlands, 2Department of Epidemiology and Biostatistics, VU University, Amsterdam Medical Center, Amsterdam, the Netherlands, 3BarcelonaBeta Brain Research Center, Fundacio Pasqual Maragall, Barcelona, Spain, 4Hospital Pitié-Salpêtrière, IM2A, PARIS, France, 5Department of Developmental Psychology, University of Santiago de Compostela, Spain, 6Clinical Neurosciences, Neurourlogy, University of Helsinki and Helsinki University Hospital, Finland, 7University of Edinburgh, United Kingdom, 81st Department of Neurology, Aristotle University of Thessaloniki, Greece, 9Greek Association of Alzheimer’s Disease and Related Disorders, Greece, 10Bracopa Hospital, Paris, France II Neurolog Aging Research, University of Heidelberg, Germany

Susan Abushakra MD*, Bruno Vellas MD, Serge Gauthier MD, Anton Postoeinsson MD, Carl Sadowsky MD, Aidan Power MD, Larry Shen PhD, Lu Wang MS, Tim Lin MS, John Hey PhD, Martin Tolar MD PhD
*Alzheimer’s, Inc, Framingham, MA, USA, 2University of Toulouse, Toulouse, France, 3McGill University, Montreal, Canada, 4University of Rochester, Rochester, New York, 5Palm Beach Neurology and Nova SE University, Fort Lauderdale, Florida, 6Pharmapace, Inc., San Diego, CA

Ana Espeset, PhD, Begona Hernández-Obisaguirre, PhD, Sonia Moreno-Grau, MSC, Luca Kleineidam, MSC, Stefanie Heilmann, PhD, Isabel Hernández, MD, PhD, Steffen Wolfsgruber, Dipl.-Psych, Holger Wagner, MSC, Maitée Rosende-Roca, MD, Ana Mauleón, MD, Liliana Vargas, MD, Asunción Lafuente, MD, Octavio Rodríguez-Gómez, MD, Carla Abdelnour, MD, Silvia Gis, MD, PhD, Marta Marquié, MD, PhD, Miguel A. Santos-Santos, MD, PhD, Ángela Sanabria, PhD, Gemma Ortega, PhD, Gemma Monté, PhD, Alba Pérez, MSC, Marta Ibarría, MSC, Susana Ruiz, MSC, Johannes Kornhuber, MD, PhD, Oliver Peters, MD, PhD, Lutz Fröhlich, MD, PhD, Michael Hüll, MD, Jens Wiltfang, MD, Martin Scherer, MD, Tobias Luch, Dipl.-Psych, Steffi Riedel-Heller, MD, Laura Montreuil, MSC, Pilar Cañabate, PhD, Mariola Moreno, MSC, Silvia Prechtler, MSC, Nuria Aguiler, MSC, Iztár de Rojas, MSC, Adela Orellana, PhD, Montserrat Alegría, PhD, Sergio Valero, PhD, Markus M Nöthen, MD, Michael Wagner, PhD, Franit Jussen, PhD, Wolfgang Maier, MD, LLuis Tárrega, MSC, Mercé Boada, MD, PhD, Alfredo Ramirez, MD, PhD, and Agustin Ruiz, MD, PhD
*Research Center and Memory Clinic Fundació ACE. Institut Canari de Neurolègiques Aplicades, IJIC-Barcelona, Spain, 2German Center for Neurodegenerative Diseases (DZNE), Bonn, Germany, 3Department for Neurodegenerative Diseases and Geriatric Psychiatry, University Hospital Bonn, Bonn, Germany, 4Department of Psychiatry and Psychotherapy, University of Cologne, Cologne, Germany, 5Institute of Human Genetics, University of Bonn, Bonn, Germany, 6Department of Genomics, Life and Brain Center, University of Bonn, Bonn, Germany, 7Department of Psychiatry and Psychotherapy, University of Bonn, Bonn, Germany, 8Department of Psychiatry and Psychotherapy, University Clinic Erlangen, Erlangen, Germany, 9Department of Psychiatry, Charité University Medicine, Berlin, Germany, 10Department of Geriatric Psychiatry, Central Institute of Mental Health, Medical Faculty Mannheim, University of Heidelberg, Mannheim, Germany, 11Center for Geriatric Medicine and Section of Gerontopsychiatry and Neuropsychology, Medical School, University of Freiberg, Freiberg, Germany, 12Department of Psychiatry and Psychotherapy, University of Göttingen, Göttingen, Germany, 13Department of Primary Medical Care, University Medical Center Hamburg-Eppendorf, Hamburg, Germany, 14Institute of Social Medicine, Occupational Health and Public Health, University of Leipzig, Leipzig, Germany
CTAD 2018

POSTERS PRESENTATION

P143 - Baseline characterization of the European prevention of Alzheimer’s dementia (EPAD) longitudinal cohort study (LCS)

Michael T. Ropach, PhD1, John Harrison, PhD2, Joel Kramer, PsyD3, Christopher Randolph, PhD4, Jeffrey Kaye, MD5, Bruce Albala, PhD6, Karen Ritchie, PhD7-9

1Strategic Global Research & Development, Half Moon Bay, USA, 2Meis Cognition Ltd, UK, 3Alzheimer Center VUmc, Amsterdam, Netherlands, 4Department of Neurology, Memory and Aging Center, University of California at San Francisco, San Francisco, USA, 5Department of Neurology, Loyola University Medical Center, Maywood, USA, 6Neurology and Biomedical Engineering, Oregon Health and Science University, Portland, USA, 7Institut National de la Santé et de la Recherche Médicale, U1061 Neuropsychiatrie, Montpellier, France, 8Faculty of Medicine, University of Montpellier, Montpellier, France, 9Center for Dementia Prevention, University of Edinburgh, Edinburgh, UK

P144 - Two distinct modelling approaches of cognitive decline and time to diagnosis of MCI/dementia to inform study design and to improve risk prediction in preclinical Alzheimer’s Disease

Angelita Caputo, PhD1, Ana Graf, MD2, Cristina Lopez Lopez, PhD, MD3, Valery Risson, PhD4, Giulia Lestini, PhD5, Neva Coello, PhD6, Amy Racine, PhD7, Ines Paule, PhD8, Luyuan Qi, PhD9, Helene Karcher, PhD9

1Novaris Pharma AG, Basel, Switzerland, 2Analytica Laser, a Certara company, Paris, France, 3Analytica Laser, a Certara company, London, UK

P146 - Comparison of sleep measurements from actigraphy to self-reported sleep diaries

Kirsti Kinnunen, PhD1, Richard Joules, PhD1, Janet Munro, MPH2, Iain Simpson PhD3, Robin Wols, PhD2, Yves Dauvilliers, MD PhD3

1XICO Plc, London, UK, 2Imperial College London, London, London, UK, 3Sleep Unit, Department Neurology, Centre Hospitalier Universitaire, Montpellier, INSERM U1061, France

P147 - Using DCTclock’s clinically-interpretable artificial intelligence for differentiating cognitively healthy subjects from amnestic Mild Cognitive Impairment and probable Alzheimer’s Disease

William Souillard-Mandari1, Braydon Schaible2, Randall Davis PhD3, Rhoda Au PhD3, Dana Penney PhD3

1Digital Cognition Technologies, Inc., Waltham, MA, USA, 2MIT Computer Science and Artificial Intelligence Laboratory, Cambridge, MA, USA, 3Boston University Schools of Medicine and Public Health, Boston, MA, USA, 4Lahey Hospital and Medical Center, Burlington, MA, USA

P148 - Advancing Clinical and Biomarker Research in AD: The LEAD Study

Ljana G. Apostolova, MD, Paul Aisen, MD, Ani Eloyan, PhD, Brian Fagan, PhD, Tatiana Foroud, PhD, Constantine Gatsonis, PhD, Clifford Jack, MD, Joel Kramer, PsyD, Robert Keoppe, PhD, Andrew Saykin, PsyD, Arthur Toga, PhD, Prashanthi Vemuri, PhD, Gregory Day, MD, MSc, Neill Graff-Radford, MD, Lawrence Honig, MD, David Jones, MD, Sterling Johnson, PhD, Joseph Masdeau, MD, Mario Mendez, MD, Chadly Onyike, MD, Emily Rogalski, PhD, Steve Salloway, MD, David Wolz, MD, Thomas Wingo, MD, Maria Cantillo, PhD, Brad Dickerson, MD, Gil Rabinovici, MD

P149 - Measuring Pre-Clinical Cognitive Decline over Time: Separating and Combining Alzheimer’s Specific Decline and Cognitive Decline Related to Aging in Cognitive Composite Scores

Suzanne Hendrix, PhD1, Noel Ellison, MS1, Jessica B. Langbaum, PhD2, Kewei Chen, PhD3 and David A. Bennett, MD4

1Pentara Corporation, Millcreek, UT, USA, 2Arizona Alzheimer’s Consortium, Phoenix, AZ, USA, 3University of Arizona, Tucson, AZ, USA, 4Rush University, Chicago, IL, USA

Late Breaking Posters

LBP41 - Effects of 2-year walnut supplementation on cognitive decline in healthy elders: The Walnuts And Healthy Aging (WAHA) study

Nina Coll-Padrós1, Alexia Sala-Vila2, Cinta Valls-Pedret1, Mercè Serra-Mir23, Montserrat Cofán23, Irene Roth2, Tania Freitas-Simoes2, Mónica Domènech1, Lidia Vaqué-Alcázar4, David Bartrés-Faz5, Sujaitha Rajaram6, Joan Sabaté6, Emilio Ros7-9

1Alzheimer Disease and Other Cognitive Disorders Unit, Neurology Service, Hospital Clinic and Institut d’Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Barcelona, Spain, 2Lipid Clinic, Endocrinology and Nutrition Service, Hospital Clinic, Barcelona, Spain, 3CIBER Fisiopatología de la Obesidad y Nutrición (CIBEROBN), Instituto de Salud Carlos III (ISICIII), Spain, 4Institut de Neurociències, Universitat de Barcelona, Barcelona, Spain, 5Neurocenter, Department of Neurology, University Hospitals of Kuopio, Kuopio, Finland, 6Clinical Trials Unit, Department of Gastroenterology, Karolinska University Hospital, Huddinge, Sweden, 7Department of Experimental Medicine, Karolinska University Hospital, Huddinge, Sweden, 8Deutsches Institut für Demenz Prävention (DIDP), Medical Faculty, Saarland University, Homburg, Germany, 9Department of Experimental Medicine, Saarland University, Homburg, Germany

LBP42 - ADCOMS: a post-hoc analysis using data from the LipiDiDiet trial in prodromal Alzheimer’s disease

Suzanne B. Hendrix, PhD1, Hilikta Soininen, MD, PhD2, Pieter Jelle Visser, PhD3, Alina Solomon, MD, PhD2, Miia Kivipelto, MD, PhD2, Tobias Hartmann, PhD4 on behalf of the LipiDiDiet clinical study group

1Pentara Corporation, Salt Lake City, UT, USA, 2Department of Neurology, Institute of Clinical Medicine, University of Eastern Finland and Kuopio University Hospital, Kuopio, Finland, 3Neurocenter, Department of Neurology, Kuopio University Hospital, Kuopio, Finland, 4Department of Psychiatry and Neuropsychology, Alzheimer Center Limburg, University of Maastricht, Maastricht, the Netherlands, 5Department of Neurology, Alzheimer Center, VU University Medical Center, Amsterdam, the Netherlands, 6Department of Clinical Geriatrics, NIVS, Karolinska Institutet, Huddinge, Sweden, 7Department of Experimental Medicine, Karolinska University Hospital, Huddinge, Sweden, 8Deutsches Institut für Demenz Prävention (DIDP), Medical Faculty, Saarland University, Homburg, Germany, 9Department of Experimental Medicine, Saarland University, Homburg, Germany
LBP43 - Intraventricular Injection of Human Umbilical Cord Blood Mesenchymal Stem Cells in Patients with Alzheimer’s Disease Dementia: A Phase I Clinical Trial
Hee Jin Kim, MD, PhD1,2, Kyung Rae Cho, MD2,3, Hyemin Jang, MD, PhD2,3, Jung Il Lee, MD, PhD2,3, Seongbeom Park, MD, PhD1,2, Soo Jin Choi1, Sung Tae Kim, MD, PhD1,2, Seung Hwan Moon, MD, PhD1,2, Kyung-Han Lee, MD, PhD1,2, Sang Won Seo, MD, PhD2,3, Duk L. Na, MD, PhD1,2
Departments of 1Neurology, 2Neurosurgery, 3Radiology, and 4Nuclear Medicine Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea, 1Neuroscience Center, Samsung Medical Center, Seoul, Korea, 3Biomedical Research Institute, MEDIPOST Co., Ltd, Seoul, Korea, 1Department of Clinical Research Design & Evaluation, SAIHST, Sungkyunkwan University, Seoul, Korea, 4Department of Health Sciences and Technology, SAIHST, Sungkyunkwan University, Seoul, Korea

LBP44 - Exploratory analysis of results from the NILVAD trial suggest benefit in very mild AD subjects
Michael Mullan, MBBS, PhD1,2, Laila Abdullah, PhD1,2, Heather Langlois2, Fiona Crawford, PhD1,2, Anders Wallin, MD1, Suzanne Hendrix, PhD1, Kaj Blennow, MD, PhD1, Brian Lawlor, MBBS1,2. The NILVAD consortium
1Archer Pharmaceuticals, Sarasota, FL, USA, 2Roskamp Institute, Sarasota, FL, USA, 1Department of Psychiatry and Neurochemistry, Institute of Neuroscience and Physiology, Sahlgrenska Academy, University of Gothenburg, Sweden, 1Pentara Corporation, Salt Lake City, UT, USA, 1Clinical Neurochemistry Laboratory, Sahlgrenska University Hospital/Mölndal, Mölndal, Sweden, 1Trinity College Dublin, Dublin, Ireland

LBP45 - Can digital footprints capture clinically relevant gait endpoints in non-clinically setting: a Proof of Concept?
Marie McCarthy1, Crystal Gon2
1ICON PLC, Dublin, Ireland, 2Trinity College Dublin, Ireland

LBP46 - Using the power of Dementias Platform UK (DPUK) cohorts to investigate the longitudinal effects of childhood adversity on adult cognition and health outcomes: implications for cognitive change and dementia outcomes
Sarah Bauermeister, PhD and John Gallacher, PhD
University of Oxford, Department of Psychiatry, Oxford, UK
P6 - Evaluation of titers of antibodies against peptides of subunits NRI and NR2B of glutamate receptor by enzyme-linked immunosorbent assay in psychiatric patients with anti-thyroid antibodies
Takahiro Itcura, MD, PhD, Yotohamacity University Psychiatry

P14 - Anosognosia in Mild Cognitive Impairment and Dementia
Dong Won Yang1, Ahro Kimi Dong Woo Lee2, Hyun Jeong Han2, Jun Hong Lee2, Jun-Young Lee2, Kee Hyung Park2, Kiyung Won Park2, SangYun Kim3, Seong Hye Choi6, Young Chul Yoon5
1Department of Neurology, Catholic University of Korea, Seoul, Korea, 2Department of Psychiatry, Inje University Sanggye Paik Hospital, Seoul, Korea, 3Department of Neurology, Myongji Hospital, Goyang, Korea, 4Department of Neurology, Ewha Womans University Hospital, Seoul, Korea, 5Department of Neurology, National Health Insurance Corporation Ilsan Hospital, Goyang, Korea, 6Department of Neurology, Seoul St. Mary's hospital, Catholic University of Korea, Seoul, Korea

P24 - Clinical correlates of types of memory complaints in mild cognitive impairment
Seon Young Ryu1, Dong Sung Lee1, Dong Woo Lee2, Hyun Jeong Han2, Jun Hong Lee2, Jun-Young Lee2, Kee Hyung Park2, Kiyung Won Park2, SangYun Kim3, Seong Hye Choi6, Young Chul Yoon5
1Neurology Department, Daejeon St. Mary's Hospital, College of Medicine, The Catholic University of Korea, Daejeon, South Korea

P29 - A comparison between brief episodic memory and semantic memory tasks within a screening test for mild cognitive impairment
Pamela Vaccia EdS1, Katherine Kruetz, MS1
1Bioclinica Research, The Villages, FL, USA

P33 - Comparative evaluation of tests for the cognitive dysfunction screening in the national medical check-up
Ahro Kim1, Dong Won Yang1, Dong Woo Lee2, Hyun Jeong Han2, Jun Hong Lee2, Jun-Young Lee2, Kee Hyung Park2, Kiyung Won Park2, SangYun Kim3, Seong Hye Choi6, Young Chul Yoon5
1Department of Neurology, Seoul St. Mary's Hospital, Catholic University of Korea, Seoul, Korea, 2Department of Psychiatry, Inje University Sanggye Paik Hospital, Seoul, Korea, 3Department of Neurology, Myongji Hospital, Goyang, Korea, 4Department of Neurology, Ewha Womans University Hospital, Seoul, Korea, 5Department of Neurology, National Health Insurance Corporation Ilsan Hospital, Goyang, Korea, 6Department of Psychiatry, Inje University Sanggye Paik Hospital, Seoul, Korea

P41 - Cognitive impairment under treatment with 2nd and 3rd generation antihistamines in elderly subjects
Georg Adler, Nadja Baumgart
1Institut für Studien zur Psychischen Gesundheit, Mannheim, Germany

P42 - Using Bayesian models to method normative CANTAB cognition data across adulthood
Pasquale Dente1, Elizabeth Baker1, Jack Cotter1, Francesca Cormack1, Jennifer H Barnett12
1Cambridge Cognition Limited, Cambridge, UK, 2University of Cambridge, Cambridge, UK

P47 - Predicting the course of Alzheimer’s
Samuel Jodl1, PhD2, Dan Li, PhD2, Wesley K. Thompson, PhD2, Michael S. Rafi1, MD, PhD1, Paul S. Aisen1, MD, and Michael C Donohue, PhD1
1Alzheimer’s Disease and other Cognitive Disorders Unit, Neurology Department, Hospital Clinic, Barcelona, Spain, 2Global Brain Health Institute, Trinity College Dublin, Dublin, Ireland, 3Altaïda AG, Lucerne, Switzerland, 4Departamento de Medicina, Facultad de medicina and health sciences, University of barcelona, 5School of Psychology, Trinity College Dublin, Dublin, Ireland

P48 - Impaired delayed recall on the International Shopping List Task predicts amyloid positivity and longitudinal decline in CDR-SB scores in MCI
Sharon Rosenzweig-Lipson, PhD1, Richard Mohs, PhD2, Paul Maruff, PhD2, Michela Gallagher, PhD3, and Arnold Babher, PhD3
1Agenebio, Inc, Baltimore, MD, USA, 2Cogstate Ltd, Melbourne, Victoria, Australia, 3Johns Hopkins University, Baltimore, MD, USA

P49 - MMSE screening data quality for Alzheimer’s disease studies across countries
Jordan Mark Sarbone, BA1, Todd M. Solomon, PhD1, H. Todd Feaster, PsyD1, Macarena Garcia-Valdecasas Colell, MSc1, David S. Miller, MD, MA1
1Brachet, Wayne, PA, USA, 2Boston University School of Medicine, Boston, MA, USA, 3Brachet, Reading, UK
P50 - Affective variability predicts cognitive fluctuation and decline in older adults
Edward Zamrini, MD1, Michael Malek-Ahmadi, PhD2, Kathy O’Connor, Sharon Schofield1
Banner Sun Health Research Institute, Sun City, USA, 1Banner Alzheimer’s Institute, Phoenix, USA

P51 - Validation of the geriatric depression scale in the elderly Korean with Alzheimer’s disease
Moon Ho PARK, MD, PhD1, Do-Young KWON, MD, PhD
Department of Neurology, Korea University Ansan Hospital, Ansan, South Korea

P52 - Can TMTblack and white predict the white matter hyperintensity of MRI in the community based elderly?
Young Chul Youn, MD, PhD
Neurology Department, Chung-Ang University College of Medicine, Seoul, Korea

P55 - CANTAB tests predict change in global functioning in patients with amnestic mild cognitive impairment
Elizabeth Bate1, Peter Annas PhD2, Giovanni B. Frisoni, MD, PhD3, David Bartres-Faz3, PD1, Beatrix Bosch3, MD, PhD, Jose Luis Molinuevo, MD, PhD1, Mira Didic, MD, PhD4,5, Francesca De Anna4,5, Lucilla Pannetta, MD, PhD5, Nicola Salvatori PhD5, Jens Wiltfang, MD, PhD51, Flavio Nobili, MD, PhD1, Nicola Gitter, Psy D1, Peter Schönheinich, MD, PhD1, Pieter J. Visser, MD, PhD5, Paolo M. Rossini, MD, PhD8, Paolo Chiovenda, MA1, Pierre Payoux, MD, PhD2, Andrea Sorici, MD, PhD3, Marco Salvato, PhD4, Magda Tolsati, MD, PhD4, Jill C. Richardson, PhD4, Régis Bordet, MD, PhD1, Olivier Blin, MD, PhD3, Gianluigi Forloni5 on behalf of the PharmaCog Consortium
1Cambridge Cognition Ltd, Batistisham, Cambridge, UK, 2Evidera, Boston, USA, 3Evidera, London, UK, 4Evidera, Montreal, Canada

P63 - Validating simulated cognition trajectories based on ADNI against trajectories from the National Alzheimer’s Coordinating Center (NACC) dataset
Ali Tafazzoli, PhD1, Josh Weng, PhD2, Kelly Sutton, PhD1, Michal Lithewicz, MSC1, Ameya Chavan, BS1, Mira Krotena, MSC1, Anuraag Kansal, PhD1
Evidera, Bethesda, MD, USA, 2Evidera, Waltham, MA, USA, 3Evidera, London, UK, 4Evidera, Montreal, Canada

P68 - Recruitment using the DCTclockTM
Daniel Lawler MD1, Stephen Thein PhD1
1Pacific Research Network Inc., San Diego, CA, USA

P70 - Strategy or symptom? semantic clustering and risk of Alzheimer’s disease
Jamie Ford, MSC1, Bang Zheng, MSC2, Barbara Hurtado, MA, CPsychol, Chi Udeh-Momoh, MSC, PhD3, Geraint Price, MSC, D Clin Psy1
1Imperial College London, UK

P72 - Tau is associated with longitudinal memory decline in healthy subjects: the need for an early detection of subtle cognitive changes
Adria Tort-Merino, MSC1, Jaume Olives, MSC1, Maria León, MSC1, Claudia Peñaloza, PhD3, Natalía Valech, MSC2, Petra Grönholm-Nyman, PhD3, Pablo Martínez-Lage, MD, PhD2, Juan Fortea, MD, PhD3,4, José Luís Molinuevo, MD, PhD1,3, Raquel Sánchez-Valle, MD, PhD2,4, Matti Laine, PhD3, Antonio Rodríguez-Fornells, PhD3,4,5, Lorena Rami, PhD5,6
1Alzheimer’s Disease and Other Cognitive Disorders Unit; Neurology Service, Hospital Clinic, Barcelona, Spain, 2Cognition and Brain Plasticity Group, Bellvitge Biomedical Research Institute- IDIBELL, L’Hospitalet de Llobregat, Barcelona, Spain, 3Department of Psychology, Åbo Akademi University, FIN-20500 Turku, Finland, 4Neurología, Fundación CYTA- Alzheimer Foundation, Centro de Investigación y Terapias Avanzadas, San Sebastián Guipúzcoa España, 5Memory Unit, Department of Neurology, Hospital de la Santa Creu i Sant Pau and Institute of Biomedical Research, Barcelona, Spain, 6Centro de Investigación Biomédica en Red de Enfermedades Neurodegenerativas Neurodegenerativas, CIBERNED, Spain, 7Barcelonaβeta Brain Research Center, Pasqual Maragall Foundation, Barcelona, Spain, 8August Pi i Sunyer Biomedical Research Institute (IDIBAPS), Barcelona, Spain, 9Catalan Institute for Research and Advanced Studies (ICREA), Barcelona, Spain, 10Department of Cognition, Development and Education Psychology, Campus Bellvitge, University of Barcelona, Barcelona, Spain

P75 - Flurries and flukes: recognising unrepresentative performance on cognitive tests
Geraint Price, D Clin Psy1, Bowen Su, MD4
1Imperial College London, UK
P87 - Assessing decline in visuospatial working memory associated with subjective cognitive impairment using a tablet-based measure of hippocampal-dependent learning
Alexandra S. Atkins1, Anzalee Khan1,2, Daniel Ulshen1, John Harrison3,4, Brenda L. Plassman5, Kathleen A. Welsh-Bohmer6 & Richard S.E. Keefe7
1NeuroCog Trials, Durham, NC, 2Nathan S. Kline Institute for Psychiatric Research, Orangeburg, NY, 3Alzheimer Center, VUMc, Amsterdam, The Netherlands, 4PPN, King's College, London, UK, 5Duke University Bryan ADRC, Durham, NC, 6Duke University Medical Center, Durham, NC, 7Duke University Medical Center, Durham, NC

P88 - Severe cognitive impairment in older adult heart failure patients: Preliminary findings from the Deus ex Machina study
Emilia Moreira1, Psy, MPH, PhD1, Sónia Martins1, Psy, PhD1, Luis Filipe Azevedo1, MD, PhD2,3, José SilvaCardoso1, MD, PhD1,4, Lia Fernandes1, MD, PhD1
1Center for Health Technology and Services Research/CINTESE, Faculty of Medicine, University of Porto, Portugal, 2Department of Clinical Neurosciences and Mental Health, Faculty of Medicine, University of Porto, Portugal, 3Department of Community Medicine, Information and Health Decision Sciences/MEDCIOS, Faculty of Medicine, University of Porto, Portugal, 4Department of Medicine, Faculty of Medicine, University of Porto, Portugal, 5Department of Cardiology S. João Hospital Center, Porto, Portugal, 6Clinic of Psychiatry and Mental Health, S. João Hospital Center, Porto, Portugal

P89 - The effect of dizziness in patients with cognitive impairments
Seunghoon Na1, MD, In-Uk Song1, MD, PhD1
Department of Neurology, Incheon St. Mary's Hospital, the Catholic University of Incheon, Korea

P151 - Selection of depression-specific dementia cases with replication in two cohorts
Donald R. Royall1, MD1,4, Raymond F. Palmer1, PhD2
1Department of Psychiatry, The University of Texas Health Science Center at San Antonio (UTHSCSA), San Antonio, Texas, USA, 2Department of Medicine, UTHSCSA, San Antonio, Texas, USA, 3Department of Family & Community Medicine, UTHSCSA, San Antonio, Texas, USA, 4South Texas Veterans Health Administration Geriatric Research Education and Clinical Center (GRECC), San Antonio, Texas, USA

P152 - Selection of depression-specific dementia cases with replication in two cohorts
Donald R. Royall1, MD1,4, Raymond F. Palmer1, PhD2
1Department of Psychiatry, The University of Texas Health Science Center at San Antonio (UTHSCSA), San Antonio, Texas, USA, 2Department of Medicine, UTHSCSA, San Antonio, Texas, USA, 3Department of Family & Community Medicine, UTHSCSA, San Antonio, Texas, USA, 4South Texas Veterans Health Administration Geriatric Research Education and Clinical Center (GRECC), San Antonio, Texas, USA

P153 - Assessment and speech-language intervention program in Non-Fluent Primary Progressive Aphasia: A case study
Beatriz Valles-González1 & Vicent Rosell-Clari2
1Speech and Language Pathology Clinic. Lluís Alcanyís Foundation-Universitat de Valencia, 2Basic Psychology Department. Universitat de Valencia

P154 - Prediction of APOE ε4 Burden from Cognitive Assessment
Royal DR1,4, Palmer RF1,4 for the Alzheimer’s Disease Neuroimaging Initiative1
1Departments of Psychiatry, 2Medicine, 3Family & Community Medicine, The University of Texas Health Science Center at San Antonio and the 4South Texas Veterans Health Administration Geriatric Research Education and Clinical Center (GRECC)

P155 - Could Telemedicine improve neurocognitive disorders detection and diagnosis in nursing home?
Armelle Leperre-Desplanches1, Isabelle Hauger1, Sylvain Gaulier1, Antonis Politis2, Shima Mehrabian1, Audrey Maillet1, Pierre Krolak-Salmon2
1Clinical and Research Memory Centre, Lyon Institute for Elderly, Hospices Civils de Lyon, Inserm UMR1028, CNRS UMR 5292, Lyon University, France, 2Résidence Talanssa, Talence, France, 3National and Kapodistrian University of Athens, Athens, Greece, 4Clinic of Neurology, UH “Alexandrovskia”, Medical University, Sofia, Bulgaria

P156 - Cognitive Blahouts in Mild Cognitive Impairment of the Amnestic Type and mild Alzheimer’s Dementia
Georg Adler1, Agnies Marczat1, Jana Binder1, Katharina Gnosa2
1Institut für Studien zur Psychischen Gesundheit, Mannheim, Germany

P157 - Feasibility of the neuropsychological battery camcomg-ds for the detection of cognitive decline in people with down syndrome
Laura Videla1,2, Bessy Benejam1, María Carmona-Iragui1,2, Susana Fernández1, Isabel Barroeta1,2, Sebastián Videla1, Alberto Lledó1,2, Rafael Blesa1,2, Juan Fortea1,2
1Alzheimer Unit - Douan, Douan Medical Center, Fundació Catalana Síndrome de Down, 2Memory Unit of the Neurology Service of the Hospital de la Santa Creu and Sant Pau, Biomedical Research Institute of Sant Pau, Universitat Autònoma de Barcelona, 3Central Biomedical Research Center (CIBERNED)

P158 - Distinct patterns of cognitive decline between early-onset Alzheimer’s disease and late-onset Alzheimer’s disease
Adrià Tort Meringa1, MSc1, Jaume Olives1, MSc1, Neus Falgás1, MD1, Mircea Balasa1, PhD1, Magda Castellvi1, MSc1, Sergi Borrego1, MD1, Beatriz Bosch1, PhD1, Maria León1, MSc1, Ana Salinero1, MSc1, Guadalupe Fernández1, RN1, Anna Antonell1, PhD1, Raquel Sánchez-Valle1, MD, PhD1, Lorena Rami1, PhD1, Albert Lladó1, MD, PhD1
1Alzheimer’s Disease and other Cognitive Disorders Unit, Neurology Service, Hospital Clinic, Barcelona, Spain
PI59 - High level of plasmatic amyloid Aβ 1-40 increase the risk of cognitive decline in 3C study with 14 years of follow-up
Audrey Gabelle, MD, Ph.D1,2, Laure-Anne Gutierrez, MS3,4, Thibault Mura M.D, Ph.D3,4, Jean-François Dartigues, Ph.D1,4, Olivier Rouaud, MD1, Jean-Charles Lambert Ph.D1,5,6, Catherine Helmer, Ph.D1,4, Claudine Ben M.D, Ph.D1,3
1Memory Research and Resources Center, Montpellier University Hospital, Montpellier, 2Inserm U1061, La Colombière Hospital, Montpellier, 3University of Montpellier, 4MUSC University, Montpellier, 5Bordeaux University, Inserm, Bordeaux Population Health Research Center, UMR 1219, Bordeaux, France, 6CHU Bordeaux, Department of Public Health, F-33000 Bordeaux, France, 7CHRU Dijon, Centre Mémoire Ressources et Recherche, Dijon, France, 8CHRU de Lille, Lille, France, 9INSERM U744, Lille, France, 10Institut Pasteur de Lille, Lille, France, 11Université de Lille Nord de France, Lille, France

PI62 - Using graphical hierarchical bayesian cognitive process models applied to common memory tests to detect ad pathology within normal subjects
William R. Shankle, MS, MD1,2,3, Junko Hara, PhD1,3, Jason R. Boch, MA1, Dennis Fortier, MBA1, Tushar Mangrola, MS1, Michael Lee, PhD2, Gregory E. Alexander, PhD2, William H. Batchelder, PhD3, Ronald C. Petersen, MD, PhD5, Walter Kremers, PhD3
1Medical Care Corporation, Newport Beach, CA, USA, 2Dept. of Cognitive Sciences, University of California at Irvine, Irvine, CA, USA, 3Pickup Family Neuroscience Institute, Hoag Memorial Hospital, Newport Beach, CA, USA, 4Mayo Clinic, Rochester, MN, USA

Late Breaking Posters

LBP47 - Strategic Memory Alzheimers Rehabilitation Training (SMART) Memory Program for Amnestic Mild Cognitive Impairment (aMCI): Reporting the Results of a Randomized Clinical Trial
John W. DenBoer, Ph.D, SMART Brain Aging, Inc

LBP48 - Memory errors of commission rather than errors of omission discern aging and early Alzheimer’s disease
Matthias W. Riepe, MD, Claudia Lanza, PhD, Karolina Sejunaite, MS
Department of Psychiatry and Psychotherapy II, Mental Health & Old Age Psychiatry, Ulm University, Ulm, Germany

LBP49 - Standard cognitive assessment in the era of biomarkers and disease-modifiers
Marina Boccacci, PsyD, PhD1,2, Stefano Cappa, MD, PhD2, Bruno Dubois, MD3, Jean Georges4, Matthias Kliegl, PsyD, PhD3, Bengt Winblad, MD, PhD5, David Salmon, PhD1, Giovanni Frisoni, MD1,2, Andreas Monsch, PsyD, PhD3, for the Task Force for Harmonizing Neuropsychological Assessment for Dementing Neurodegenerative Disorders
1LANVIE, Laboratory of Neuroimaging of Aging, University of Geneva, Geneva, Switzerland, 2IRCCS S.Giovanni di Dio, Fatebenefratelli, Brescia, Italy, 3Dementia Research Centre, Hôpital Prés-Saint-Pierre, Paris, France, 4Alzheimer Europe, 5Laboratory of Cognitive Aging, University of Geneva, Geneva, Switzerland, 6Karolinska University Hospital, Stockholm, Sweden, 7Department of Neurosciences, University of California San Diego School of Medicine, United States, 8University of Basel, Basel, Switzerland

LBP50 - Lanabecestat: Rater performance and error characteristics of efficacy assessments in the DAYBREAK-ALZ study
Allette M. Wessels, PhD1, Jordan Mark Barbone, BA2, Danielle T. DiGregorio, PsyD2, David S. Miller, MD, MA2, Jamie A. Mullen, MD3, & John R. Sims, MD4
1Eli Lilly and Company, Indianapolis, IN, USA, 2Brachet, Wayne, PA, USA, 3AstraZeneca Pharmaceuticals, Cambridge, MA, USA

LBP51 - iPSC model of CHRFAM7A effect on a7 nicotinic acetylcholine receptor function may explain the translational gap in drug development
Ivanova Ilnatovich1, Tapan Nayani1, Aya Ouf1, Norbert Sule2, Barbara Birhaya1, Lee Chaves1, Anthony Auerbach1
1SUNY at Buffalo, 2Rochswell Cancer Institute

LBP52 - Effects of Age and CSF measures of Tau on Mnemonic Discrimination of Objects and Scenes in Medial Temporal Lobe Pathways
David Berron, PhD1,2, Arturo Cardenas-Blanco, PhD1, Daniel Bitiner, MD1, Coraline D. Metzger, MD, PhD1, Annika Spottke, MD3,7, Michael Heneka, MD4,7, Klaus Fließbach, MD1,2, Anja Schneider, MD1,2, Stefan J. Teipel, PhD, MD1,2, Michael Wagner, PhD1,2, Oliver Specht, Prof. Dr.7,5, Frank Jessen, MD, Prof. Dr.1,2, Emnah Düzel, MD1,4,5,6, and the DELCODE study group
1Clinical Memory Research Unit, Department of Clinical Sciences Matida, Lund University, Lund, Sweden, 2University Hospital Magdeburg, Magdeburg, Germany, 3German Center for Neurodegenerative Diseases, Magdeburg, Germany, 4German Center of Neurology and Dementia Research (IKND), Otto-von-Guericke University, Magdeburg, Germany, 5Department of Neurology, University Hospital of Bonn, Bonn, Germany, 6German Center for Neurodegenerative Diseases (DZNE), Magdeburg, Germany, 7Institute of Cognitive Neurology, and Dementia Research (IKND), Otto-von-Guericke University, Magdeburg, Germany, 8Department of Neurology, University Hospital of Bonn, Bonn, Germany, 9Department of Psychosomatic Medicine, Rostock University Medical Center, Rostock, Germany, 10German Center for Neurodegenerative Diseases, Rostock, Germany, 11Department of Neurodegenerative Diseases and Geriatric Psychiatry, University Hospital, Bonn, Germany, 12Department of Biomedical Magnetic Resonance, Otto-von-Guericke University, Magdeburg, Germany, 13Department of Psychiatry, University Hospital Cologne, Cologne, Germany
Theme 7. Behavioral disorders and clinical trials

**P32 - Effect of memantine on behavioral and psychological symptoms of dementia (BPSD) of Alzheimer’s disease** - Study of changes in cerebral blood flow by spect imaging

**Aims**

Kiyoshi Kanaya¹, Shine Abe²

¹MD, Geriatric medicine, Tokyo Medical University Hachioji medical center, ²MD, Geriatric medicine, Tokyo Medical University Hachioji medical center

---

**P37 - Clusterization of behavioral and psychological symptoms of dementia (BPSD)**

Timofey L. Galanin, MD, PhD, Anton Y. Bespalov, MD, PhD, Hans J. Moebius, MD, PhD

¹EXCIVA, Am, Germany, ²Valdman Institute of Pharmacology, Pavlov First Saint Petersburg State Medical University, St. Petersburg, Russia

---

**P43 - The effect of dizziness in patients with cognitive impairments**

Seunghee Na, MD, In-Uk Song, MD, PhD

Department of Neurology, Incheon St. Mary’s Hospital, the Catholic University of Korea, Incheon, Korea

---

**P163 - A multicenter, randomized trial to assess efficacy of Therapeutic Intervention Program for Dementia Caregivers (I-CARE)**

Jihye Hwang, MD, PhD, Geon-Ha Kim, MD, PhD, Hae-Ri Na, MD, PhD, Soo-Jin Cho, MD, PhD, Kyung-Ho Yu, MD, PhD, Do Hoon Kim, MD, PhD, Jae-Hong Lee, MD, PhD, Seong-Hye Choi, MD, PhD

²Department of Neurology, Keimyung University School of Medicine, ¹Department of Neurology, Ewha Womans University School of Medicine, ¹Department of Neurology, Babath Memorial Hospital, ³, ⁴Hallym University School of Medicine, ⁵University of Ulsan College of Medicine, Department of Neurology, ⁶Inha University School of Medicine

---

**Late Breaking Posters**

**LBP53 - Prevalence of obstructive sleep apnea in Alzheimer’s disease patients**

Anna Carnes, PhD, Carme Jorge, MD, Benitez ID, Faride Daktorzada, Olga Minguez, Raquel Huerto, Montse Pujol, MD, PhD, Anna Gaeta, MD, Alfonso Arias, MD, Aurora Gibert, Manuel Sanchez de la Torres, MD, PhD, Ferran Barbé, MD, PhD, Gerard Piñol-Ripoll, MD, PhD

¹Unitat Trastorns Cognitius, Clinical Neuroscience Research, IRBLleida-Hospital Universitari Santa Maria Lleida (Spain), ²Group of Translational Research in Respiratory Medicine, Hospital Universitari Arnau de Vilanova and Santa Maria, IRBLleida, Lleida, Spain, ³Centro de Investigación Biomédica en Red de Enfermedades Respiratorias (CIBERES), Madrid, Spain
Theme 8. Health economics and clinical trials

P17 - Effect of physical activity on the progression of Alzheimer’s disease: the CREDOS study
Seong Hye Choi1, Jee Hyang Jeong2, Eun-Joo Kim3, Kyung Won Park4, Bora Yoon5, Soo Jin Yoon6, Yang-Ki Minn7, Young Ju Suhn8
1Department of Neurology, Inha University School of Medicine, Incheon, South Korea, 2Department of Neurology, Ewha Womans University School of Medicine, Seoul, South Korea, 3Department of Neurology, Pusan National University School of Medicine, Busan, South Korea, 4Department of Neurology, Dong-A Medical Center, Dong-A University College of Medicine, Busan, South Korea, 5Department of Neurology, College of Medicine, Konkuk University, Daejeon, South Korea, 6Department of Neurology, Eulji University School of Medicine, Daejeon, South Korea, 7Department of Neurology, Hallym University Kangnam Sacred Heart Hospital, Hallym University College of Medicine, Seoul, South Korea, 8Department of Biomedical Sciences, Inha University School of Medicine, Incheon, South Korea

P40 - The Survey for Current State and Dognition of Activities of Daily Living in Korean dementia patients
Kee Hyung Park, MD, PhD1, Chan-Nyoung Lee, MD, PhD2, Hojin Choi, MD, PhD3
1Department of Neurology, Gachon University, Gil Medical Center, Incheon, Korea, 2Department of Neurology, Korea University College of Medicine, Seoul, Korea, 3Department of Neurology, Hanyang University Guri Hospital, Guri, Korea

P58 - Young onset diseases care pathways. Parcours des malades Alzheimer et apparentés jeunes - PARMAAJ
Adeline Rollin-Sillaire, MD1,2, Brigitte Leprince3, Catherine Adnet-Bonte, MD3, Laetitia Breuilh, PhD2, Florence Pasquier, MD, PhD3
1Centre National de Référence des Malades Alzheimer Jeunes, Neurology Department, Centre Hospitalier Universitaire de Lille, France, 2Excellence Laboratory DISTALZ, Inserm U1171, Univ Lille, 3Meotis, Centre Hospitalier Universitaire de Lille, France

P164 - Dutch online registry for recruitment of participants for dementia studies
Marissa D. Zwan, PhD1, Derek Flenniken2,3, Shannon Finley, MA2, Aaron Ulbricht2,3, Rachel Nosheny, PhD2,3, Wiesje M. van der Flier, PhD1, Philip Scheltens, MD, PhD1, Diana Truran-Sacrey2, Michael W. Weiner, MD2,3, Niels D. Prins, MD, PhD1
1Alzheimer Center & Department of Neurology, Neuroscience Campus Amsterdam, Amsterdam UMC, Amsterdam, the Netherlands, 2Center for Imaging of Neurodegenerative Diseases, San Francisco Veteran’s Administration Medical Center, San Francisco, USA, 3UCSF Department of Radiology and Biomedical Imaging, San Francisco, USA
Theme 9. Epidemiology and clinical trials

P17 - Awareness of Alzheimer’s dementia as their own disease in Asian Countries
San Jung, YongSoo Shim, SangYun Kim
Department of Neurology, Hallym University Medical Center, Kang Nam Sacred Heart Hospital, Seoul, Korea; Department of Neurology, College of Medicine, The Catholic University of Korea, Bucheon St. Mary’s Hospital, Seoul, Korea; Department of Neurology, Seoul National University College of Medicine & Clinical Neuroscience Center, Seoul National University Bundang Hospital, Seoul, Korea

P38 - Subjective memory complaints are related to the social participation and leisure activities: TOyoake Integrated Care Study (TOICS)
Hajime Takechi, MD, PhD1, Atsira Tsuzuki, RPT, DMSc2, Komachi Matsumoto, Ms3, Hiroyuki Nishiyama, Mr4, Masatoshji Ogawa, Mr5, Yoshikiyo Kanada, RPT, DMSc2
1Department of Geriatrics and Cognitive Disorders, School of Medicine, Fujita Health University, Aichi, Japan; 2Faculty of rehabilitation, School of Health Science, Fujita Health University, Aichi, Japan; 3Department of community care, Toyoake city municipal office, Aichi, Japan; 4Gyosei Corporation, Tokyo, Japan

P46 - Alzheimer’s disease drug development pipeline: 2018
Jeffrey Cummings, MD, ScD1, Garam Lee, PharmD1, Aaron Ritter, MD1, Kate Zhong, MD2
1Cleveland Clinic Lerner Center for Brain Health, Las Vegas, NV, USA; 2Global Alzheimer Platform, Washington, D.C., USA

P165 - Association between amyloid status and multiple chronic diseases in European Prevention of Alzheimer’s Dementia (EPAD): network and cluster analyses
Lucy E Stirland, MBChB, MRCPsych1, Tom C Russ MBChB, PhD, MRCPsych2, Graciela Muniz Terrera, PhD3, Craig W Ritchie MBChB, PhD, MRCPsych1
1Centre for Dementia Prevention, University of Edinburgh, Edinburgh, UK; 2Alzheimer Scotland Dementia Research Centre, Edinburgh, UK

P166 - Concord-AD: An International Network of Cohorts for Better Understanding Alzheimer’s Disease
Samantha C Burnham, PhD1, Preciosa M Coloma, MD, PhD5, Teresa J. Christainson6, BS, Jean-François Dartigues, MD, PhD7,8, Rachelle Doody, MD, PhD1,7, Oshar Hansson, MD, PhD1, Catherine Helmer, MD, PhD8,9, Joseph S Kass, MD, JD1,10, Colin L Masters, MD11,2, Sebastian Palmqvist, MD, PhD12,14,15, Valory N Pavlik, PhD1, Ronald C. Petersen, MD, PhD1,12,13, Rosebud O. Roberts, MD, MB ChB, MS13,15, Maria Vassilaki, MD, MPH, PhD6,16, Barbara Schaubel17 and Mary Sano18
1eHealth, CSIRO Health & Biosecurity, Melbourne, Australia; 2Product Development Personalised Health Care, Data Science, F. Hoffmann-La Roche Ltd, Basel, Switzerland; 3Department of Neurology, Mayo Clinic, Rochester, MN, USA; 4Bordeaux University, Bordeaux, France; 5INSERM U897, Bordeaux, France; 6Clinical Memory Research Unit, Lund University, Malmo, Sweden; 7INSERM, U977-Epidemiologie-Biostatistique, Bordeaux, France; 8F. Hoffmann-La Roche Ltd, Basel, Switzerland; 9Clinical Memory Research Unit, Lund University, Malmo, Sweden; 10The Florey Institute of Neuroscience and Mental Health, Parkville, Australia; 11Department of Neurology, Ståne University Hospital, Lund, Sweden; 12Department of Health Sciences Research, Division of Epidemiology, Mayo Clinic, Rochester, MN, USA; 13Product Development Medical Affairs, F. Hoffmann-La Roche Ltd, Basel, Switzerland; 14Department of Psychiatry, Alzheimer’s Disease Research Center, Icahn School of Medicine at Mount Sinai, New York, NY, USA; 15Vander J. Peters VA Medical Center, Bronx, NY, USA

P167 - Cognitive and brain structural correlates of insomnia symptoms in middle-aged healthy adults
Oriel Grau-Rivera1, Juan Domingo Gispert2, Grégory Operto2, Carles Falcó1, Raffaele Cacciaglia1, Gonzalo Sánchez-Benavides2, Anna Bugulat1, Nina Gramunt1, Emma Salvador1, Marc Suárez-Calvet2, Carolina Minguilión1, Karine Fauria1, José Luis Molinuevo2,3,4
1BarcelonaBeta Brain Research Center, Catalonia, Spain; 2CIBER Frailty and Healthy Ageing (CIBERFAS), Madrid, Spain; 3CIBER Epidemiología y Salud Pública (CIBERESP), Madrid, Spain; 4Institut d’Investigació Biomèdica August Pi i Sunyer (IDIBAPS), Barcelona, Catalonia, Spain

P168 - A Phase II randomized clinical trial of high-dose versus standard-dose Vitamin D3 in an ethnically diverse sample of older adults
John Olichney, MD1, Charlie DeCarli, MD2, Joshua W Miller, PhD2, David Johnson, PhD1, Sarah Tomaszewski-Farias, PhD1, Bruce Hammoch, PhD3, Brittany Dugger, PhD1, Lee-Way Jin, MD, PhD4, Mary McPhail-Ciufo, DO5, Robert Sookooh, BS5, Dan Mungas, PhD6, Danielle Harvey, PhD6
1Neurology Department, University of California Davis, Sacramento, CA, USA; 2Department of Nutritional Sciences, Rutgers, The State University of New Jersey, New Brunswick, NJ; 3Department of Entomology & Comprehensive Cancer Center, University of California Davis, Davis, CA, USA; 4Pathology Department, University of California Davis, Sacramento, CA, USA; 5Psychology Department, University of California Davis, Davis, CA, USA; 6Department of Public Health Sciences, University of California Davis, Davis, CA, USA

Late Breaking Posters

LBP54 - Psychometric methodologies to increase scale-reliability in dementia-focused epidemiology: Outcomes from the European Prevention of Alzheimer’s Disease Study and UK Biobank
Sarah Bauermeister, PhD and John Gallacher, PhD
University of Oxford, Department of Psychiatry, Oxford, UK
LBP55 - STOPBANG and Berlin Questionnaire as screening tools to identify obstructive sleep apnea in Alzheimer’s disease
Anna Carnes, PhD1, Benitez ID2,3, Faride Dakterzada1, Olga Minguez2, Raquel Huerto1, Montse Pujol2, MD, PhD, Anna Gaeta, MD2, Alfonso Arias1, MD, Aurora Gibert1, Manuel Sanchez de la Torres1, MD, PhD, Ferran Barbé2,3, MD, PhD, Gerard Piñol-Ripoll1, MD, PhD
1Unitat Trastorns Cognitius, Clinical Neuroscience Research, IRBLleida-Hospital Universitari Santa Maria, Lleida, Spain, 2Group of Translational Research in Respiratory Medicine, Hospital Universitari Arnau de Vilanova and Santa Maria, IRBLleida, Lleida, Spain, 3Centro de Investigación Biomédica en Red de Enfermedades Respiratorias (CIBERES), Madrid, Spain

LBP56 - Exposure to benzodiazepines and development of Alzheimer’s disease: a cohort study in a Health Region of Catalonia between 2002 and 2015
Carnes A1, Torres-Bondia, FI1, de Batlle J2, Piñol-Ripoll, G1
1Unitat Trastorns Cognitius, Clinical Neuroscience Research, IRBLleida-Hospital Universitari Santa Maria, Lleida, Spain, 2Group of Translational Research in Respiratory Medicine, Hospital Universitari Arnau de Vilanova and Santa Maria, IRBLleida, Lleida, Spain
Theme 10. Animal model and clinical trials

**P102** - Concussive head injury exacerbates Alzheimer’s disease brain pathology. Superior neuroprotection by Co-administration of TiO2 nanowired Cerebrolysin together with antibodies to neuronal nitric oxide synthase and mesenchymal stem cells

Hari Shanker Sharma, José V Lafuente, Dafin F Muresanu, Rudy J Castellani, Mark A Smith, Ala Nozari, Ranjana Patnaik, Z Ryan Tian, Asya Ozhizilcik, Stephen D Skaper, Herbert Mössler, Aruna Sharma
1International Experimental CNS Injury & Repair (IECNSIR), Laboratory of Cerebrovascular Research, Dept. of Surgical Sciences, Anesthesiology & Intensive Care Medicine, Uppsala University Hospital, Uppsala University, Uppsala, Sweden, 2Dept of Neurosciences, University of Basque Country, Bilbao, Spain, 3Dept. Clinical Neurosciences, University of Medicine & Pharmacy, Cluj-Napoca, Romania, 4”RoNeuro” Institute for Neurological Research and Diagnostic, Cluj-Napoca, Romania, 5University of Maryland, Dept. of Pathology, Baltimore, MD, USA, 6Case Western Reserve Medical University, Dept. of Pathology, Cleveland, OH, USA, 7Anesthesiology, Massachusetts General Hospital, Harvard University, Boston MA, USA, 8School of Biomedical Engineering, Dept. of Biomaterials, Indian Institute of technology, Banaras-Hindu University, Varanasi, India, 9Dept. Chemistry & Biochemistry, University of Arkansas, Fayetteville, AR, USA, 10Ever NeuroPharma, Oberburgau, Austria

**P103** - Sleep deprivation aggravates Alzheimer’s disease brain pathology. Enhanced neuroprotection by nanowired delivery of cerebrolysin with alpha melanocyte stimulating hormone and antibodies to alpha-synuclein

Aruna Sharma, José V Lafuente, Dafin F Muresanu, Rudy J Castellani, Mark A Smith, Ala Nozari, Ranjana Patnaik, Z Ryan Tian, Asya Ozhizilcik, Herbert Mössler, Hari S Sharma
1International Experimental CNS Injury & Repair (IECNSIR), Laboratory of Cerebrovascular Research, Dept. of Surgical Sciences, Anesthesiology & Intensive Care Medicine, Uppsala University Hospital, Uppsala University, Uppsala, Sweden, 2Dept of Neurosciences, University of Basque Country, Bilbao, Spain, 3Dept. Clinical Neurosciences, University of Medicine & Pharmacy, Cluj-Napoca, Romania, 4”RoNeuro” Institute for Neurological Research and Diagnostic, Cluj-Napoca, Romania, 5University of Maryland, Dept. of Pathology, Baltimore, MD, USA, 6Case Western Reserve Medical University, Dept. of Pathology, Cleveland, OH, USA, 7Anesthesiology, Massachusetts General Hospital, Harvard University, Boston MA, USA, 8School of Biomedical Engineering, Dept. of Biomaterials, Indian Institute of technology, Banaras-Hindu University, Varanasi, India, 9Dept. Chemistry & Biochemistry, University of Arkansas, Fayetteville, AR, USA, 10Ever NeuroPharma, Oberburgau, Austria

**P104** - The effect of crenezumab on beta-amyloid toxicity–induced synapse loss, neurofibrillary tangles and cell death in human neurons in vitro

Ben Chih, PhD, Reina A. Bassil, BS, Shirley Ng, BS, Maureen Beresini, PhD
Genentech, Inc., South San Francisco, CA, US

Late Breaking Posters

**LBP58** - Disease modifying therapy by targeting generic protein secondary structure of pathological oligomers at any stages of Alzheimer’s Disease models

Fernando Goni, PhD, Krystal Herline, PhD, Mitchell Marta-Ariza, MSc, Frances Prelli, MSc and Thomas Wisniewski, MD
1New York University School of Medicine, New York, USA
POSTERS PRESENTATION

Theme 11. New therapies and clinical trials

P5 - Therapeutic monitoring and prediction of the effectiveness of neurotrophic therapy in patients with mild cognitive impairment of the amnestic type
Gavrillova S.1, Volpina O.1, Kolytchalov I.1, Ponomareva E.1, Seleznева N.2, Fedorova Y. B., Karaev D.1, A. V. Kamynin
1Mental Health Research Center, Moscow, Russia, 2Institute of bioorganic chemistry M.M.Semyachkin and Y.A.Ovchinnikov Russian Academy of Sciences, Moscow, Russia

P11 - IIß-hydroxysteroid dehydrogenase type 1 inhibitors pharmacological mechanism of potential therapeutic uses-a systematic review
Sarah Gregory1, John W. Ketelbeby1, Tamara Miller1, Vincent S Ruffles2, Craig W. Ritchie1
1University of Edinburgh, Edinburgh, UK, 2Actinogen Medical Ltd, Sydney, New South Wales, Australia

P20 - SUVN-502 - Baseline characteristics of phase 2a study in moderate Alzheimer’s disease - First-in-class Triple combination of SUVN-502+Donepezil+Memantine - A Promising new approach for the symptomatic treatment of Alzheimer’s Disease
Ramamritha Nirogi, PhD, Jyothsna Ravula, MS, Satish Jetta, MS, Koteswara Mudigonda, PhD, Vinod Kumar Goyal, MS, Santosh Kumar Pandey, MS, Gopinadh Bhryapuneni, PhD, Renny Abraham, PhD, Vijay Benade, MS, Pradeep Jayarajan, PhD, Anil Shinde, PhD, John Ieni, PhD and Venkat Jasti, MS
1Discovery, Research, Sun Life Sciences Ltd, Hyderabad, India

P23 - Efficacy and safety of trigriluzole (BHV-4157) in patients with mild to moderate Alzheimer’s dementia: T2 PROTECT AD phase 2 study design
Irfan A. Qureshi, M.D.1, Karen Messer, Ph.D.2, Kirsten Ericson, Ph.D.2, Robert M. Berman, M.D.1, Carolyn Revta3, Tilman Oltersdorf, M.D.2, Branko Huisa, M.D.2, Diane Jacobs, Ph.D.2, David Salmon, Ph.D.2, Doug Galasko, M.D.2, Thomas O. Obisesan, M.D.3, Neelum Aggarwal, M.D.4, Jacobo Mintzer, M.D.1, Judith Heidebrink, M.D.4, Amanda Smith, M.D.2, Miranda N. Reed, Ph.D.4, Holly C. Hunsberger, Ph.D.4, Lisa Donahue5, Kimberly Gentile1, David A. Stock, Ph.D.1, Vladimir Conic, M.D.1, Howard Feldman, M.D.1
1Bohoven Pharmaceuticals, Inc, New Haven, CT, USA, 2Alzheimer’s Disease Cooperative Study, University of California at San Diego, La Jolla, CA, USA, 3Howard University, Washington, DC, USA, 4Rush University Medical Center, Chicago, IL, USA, 5Vanderbilt University, Nashville, TN, USA, 6University of Michigan, Ann Arbor, MI, USA, 7University of South Florida Health Byrd Alzheimer Institute, Tampa, FL, USA, 8Auburn University, Auburn, AL, USA

P56 - Gamma-secretase modulation has multiple anti-amyloidogenic effects in vivo
Bengt Winblad1, Gunnar Nordvall1,2, Ping Yan1, Johan Lundqvist1,2, Johan Sandin1,2, Henrik Biverståhl1, Henrik Zetterberg1, Rebechta Klintenberg1, Mats Ferm1, John R Cimito1, Jin-Moo Lee1
1AlzCure Pharma AB, Drug Discovery & Development, Huddinge, Sweden, 2AlzCure Foundation, Preclinical Research, Huddinge, Sweden, 3AlzCure, 4Karolinska Institutet, Dept NVS, Div of Neurogeriatrics, Solna, Sweden, 5Washington University School of Medicine, Dept of Neurology, St Louis, USA, 6Karolinska University Hospital, Geriatric Clinical Trial Unit, Huddinge, Sweden, 7 Sahlgrenska University Hospital, Clinical Neurochemistry Laboratory, Mölndal, Sweden

P60 - Discovery of novel molecular chaperone modulators for the treatment of tau pathogenesis in Alzheimer’s disease
Rainish Kumar, PhD1, Pavel Pavlov, PhD1, Bengt Winblad, MD, PhD1,2
1Department of Neurobiology, Care Sciences and Society, Center for Alzheimer Research, Division of Neurogeriatrics, Karolinska Institutet, Solna, Sweden, 2Department of Geriatric Medicine, Karolinska University Hospital, Huddinge, Sweden

P79 - CogniXtra preventive treatment affords neuroprotection against amyloid beta 25-35 peptide-induced toxicity in mice
Francois J. Roman1, PhD, Johann Meunier1, PhD, Laura Ceolin1, PhD, Jean-Marie Boulanger2, MS, Guillaume Blivet2, MS, Jacques Touchon3, MD, PhD
1Amylgen, Montferrier-sur-Lez, France, 2Health Optimization Devices B.V, Maastricht, Netherlands, www.cognixtra.com, 3Montpellier, France, 4INSERM U1061 & Montpellier University, Montpellier, France

P84 - Clinical Development of AXS-05 (Dextromethorphan/Buproprion) for Agitation Associated with Alzheimer’s Disease
Herriot Tabuteau, MD1, Amanda Jones, PharmD1, Cedric O’Gorman, MD1
1Axsome Therapeutics Inc, USA

P85 - Pharmacokinetics and safety profile of intravenous administration of Allopregnanolone in patients with early Alzheimer’s disease
Cerson D. Hernandez, MD, MPH1, Naoko Kono, MPH1, Claudia M. Lopez, BS1, Ron Irwin, PhD2, Kathleen Rodgers, PhD2, Jimmy Wu, PhD2, Rosario Molina, PhD1, Sonja Pawluczyl1, MD1, Meng Law, MD1, Wendy Mach, PhD1, Loren Schneider, MD, MS1, Roberta D. Brinton, PhD1
1Center for Innovation in Brain Science, University of Arizona, Tucson, Arizona, USA, 2Department of Preventive Medicine, Keck School of Medicine of the University of Southern California, Los Angeles, CA, USA, 3School of Pharmacy, University of Southern California, Los Angeles, CA, USA, 4TOMO Pharmacometrics, LLC, San Mateo, USA, 5Department of Psychiatry & The Behavioral Sciences, Keck School of Medicine of the University of Southern California, Los Angeles, CA, USA, 6Department of Radiology, Keck School of Medicine of the University of Southern California, Los Angeles, CA, USA
PI05 - SM07883, a novel DYRK1A inhibitor, reduced Tau pathology – discovery and preclinical development of a potential therapeutic for Alzheimer’s disease
Benoit Melchior, PhD1, Carolyn Lai1, Karen Duong-Polk1, Amanda Tijbro1, Lauren Pitzer1, Joshua Stewart1, Luis Dellamy1, Scott Anderson1, Brian Hofhien1, Chiao-Wen Chen, PhD1, Charlene Baroga, PhD1, Gopi Mittapalli, PhD1, Sunil KC, PhD1, Philippe Marchand, PhD1, and Yusuf Yazici, MD1
Samumed, LLC, San Diego, USA

PI06 - Apabetalone, a BET bromodomain inhibitor, suppresses inflammatory mediators in microglia and vascular endothelial cells that contribute to neurodegenerative disease
Ewelina Kulihowska1, Emily Daze1, Sylwia Wasiatk1, Dean Gilham1, Laura M. Tsujikawa1, Brooke Rahai1, Stephanie C. Stotz1, Christopher Halliday2, Ravi Jahagirdar1, Norman C. W. Wong1, Michael Sweeney2
1Resverlogix Corp, Calgary, AB, Canada; 2Resverlogix Inc, San Francisco, CA, USA

PI07 - Clinico-radiological recovery of ARIA-like events in corticosteroid-treated CAA-ri patients: implications for the management of ARIA side effects of anti-amyloid immunotherapy
Fabrizio Piazza, PhD2,3, on behalf of The iCAβ International Network Collaborators and The CAA Study Group of the Italian Society of Neurology for dementia; Jacopo C. DiFrancesco1,2,3,4, Maria Luisa Zedde1, Federica Angiulli1, Rosario Pascarella1, Roberto Marconi1, Francesco Perini1, Alberto Villarejo-Galende5, Mario Cirillo4, Berardino Orlandi1,4, Ivara Masafumi4, Mehdi Touati1, Hagiwara Yuta5, Juan F. Vázquez-Costa5, Massimo Caulo1,2,3, Shima Arisushi6, Alessia Giossi1, Ricardo Nitrini7, Massimo Muscico7,8, Main Network Collaborators:
1The inflammatory cerebral amyloid angiopathy and Alzheimer’s disease Biomarkers (iCAβ) International Network; University of Milano Bicocca, Monza, Italy; 2The CAA Study Group of the Italian Society of Neurology for dementia (SINdem); University of Milano Bicocca, Monza, Italy; 3National Research Council, Sezara, Italy; 4Arcispedale Santa Maria Nuova-I.R.C.CS, Reggio Emilia, Italy; 5Department of Neuroscience, Ospedale Misericordia, Grosseto, Italy; 6St. Bonito Hospital, Vicenza, Italy; 7Hospital 12 de Octubre CIBERNED, Madrid, Spain; 8Università della Campania ‘Luigi Vanvitelli’, Seconda Università degli Studi di Napoli, Italy; 9S. Filippo and Nicola Hospital in Avezzano, L’Aquila, Italy; 10National Cerebral and Cardiovascular Center, Osaka, Japan; 11Dana-Farber Brigham and Women’s Hospital, Boston, Massachusetts, Inserm U1027, CNRS UMR 7225, Sorbonne Universités, Paris, France; B & USA; 15St. Mariana University School of Medicine, Kobe, Japan; 16Instituto de Investigación Sanitaria La Fe (IS La Fe), Valencia, Spain; 17University «G. d’Annunzio», Chieti, Italy; 18Kyoto University Graduate School of Medicine, Kyoto, Japan; 19O.U. of Neurology, ASST Cremona, Italy; 20University of São Paulo School of Medicine, São Paulo, Brazil

PI08 - Clinical Pharmacokinetics and Pharmacodynamics Demonstrate Once-Weekly CorplexTM Donepezil Transdermal System as a Therapeutic Alternative to Daily Oral Aricept
Bobby Singh, Corium International, Inc., 235 Constitution Drive, Menlo Park, California, USA

Late Breaking Posters

LBP59 - Triple therapy with SUVN-502, a 5-HT6 antagonist, donepezil and memantine in moderate alzheimer’s disease: Baseline patient characteristics in phase-2a study
Alireza Atri1, MD, PhD1, Jeffrey L. Cummings, MD, ScD1, John Ieni, PhD2, Venkat Jasti, MS3, Ramatrishna Nirogi, PhD3
1Banner Sun Health Research Institute/Banner Health; Sun City, AZ, USA; 2Center for Brain/Mind medicine, Department of Neurology, Brigham and Women’s Hospital and Harvard Medical School, Boston, MA, USA; 3Cleveland Clinic, Las Vegas, NV, USA; 4Discovery Research, Suven Life Sciences, Hyderabad, India

LBP60 - Clinical polysomnography trial of suvorexant for treating insomnia in Alzheimer’s disease: trial design and baseline characteristics of participants
W.J. Herring, MD1, P. Ceesay, PhD2, E. Snyder, PhD2, D. Bliwise, MD2, K. Budd, BS3, J. Hutzelmann, BS3, J. Stevens, BS3, D. Michelson, MD3
1Merck & Co, Inc., Kenilworth, NJ, USA; 2Emory University School of Medicine, Atlanta, GA, USA

LBP61 - Neuroprotective effect of a new photobiomodulation technique against amyloid Aβ25-35 peptide induced toxicity in mice might support a novel hypothesis for therapeutic approach of Alzheimer’s disease
Guillaume J. Blivet, MS1, Laura Auboyer, PhD2, Johann Meunier, PhD3, François J. Roman, PhD4, Jacques Touchon, MD, PhD1,2,4
1REGEnLIFE SAS, Montpellier, France; 2Amylgen SAS, Montferrier-sur-Lez, France; 3INSERM U1061, Montpellier, France; 4Neurology Department, University of Montpellier, France

LBP62 - Interest of REGEnLIFE RGN530 photobiomodulation medical device for the treatment of Alzheimer’s disease: a double-blind, randomized sham-controlled trial to evaluate the safety and efficacy
Audrey Gabelle1, MD, PhD2,3, Thibault Mura, MD, PhD2,3, Kérim Bennys, MD3, Sophie Navucet, MS2, Martine Flores, MS2, Laura Auboyer, PhD2,4, Guillaume J. Blivet, MS1,5, Jacques Touchon, MD, PhD1,2
1Memory Research and Resources Center of Montpellier, Department of Neurology, Montpellier University Hospital, France; 2MUSE University, INSERM U1061, Montpellier, France; 3Departement of Epidemiologic and Clinical Research, La Colombiere Hospital, Montpellier, France; 4REGEnLIFE SAS, Montpellier, France
CTAD 2018 would like to thank its privileged partners for their continued support of CTAD.

Gold Sponsors

[Logos of sponsors: Abbvie, Biogen, Eisai, Grifols, Aracnon Biotech, IQVIA, Janssen, Lilly, Lundbeck, Pfizer, Roche]
Address
Fairmont Rey Juan Carlos I & Palacio de Congresos de Cataluña
Av. Diagonal 661 - 671
Barcelona
Spain 08028

Map of the conference hotel and congress center

Congress venue maps
**Conference Room:**
All sessions will take place in the Auditorium.

**Coffee Breaks and Poster Sessions:**
Breaks and poster presentations will be held in the dedicated area across from the auditorium. This year all posters for all the different themes will be presented during the entire conference. Meet our poster presenters during the coffee breaks. A poster assistance desk will be available at the entrance to locate the posters.

**Lunches**: (only for attendees who purchased the lunch package) will be served next to the Poster Session in a dedicated area please present your badge at the entrance.

*Please note that there is no possibility of buying lunches onsite*

**Speaker Ready Room - Preview room - Hours of Operation**
- Wednesday, October 24: 1pm to 6pm
- Thursday, October 25: 7:30 am to 6pm
- Friday, October 26: 7:30 am to 6pm
- Saturday, October 27: 7:30 am to 5pm

**Networking coffee time:** In addition to the regular coffee breaks we suggest that you enjoy a cup of coffee with your peers and increase your networking time around the conference starting times
- Wednesday, October 24: 3:15pm to 4:00pm
- Thursday, October 25: 7:45am to 8:30 am
- Friday, October 26: 7:45am to 8:30am
- Saturday, October 27: 7:45am to 8:30am and 3:00pm to 4:00pm

**Free WiFi Available at CTAD**
Network: CTAD2018
Password: CTAD2018
Conference Mobile App

CTAD 2018 has its own Mobile App!

The App will be available for download on October 22, 2018 on the Apple App Store and Google Play (Search CTAD 2018) to be used on your mobile phone but also on large devices like an iPad or laptop computer.

The conference is right at your fingertips: discover the program, read the abstracts, learn more about our speakers, network with other participants and so much more!

Keep in touch

BARCELONA 2018

CTAD Congress
Phone: +33 (0)4 67 10 92 23
Email: ctad@ant-congres.com
www.ctad-alzheimer.com

Follow us on

@CTADConference
CTAD Alzheimer
CTAD Conference

#CTAD18

www.ctad-alzheimer.com
December 4–7, 2019
SAN DIEGO, California
Hilton Bayfront San Diego